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Abstract 
The widespread use of antibiotics has played a significant role in the emergence of 
resistant bacteria. It is of great interest and need to develop novel, effective and safe 
antimicrobial therapeutics. The biosynthesis of bacterial cell wall peptidoglycan is an 
intricate process that has become a popular target for antibiotics. Lytic protein E of 
Bacteriophage ΦX174 was found to inhibit peptidoglycan biosynthesis via an 
unknown interaction with integral protein MraY. Genetic studies have revealed that 
E-mediated lysis is dependent on the interaction between Phe288 of MraY and the 
transmembrane segment of protein E. 
We have constructed an α-helical model for the predicted transmembrane interactions 
between protein E and MraY and shown that favourable interactions can be formed 
between Phe288 and the RWXXW motif of protein E. In this thesis, analogues of the 
RWXXW motif were synthesised in solution and via solid phase peptide synthesis 
using 2-chlorotrityl chloride resin as the polymeric support. The inhibitory activity of 
these analogues was determined on a continuous fluorescence assay against 
membrane bound MraY. Inhibition studies on site-directed mutants of E. coli MraY 
were also conducted. Testing the inhibitory activity of RWXXW analogues provided 
compelling information on the importance of protein E residues for the inhibition of 
MraY. Peptides which contained a tryptophan residue were especially good inhibitors 
of MraY presumably due to their interaction with Phe288. Mutation of Phe288 caused 
a dramatic decrease or complete loss to the inhibitory activity of peptides containing 
an aromatic residue.  
Some analogues also contained antibacterial activity across multiple strains of 
bacteria including E. coli, B. subtilis and P. putida with MIC values as low as 
8μg/mL.  To confirm if MraY was the target enzyme, E. coli cells overexpressing 
MraY were treated with RWXXW analogues. An increase in the MIC of RWXXW 
analogues signified that the MraY was the lysis target.  
In the course of the project, we noticed that members of the UPA class of natural 
products contained some structural features that are also found in the RWXXW motif.  
These natural products were tested for activity against site-directed mutants of E. coli 
MraY. Results showed that Phe288 plays some role in the inhibition of MraY by 
pacidamycin. This work identifies a promising target for the development of novel 
antimicrobial agents that is located on the outer face of the cytoplasmic membrane.     
1 
 
Chapter 1:  Introduction 
 
 
The application of antibiotics into human medicine has had an enormous effect on the 
treatment of infectious diseases, the advances in medical procedures and the evolution 
of cells.  Prior to Alexander Fleming’s discovery of Penicillin in 1928, simple wounds 
and infections were left untreated, often leading to death
1
. At the time of his 
discovery, bacterial infections such as tuberculosis, pneumonia, enteritis and nephritis 
plagued the lives of over 388,790 people in the United States
2
. Bacterial infections 
remained one of the top leading causes of death in the United States until the 1950’s 
when penicillin was mass produced, increasing the life expectancy to 68 years
3
. The 
mass production and affordability of antibiotics had a tremendous impact on the 
success of invasive medical procedures such as surgery and chemotherapy
4
,  however, 
with the discovery, affordability and success of such powerful drugs looms 
overconsumption, dependence and abuse.  
Antibiotics are often administered as default measures for treatment of minor and/or 
irrelevant illnesses. Some infections such as bronchitis will resolve on its own with 
sleep, plentiful fluids, aspirin and deep inhalations in 1-2 weeks without leaving any 
permanent damage
5
.  Even so, many bronchitis patients are misprescribed antibiotics 
to ease the suffering and shorten the length of illness. Such over consumption and 
generalized use of any drug will inevitably result in antibiotic resistance.   
2 
 
1.1 Resistance 
 
 
After multiple exposures to the same class of antibiotics, bacteria have developed an 
extraordinary ability to recognize, export and even modify antibiotic compounds.   
Resistant genes usually arise by random genetic mutation, which can produce a new 
resistance trait or strengthen an existing one. These resistant genes are then readily 
spread to neighbouring bacteria through horizontal gene transfer such as conjugation, 
transformation and transduction
6
.  
To ward off destruction, resistant genes can eliminate cellular entry ports, code for 
efflux pumps that eject antibiotics out of the cell or code for enzymes that degrade or 
chemically alter the antibiotics or the target so that it is resistant to the antibiotic 
(Figure 1.1)
7
. In addition to these methods, bacteria also produce enzymes which 
correct the damages done by antibiotics.  
 
 
Figure 1.1: Bacterial resistance to antibiotics
7
. The production of (a) Efflux pumps (b) Degrading 
enzymes and (c) Chemically altering enzymes are various modes of resistance. 
 
 
The first example of resistance to an antibiotic was observed in the early 1940’s, 12 
years after the discovery of penicillin, when an increase in the MIC for S. aureus was 
observed
8
. Within 20 years, over 80% of S. aureus clinical isolates were resistant to 
3 
 
penicillin
9. This resistance evolved from the production of penicillinase, a group 2 β-
lactamase
10
 capable of hydrolysing penicillin at the β-lactam ring11,12 (Figure 1.2). 
 
Figure 1.2: Penicillinase activity in β-lactam ring opening 
  
To counter act the activity of β-lactamases, a new class of penicillin antibiotics was 
introduced; the antistaphylococcal penicillins. This class evolved from the treatment 
of penicillin with penicillin acylase which removed the natural phenyl acetyl group, 
followed by chemical acylation which attached various bulky side chains. These 
bulky side chains function to sterically hinder the antistaphylococcal penicillin 
molecules from β-lactamases13. This group of penicillins include methicillin, 
oxacillin, nafcillin, cloxacillin and dicloxacillin
14
. In 1961, British scientist Patricia 
M. Jevons isolated the first strain of methicillin resistant S. aureus bacteria, MRSA
15
.  
Resistance to methicillin was reported to be mediated by the expression of secA which 
codes for a novel penicillin-binding protein (PBP2´) with low binding affinity for β-
lactam antibiotics such as penicillin, amoxicillin, oxacillin, methicillin, and others
16-17
. 
In 1968 the first human case of MRSA was reported in Boston, Massachusetts, United 
States
18
. By 2002, CDC reported that 2.3 million persons were infected with MRSA in 
the United States
19
.   
For the treatment of severe MRSA, natural product vancomycin is typically used. 
Vancomycin is a haloorganic glycopeptide antibiotic made by the soil bacterium 
Actinobacteria Amycolatopsis orientalis (Figure 1.3).  
4 
 
 
Figure 1.3: Structure of Vancomycin 
 
Vancomycin was an effective and powerful antibiotic against S. aureus and 
Pseudomembranous enterocolitis for nearly 40 years before the evolution of 
resistance
20
. Vancomycin forms hydrogen bonds with the D-Ala-D-Ala motif of 
peptidoglycan intermediates, preventing crosslinking and ultimately the formation of 
peptidoglycan (Figure 1.4). Vancomycin Resistant Enterococci (VRE) were first 
reported in the United States and Europe in 1987
21
. 
Currently, seven resistance patterns have been reported (VanA-VanG), however less 
is known about VanD, Vane E and VanG type resistance
21
. The mechanism of 
resistance is best understood for the vanA cluster of genes. In this mechanism, 
Vancomycin acts as an inducer, activating transcription of the vanA cluser
21
. 
Translation of these genes produces a 38kDa membrane associated protein VanA. 
VanA was found to have sequence similarity to the D-Ala-D-Ala ligases responsible 
for the synthesis of the D-Ala-D-Ala dipeptide in the assembly of peptidoglycan
22-23
 
(Chapter 1.3). However, VanA was found to have modified substrate specificity in 
comparison to the Gram-negative D-Ala-D-Ala ligases. VanA is able to synthesise 
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various peptide and depsipeptide products including D-Ala-D-Lac, D-Ala-D-Met, and 
D-Ala-D-Phe in preference to D-Ala-D-Ala
24
. These alternative dipeptides can still be 
incorporated into peptidoglycan but cannot be recognized by vancomycin due to a 
missing hydrogen bond (Figure 1.4)
22,25
. As a result, crosslinking can still proceed.   
 
Figure 1.4: Structures of the Vancomycin complexes with D-Ala-D-Ala (left) and D-Ala-D-Lac 
(right)
25
. Vancomycin is unable to recognise the D-Ala-D-Lac due to a missing hydrogen bond. As a 
result polymerisation of peptidoglycan proceeds.  
 
 
VRE has become a serious concern to the scientific community given that only a 
limited amount of antibiotics are effective in treating this infection. The greatest 
concern about VRE is its potential to spread to other pathogens such as S. aureus or 
even Gram-negative bacteria
24
. 
Several Gram-negative bacteria have already acquired various forms of resistance. E. 
coli, K. pneumoniae, P. aeruginosa, and A. baumannii are opportunistic pathogens 
which are typically only dangerous to persons with comprised immune systems. 
However, recently these pathogens have evolved resistance to β-lactam antibiotics via 
the production of plasmid-mediated extended spectrum β-lactamases (ESBL)26-27. 
ESBL leads to resistance of third generation cephalosporins (e.g, cefotaxime, 
6 
 
ceftriaxone, ceftazidime) and monobactams (e.g. aztreonam)
28
. The evolution of 
multiple mechanisms of resistance including efflux pumps, impermeability and 
enzymatic inactivation have generated multidrug resistant bacteria (MDR) such as 
Pseudomonas aeruginosa MDR and Klebsiella pneumoniae MDR
29
. 
Resistance to commercially available antibiotics has increased so drastically that it is 
now considered an epidemic. Therefore, there is an urgent need for the development 
of new, effective and safe antimicrobial therapeutics that can target these increasingly 
dangerous Gram-negative and Gram-positive bacteria. 
 
1.2 Antimicrobial Peptides 
 
 
Over the past 40 years there have only been three new classes of antibiotics 
developed; lipopeptides, oxazolidinones and streptogramins which are all geared for 
the treatment of Gram positive bacteria
30
.  The lipopeptide, daptomycin is a cyclic 13-
member amino acid polypeptide with a decanoyl side-chain (Figure 1.5). It is 
proposed that  in the presence of Ca
2+
, daptomycin oligomerizes on the cytoplasmic 
membrane creating a channel that excretes important intracellular ions
31
.  
 
Figure 1.5: Structure of Daptomycin 
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The oxazolidinone class (Figure 1.6) of antibiotics work by inhibiting protein 
synthesis. The exact mechanism of action remains unknown. However, research has 
shown that it does not inhibit formation of initiator tRNA or block peptide elongation. 
Instead it has been proposed to be involved in the binding of mRNA to the 30S 
ribosomal subunit
32
.   
The streptogramins class are natural products produced by Streptomyces 
pristinaespiralis and Streptomyces virginiae (Figure 1.6). Streptogramins bind to the 
P-site of the ribosome effectively blocking protein translation
33
.   
 
Figure 1.6: Structure of the oxazolidinone Radezolid (left) and Streptogramin B (right) 
 
 
The effectiveness of streptogramins and oxazolidinones has been compromised by 
resistance. Conversely, the lipopeptide daptomycin has experienced <0.2% resistance 
in vitro and in Phase II and III clinical trials
31
. The success and near absence of 
resistance to lipopeptides has sparked the scientific community with great interest in 
the development of novel antimicrobial peptides.  
There are many advantages of peptides over conventional antibiotics. While most 
antibiotics target Gram-positive bacteria, antimicrobial peptides are effective against 
both Gram-negative and Gram-positive bacteria.  Some peptides have even been 
found to have activity against protozoa, including trypanosomes, malaria, and 
nematodes
4
. 
Antimicrobial peptides have very diverse potential application. They can be used as a 
single antimicrobial, synergistically with other antibiotics or as an immunomodulator.  
8 
 
Without directly acting on the bacteria, peptides are capable of encouraging the host’s 
natural defences to fight off the infection. For instance, synthetic peptide IMX00C1 
was found to have no antimicrobial activity in vitro (MIC ≥128 μg/ml), however 
when injected in an in vivo infection model the bacterial load was significantly 
reduced
34
.  
Another immunomodulatory property of antimicrobial peptides is their ability to 
neutralize sepsis and endotoxemia, which is a common and dangerous complication in 
systematic antibacterial drug administration
30
.  Sepsis is antagonized by the 
overstimulation of the innate immunity which occurs when bacterial signature 
molecules (for example, lipopolysaccharide) bind to Toll-Like Receptors (TLRs)
35
.  
To avoid sepsis, peptides moderate the TLR signalling response to a proactive level.  
Its ability to moderate immunity responses while simultaneously promoting 
angiogenesis and wound healing responses is quite impressive.  
The most notable advantage of peptides over conventional antibiotics is its 
invulnerability to bacterial resistance.  It takes 30 passages of P. aeruginosa in a sub-
MIC peptide to increase its resistance by two- to four-fold. Under the same 
conditions, resistance to the aminoglycoside gentamicin increases by 190-fold
30
.  The 
lack of diversity in the sequence and in the targets of conventional antibiotics renders 
it susceptible to resistance.  Conventional antibiotics target a specific enzyme or 
function of the cell. Peptides, on the other hand, have multiple targets and 
consequently multiple modes of causing cell lysis. For resistance to emerge, 
modifications would be necessary at every site of action of the peptide. Furthermore, 
as peptides are made of naturally occurring compounds, antimicrobial peptides can 
easily assimilate with other essential peptides. As a result, a resistance mechanism 
such as proteolysis could mistakenly target essential peptides, leading to cell death. 
9 
 
Even if an elegant mode of resistance were to evolve, the peptides attempt to enter the 
cell may still cause cell lyses (i.e. insertion via carpet model).   
 
1.3 Entrance into the bacterial cell 
 
 
An enormous amount of work has been invested in determining the mechanism of 
action of cationic peptides. The first obstacle peptides encounter is entrance into the 
bacterial cell. For a peptide to successfully enter the cell it must be stable, contain 
50% hydrophobic residues in order to insert into the membrane, and capable of 
adopting an amphipathic secondary structure
36
.  The first site of interaction occurs at 
the outer membrane or the cellular envelope.   
To cross the outer membrane of a Gram-negative bacteria, cationic peptides interact 
with the negatively charged glycolipid lipopolysaccharide (LPS) surface, displacing 
the magnesium ions which normally neutralize them
4
. This electrostatic interaction 
distorts the outer membrane, allowing the peptides to insert and migrate across the 
bilayer. Hancock (1997) termed this interaction as “self-promoted uptake” (Figure 
1.7). This interaction is believed to be energetically favourable, as the binding affinity 
of LPS for a typical peptide is three times stronger than that for a divalent cation.
37
  
 
Figure 1.7:Self-promoted uptake of cationic peptides
4
.  Electrostatic interaction between cationic 
peptides and LPS can create a gap in the membrane which peptides can use to cross the bilayer. 
10 
 
The initial interaction between cationic peptides and Gram-positive bacteria is very 
similar even in the absence of an outer membrane or LPS. The cellular envelope is 
rich in negatively charged teichoic and teichuronic acids. The basic residues of 
cationic peptides are able to form an electrostatic interaction with these acids, then 
enter the cell via self-promoted uptake
37
.   
There is much controversy over the fate of antimicrobial peptides after crossing the 
outer membrane barrier. Once it traverses the outer membrane or cellular envelope, 
the peptide enters a second stage of membrane interaction referred to as the threshold 
concentration
37
. The threshold concentration is heavily influenced by the peptide’s 
concentration and its ability to multimerise. The composition, fluidity and size of the 
phospholipid heads groups in the cytoplasmic membrane are also very important
38
. 
These factors facilitate different modes of insertion into the cytoplasmic membrane.  
Three distinct methods have been proposed.  
 
1.3.1 The Barrel-Stave Mechanism 
 
 
In this model, peptides are positioned in a barrel-like ring structure to form an 
aqueous pore. Initially, peptide binding at the membrane surface occurs. This forces 
the polar phospholipid head groups to dislocate
37
. The thinned membrane is then 
permeated by α-helical peptides that assemble in a barrel-like ring structure. In this 
assembly, hydrophilic residues face the centre of the pore and hydrophobic residues 
face the outside of the pore. The hydrophobic interactions between the nonpolar 
residues of the cationic peptides and the nonpolar tail of phospholipids stabilise the 
assembly
39
 (Figure 1.8).  For the barrel-stave model, an even distribution of 
hydrophobic and hydrophilic residues in cationic peptides is critical to the threshold 
11 
 
concentration. In addition, membrane fluidity and low protein composition is 
favourable.  
Fungal peptide antibiotic Alamethicin utilises the barrel-stave mechanism to cross the 
membrane. This was confirmed by oriented dichroism, neutron scattering and 
synchrotron-based X-ray scattering
40
. The open alamethicin transmembrane pore can 
contain 3-11 parallel helical molecules with a diameter of up to ~40nm
41
.  
 
 
  
 
Figure 1.8: Barrel-Stave Mechanism
39
 a) Cationic peptides bind to the phospholipid head groups 
causing the head groups to dislocate b) α-helical peptides permeate the thinned membrane and 
assemble a barrel-like ring structure with hydrophobic residues (blue) facing the phospholipidis and 
hydrophilic residues (red) facing the centre of the pore.   
 
 
1.3.2 The Toroidal pore 
 
 
In this model, lipids are intercalated with antimicrobial peptides to form a disordered 
pore. Initially, cationic peptides are oriented parallel to the cytoplasmic membrane as 
it binds to the polar head groups of phospholipids
37
. After having aggregated, one or 
two peptides begin to embed deeper into the interface causing large deviations from 
planarity in the phospholipids
42
.  The pore begins to form when the most deeply 
embedded peptide connects with the other interface forming a water pore. The water 
pore is relaxed into a toroidal shape as peptides and lipid molecules move across the 
membrane (Figure 1.9). To assist this model, the peptides must be amphiphatic. 
a) 
b) 
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In 2012, Bertelsen et al used 
13
P oriented solid-state NMR to investigate the 
interaction between antimicrobial peptide Novicidin and lipids. At high peptide 
concentrations, it was found that Novicidin forms toroidal pores with substantial 
perturbation to the lipid bilayer
43
.  
 
 
  
Figure 1.9: A schematic of magainin pores in a lipid bilayer crystallized into a regular 
hexagonal lattice
38
. a) Cationic peptide orient parallel to the phospholipids and bind to the polar head 
groups b) peptides start to embed deeper into the interface causing great deviation from planarity c) a 
water toroidal pore is formed when cationic peptides reach the cytoplasmic side of the membrane. 
 
 
1.3.3 The Carpet Model 
 
 
In this model, antimicrobial peptides cause a catastrophic break down of membrane 
integrity
4
. This process is initiated by the formation of an extensive layer or carpet of 
high density peptides on the membrane surface (Figure 1.10). When the threshold 
concentration is exceeded, the peptides disrupt the bilayer in a detergent-like-manner 
forming toroidal transient holes
44
. At such critical threshold concentrations, the 
membrane is subjected to unfavourable energetics causing it to disintegrate and form 
micelles
37
.  
There is much debate over whether pore formation is the killing mechanism of 
antimicrobial peptides. Before the collapse of the membrane, the formation of 
a) 
b) 
c) 
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transient holes may enable the passage of peptides or other small molecules into the 
cell
45
. It is plausible that inhibition of an intracellular target by these peptides or small 
molecules proceeds and influences membrane disintegration.  
  
 
Figure 1.10: The carpet model of antimicrobial-induced killing 
44
. High concentration of cationic 
peptides on the membrane surface disrupts the cytoplasmic membrane in a detergent-like manner.  
 
 
For some peptides that are known to act on intracellular targets such as Indolicidin, 
Histatin-5 and Pyrrhocoricin
46
, crossing the membrane is only the first of many 
obstacles; peptides still have the challenge of finding their intracellular targets while 
simultaneously avoiding degradation by proteases
35
.  To overcome these additional 
barriers, the dosage may have to be altered in order to make sure a sufficient quantity 
of peptides reach its target and infection can cease. Though sensible, this may lead to 
a toxicity problem, which poses a greater dilemma as peptide-mediated toxicity is not 
well understood
30. This problem could be entirely avoided if the peptides’ target was 
in the intramembrane region. For such peptides, only insertion into the cytoplasmic 
membrane will be necessary. Once inserted, the peptides can interact with its 
membrane bound targets.  Fortunately there are many vital membrane-bound enzymes 
that, if targeted, can lead to bacterial cell death. Among these enzymes include MraY 
14 
 
and MurG which catalyze two membrane-bound steps in the biosynthesis of 
peptidoglycan. 
 
1.4 Peptidoglycan 
 
 
Peptidoglycan or murein is an important bacterial heteropolymer that protects the cell 
against the lethal effects of internal osmotic pressure. Peptidoglycan is also 
responsible for preserving the characteristic shape of the cell and is intimately 
involved in the process of cell division
47
. This cellular protective coat is composed of 
long glycan chains made up of alternating units of N-acetylmuramoyl-peptides 
(MurNAc-peptides) and N-acetylglucosamine (GlcNAc) connected by a β-(1,4)-
glycosidic bond and further cross-linked through peptide chains
48
 (Figure 1.11).  
 
a)  b)  
Figure 1.11: a) Simplified schematic of peptidoglycan in gram positive bacteria b) β-(1,4) linked 
N-Acetylmuramoyl-peptide and N-Acetylglucosamine-peptide 
 
 
Peptidoglycan biosynthesis is highly conserved in bacteria, making it an excellent 
target for the development of broad spectrum antibiotics
49
.  The biosynthesis of 
peptidoglycan can be divided into three stages
50
: (I) cytoplasmic biosynthesis of 
substrates, (II) formation of monomeric building blocks and (III) polymerisation 
(Figure 1.12). 
15 
 
 
Figure 1.12: Peptidoglycan biosynthesis
51
. Stage I corresponds to the formation of lipid carrier 
undecaprenyl phosphate and MraY substrate UDP-MurNAc-pentapeptide. In stage II, MraY and MurG 
catalyse the formation of monomeric building blocks. Stage III occurs at the periplasm and involves the 
polymerisation of peptidoglycan monomers by Penicillin Binding Proteins.  
 
 
1.4.1 Cytoplasmic Biosynthesis of Peptidoglycan Substrates 
 
  
The biosynthesis of peptidoglycan begins in the cytosol or near the cytosolic face of 
the plasma membrane where a series of enzymes catalyse the synthesis of 
Undecaprenyl phosphate and UDP-MurNAc-pentapeptide
48,52,53,54
. 
Undecaprenyl phosphate (C55-P) is a 55 carbon isoprenoid (Figure 1.13). It is the only 
known lipid carrier in bacteria that facilitates the translocation of hydrophilic 
intermediates across the hydrophobic cellular bilayer
55
.  
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Figure 1.13: Structure of C55-P 
 
 
Undecaprenyl pyrophosphate (C55-PP) is synthesized by cytoplasmic enzyme 
undecaprenyl pyrophosphate synthase (UppS)
56
. UppS catalyzes the addition of eight 
(C5) isopentenyl pyrophosphate units onto a (C15) farnesyl pyrophosphate unit 
forming new cis double bonds
57
. The product C55-PP is delivered to the cytoplasmic 
membrane where undecaprenyl pyrophosphatase (UppP) dephosphorylates it 
producing C55-P
52,58
.  
Natural product bacitracin (Figure 1.14) from Bacillus subtilis has been found to bind 
to C55-PP in the presence of a divalent metal ion
59
. This in turn prevents the substrate 
from interacting with UppP leading to the arrest of bacterial peptidoglycan 
biosynthesis and ultimately cell death
60
. Overconsumption of bacitracin has inevitably 
led to resistance and contributed greatly to the emergence of MRSA strain 
ST8:USA300
61-62
.  
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Figure 1.14: Structure of Bacitracin 
 
 
The synthesis of UDP-MurNAc-pentapeptide is catalysed by a series of Mur enzymes.  
MurA to MurF are essential and highly conserved proteins in bacteria
63
(Figure 1.15). 
The first committed step in the pathway is catalysed by enolpyruvyl transferase 
MurA. MurA transfers an enolypyruvate moiety from phosphoenolpyruvate (PEP) to 
C-3 UDP-N-acetylglucosamine
64
 forming UDP-N-acetylglucosamine 3-enolpyruvyl 
ether (UDP-GlcNAc-EP)
65
.   
 
Figure 1.15: The biosynthesis UDP-MurNAc-pentapeptide. MurA catalyses the transfer of an 
enolpyruvyl unit onto UDP-GlcNAc. MurB reduces the enolpyruvyl unit producing UDP-MurNAc. 
MurC-MurF ligases attach five amino acids to the lactyl side chain of UDP-MurNAc. 
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MurA is the target of natural product fosfomycin (Figure 1.16). Fosfomycin 
irreversibly alkylates active site Cys115 preventing the acid/base catalysis necessary 
for the formation of UDP-GlcNAc-EP
66-67
.  
 
Figure 1.16: Structure of Fosfomycin 
 
 
Following MurA, MurB catalyses the reduction of the enolpyruvate moiety of UDP-
GlcNAc-EP to D-lactate, producing UDP-N-acetylmuramate (UDP-MurNAc)
54,63
.  
The addition of the pentapeptide moiety to UDP-MurNAc is performed by ATP-
dependent ligases MurC, MurD, MurE and MurF
47
. These ligases are responsible for 
the consecutive additions of L-alanine, D-glutamic acid, meso-diaminopimelic acid 
(m-DAP) or L-lysine and D-alanyl-D-alanine to the lactyl side chain of UDP-
MurNAc
68
. The final product, UDP-MurNAc-pentapeptide (Figure 1.17), is then 
delivered to the membrane where stage II of peptidoglycan biosynthesis commences.  
19 
 
 
Figure 1.17: Structure of UDP-MurNAc pentapeptide 
 
 
1.4.2 Biosynthesis of monomeric building blocks 
 
 
The biosynthesis of monomer GlcNAc-β-(1,4)-MurNAc-pentapeptide is catalysed by 
membrane bound proteins MraY and MurG
48,69-70
.   
Phospho-MurNac-pentapeptide translocase (MraY) couples UDP-MurNAc-
pentapeptide to C55-P to give undecaprenyl diphospho-MurNAc-pentapeptide (Lipid 
I) and uridine 5'-monophosphate (UMP)
69,71
. Attachment to the C55-P lipid carrier is 
crucial as it facilitates transfer of the monomer to the periplasmic side of the 
membrane at a later stage
55
.  
MraY is the target of various of antibiotics including tunicamycin, mureidomycin A, 
amphomycin, pacidamycin, muraymycin and liposidomycin B
69,72-73
.  Tunicamycin 
and amphomycin are unsuitable as novel drugs as they have mammalian toxicity due 
to preferential inhibition of the mammalian dolichyl phosphate pathway
74
. MraY will 
be discussed in further detail later (Chapter 1.4).  
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The addition of N-acetylglucosamine (GlcNAc) to the lipid I intermediate is catalysed 
by glycosyltransferase MurG
48-49
.  MurG transfers a GlcNAc moiety from UDP-
GlcNAc to the C4 MurNAc hydroxyl group of lipid I yielding lipid II, GlcNAc-β-
(1,4)-undecaprenyl-pyrophosphoryl-MurNAc-pentapeptide (Figure 1.18),  and uridine 
diphosphate (UDP)
75
.  
 
Figure 1.18: Structure of Lipid II, GlcNAc-β-(1,4)-undecaprenyl-pyrophosphoryl-MurNAc-
pentapeptide 
 
 
Lipid II is then transferred across the hydrophobic membrane to the periplasm, where 
Penicillin Binding Proteins (PBPs) polymerise lipid II to form the peptidoglycan 
layer
48
. The exact mechanism of transfer across the membrane is believed to catalysed 
by a putative flippase enzyme
47,64,74
. In 2011, Mohammadi et al provided the first 
biomedical evidence supporting Matsuhashi’s (1994) and Höltje’s (1998) hypothesis 
that FtsW, an essential division protein of the SEDS family (shape, elongation, 
division and sporulation), is a transporter of lipid II
76,77,78
.    
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1.4.3 Polymerisation 
 
 
The final stage of peptidoglycan biosynthesis involves polymerisation of lipid II 
monomer units and the binding of that polymer to the cell wall.  Polymerisation 
involves the formation of glycan chains and peptide cross-links, which are catalysed 
by glycosyltransferases (GT) and transpeptidases (TP), respectively
48
.  GT and TP 
enzymes may be present as bifunctional proteins such as Penicillin Binding Protein 2 
(PBP2) (Figure 1.19) or as monofunctional proteins
79
.   
 
Figure 1.19: Overall structure of PBP2 (PDB code 2OLU)
79
 
 
 
The condensation of glycan chains occurs at the active site of GT enzymes. Lovering 
et al (2007) proposed that active site residue E114 acts as a base and deprotonates the 
C-4 hydroxyl group of the acceptor lipid II, which concurrently attacks C-1 of the 
donor lipid II molecule in an SN
2
 manner (Figure 1.20)
79
. This produces a β-(1,4) 
linkage between the adjacent lipid II monomers and releases C55-PP. This process 
22 
 
repeats as additional monomers are flipped to the periplasm. The released C55-PP can 
then be recycled and used in stage I of peptidoglycan biosynthesis (Chapter 1.4.1). 
Alternatively, it is possible for the transglycosylation reaction to proceed in an SN
1
 
manner. The hemiacetal oxygen can stabilise the anomeric carbon facilitating the 
removal of the good leaving group, undecaprenyl pyrophosphate. The C-4 hydroxyl 
of the acceptor group could then attack the C-1 of the donor lipid II molecule to form 
the β-(1,4) linkage. 
 
Figure 1.20: Lovering et al proposed an SN
2
 mechanism for the transglycosylation of lipid II. In 
this scheme PPO is used in place of the lactyl-pentapeptide. Active site residue E114 acts as a base and 
deprotonates the C-4 hydroxyl group of the acceptor lipid II, which concurrently attacks C-1 of the 
donor lipid II producing a β-(1,4) linkage. 
 
  
The natural product moenomycin is a potent antibiotic that directly inhibits 
peptidoglycan glyosyltransferase. Though potent, (MIC values ranging from 1ng/mL 
to 100ng/mL)
80
, the suboptimal pharmacokinetic properties of this natural product 
prevents development as a novel drug
81
.  
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Transpeptidation is the ultimate enzymatic reaction in the biosynthesis of 
peptidoglycan. TP enzymes cross-link neighbouring monomers via its pentapeptide 
chain providing strength and rigidity to the overall structure of peptidoglycan.  
Cross linking is species-specific and is the most variable component of 
peptidoglycan
82
.  In most Gram-negative bacteria the cross link is between an m-DAP 
and the D-Ala at position 4 of the neighbouring pentapeptide chain
83
.   In E. coli, an 
m-DAP-m-DAP cross link can also be formed from the linkage of two m-DAP 
residues
84
. In Gram-positive bacteria, neighbouring pentapeptide chains are cross-
linked via a peptide bridge containing 1-5 glycine residues
83
. These varying cross 
linkages are illustrated in Figure 1.21. 
 
 
Figure 1.21: Peptidoglycan cross links. Gram-positive bacteria, neighbouring pentapeptide chains are 
cross-linked via a peptide bridge containing 1-5 glycine residues. In Gram-negative bacteria the cross 
link can be formed from two m-DAP residues or between m-DAP and D-Ala. 
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The transpeptidation reaction has been extensively studied in PBPs. PBPs utilize an 
active site serine residue to nucleophilically attack the carbonyl of D-Ala at position 4 
which results in the cleavage of D-Ala at position 5 and yields an enzyme-substrate 
complex
85
. This enzyme-substrate complex enhances the electrophilicity of D-Ala and 
promotes a nucleophilic attack by the m-DAP or L-Lys of the neighbouring 
pentapeptide chain (Figure 1.22).  
 
 
Figure 1.22: Transpeptidation reaction for Gram-negative bacteria 
 
 
The transpeptidation reaction of peptidoglycan biosynthesis is the target of β-lactam 
antibiotics which include penicillin, cephalosporin and other related compounds. β-
lactam antibiotics are structural analogues of the D-Ala-D-Ala linkage which 
competes and binds to PBPs preventing transpeptidation
86
. Several forms of resistance 
to β-lactam antibiotics have evolved. Bacteria can produce altered versions of PBPs 
which have a reduced affinity for β-lactam drugs (e.g. PBP2´ in MRSA), and are 
therefore able to crosslink peptidoglycan
16-17,87. Bacteria can also produce β-
lactamases, enzymes which hydrolyse the β-lactam ring effectively deactivating the 
antibiotic
88. Production of β-lactamase has become more prevalent in Gram-negative 
bacteria. 
The majority of antibiotics target the cytoplasmic and periplasmic reactions of 
peptidoglycan biosynthesis (Figure 1.16)
54
. This project will aim to identify a novel 
25 
 
antibacterial target for the membrane bounds steps of peptidoglycan biosynthesis, 
specifically MraY.  
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1.5 MraY 
 
 
Phospho-MurNAc-pentapeptide translocase (MraY) is essential for bacterial life, and 
at least one copy of the mraY gene is found in every bacteria
89
. This 40kDa protein is 
so important, that in its absence the cell cannot grow or reproduce, leading to swelling 
and ultimately cell lysis
53
. Its strong impact on viability (confirmed in E. coli and 
Streptococcus pneumonia)
90
 and its accessibility from the periplasm makes this 
protein a very promising antimicrobial target.  
The primary structure of MraY is composed of alternating hydrophobic and 
hydrophilic segments which suggests that MraY is an integral membrane protein that 
spans the cytoplasmic membrane several times
91
. Furthermore, Weppner and Neuhaus 
(1979) showed that a lipid microenvironment was required for the catalytic activity of 
MraY
92
.  
The secondary protein structure of E. coli and S. aureus MraY was predicted using β-
lactamase fusion experiments
93
, which revealed a common topological model 
consisting of ten transmembrane helices with four periplasmic loops and five 
cytoplasmic sequences
94
.  In this model, the cytoplasmic and periplasmic loops 
correspond to the hydrophilic segments of the primary protein structure while the 
transmembrane helices correspond to the hydrophobic segments, as expected
47
. This 
model was confirmed in August 2013 by Chung and colleagues whom solved the 
crystal structure of MraY from thermophile Aquifex aeolicus (Figure 1.24).    
28 
 
 
 
Figure 1.24: Crystal structure of A. aeolicus MraY
95
. a) View from within the membrane.  Each 
protomer contains 10 transmembrane helices, an interfacial helix (IH), a periplasmic β-hairpin (PB), a 
periplasmic helix (PH), and five cytoplasmic loops (loop A to loop E) The yellow sphere is Mg
2+
. The 
overall dimensions of the dimer are about 72 x 55 x 52 Å. b) Topology diagram of MraY illustrating 
the individual helixes and loops.   
 
MraY is a member of the polyprenyl-phosphate N-acetylhexosamine 1-phosphate 
transferase superfamily
96
.  Sequence homology has been found at the predicted 
cytoplasmic loops of MraY, WecA, WbcO and RgpG
96
. Nineteen polar residues 
appeared as invariant in the sequences of these MraY orthologues, some of which are 
also conserved in the whole superfamily
97
.  Conserved aspartic acid residues 115, 116 
and 267 were found to be essential for activity in E. coli MraY
47,71
. Chung et al 
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reported that in addition to these aspartic acid residues, invariant histidine residues 
located at position 324, 325 and 326 in A. aeolicus, are also crucial for enzyme 
activity. The crystal structure of A. aeolicus MraY revealed that these conserved 
residues are located in a cleft formed by the cytoplasmic and inner-leaflet membrane 
regions of TM3, TM4, TM8, and TM9b. The composition and location of these 
conserved residues suggest that this region is the active site of MraY
95
. 
 
 
Figure 1.25: The active site of A. aeolicus MraY
95
. a) Conservation mapping of one protomer of 
MraYAA. Highlighted in purple are highly conserved residues. The arrow indicates the location of the 
active site cleft. b) Zoomed in view of the active site. Residues important for catalysis and structural 
maintenance of the active site are highlighted in pink and cyan, respectively.    
a) 
b) 
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As previously mentioned, MraY plays an important role in the biosynthesis of 
peptidoglycan. Two possible catalytic mechanisms have been proposed. Heydanek et 
al (1969) proposed a two-step mechanism for the formation of lipid I by MraY.  In 
this two-step mechanism, a nucleophilic residue of MraY attacks the β-phosphate 
from UDP-MurNAc-pentapeptide displacing UMP. Following this step, the phosphate 
group in C55-P attacks the same β-phosphate, releasing the bound MraY protein and 
forming lipid I (Figure 1.26)
98
. Lloyd et al (2004) proposed that D267 in E. coli MraY 
plays the role of the nucleophile in this two-step mechanism. D115 and D116 are 
believed to be involved in Mg
2+
 chelation. Several observations support the two-step 
mechanism. In 1972, Pless and Neuhaus conducted isotope exchange experiments to 
determine the dependence of phosphatides for S. aureus MraY activity. In the absence 
of C55-P, MraY was found to catalyse the exchange of [
3
H]-uridine monophosphate 
with the UMP moiety of UDP-MurNAc-pentapeptide
98-99
. This indicates that the 
enzyme-substrate complex, MraY-Phospho-MurNAc-pentapeptide, is formed first. 
The addition of [
3
H]-UMP pushes the reaction in the reverse direction generating the 
substrate, [
3
H]-UDP-MurNAc-pentapeptide and free enzyme.  The addition of C55-P 
was found to reactivate the enzyme and allow formation of Lipid I. However, the 
addition dodecylamine or Triton X-100 inhibited the synthesis of lipid I, indicative of 
an apparent antagonistic relationship between the detergent and C55-P
47,99
.   
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Figure 1.26: MraY two-step catalytic mechanism 
 
 
Pless and Neuhaus’s experiment was criticised due to the use of nonpurified MraY97. 
The observations made by Pless and Neuhaus could have been attributed to the 
presence of endogenous C55-P or contaminating enzymes in the preparations used
47
. 
An alternative one-step mechanism has also been proposed, consisting in a direct 
attack by the phosphate oxyanion of C55-P onto the β-phosphate of UDP-MurNAc-
pentapeptide (Figure 1.27)
47
. In 2008, site-directed mutagenesis conducted by Al-
Dabbagh et al supported this one-step mechanism. In this study, enzyme activity was 
severely altered by mutation of D115, D116 and D267 but was not completely 
abolished which may be consistent with a direct attack mechanism
97
.  
 
 Figure 1.27: MraY one-step catalytic mechanism 
 
 
The mraY gene located at minute 2 on the chromosome map of E. coli
100
, can be 
amplified and cloned into several expression vectors including pTrc99A, pET52b and 
pET28b
91,94,101
. Previous reports have shown that the use of detergents such as n-
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dodecyl-β-D-maltoside, N-lauroyl-sarcosine, Triton X-100 or CHAPS, can facilitate 
extraction of MraY from various cell membranes
71-72,
 
94
. However, attempts to purify 
E. coli MraY has been unsuccessful even as a His6 tag fusion protein
94
. As a result, 
previous reports have used only partially pure or membrane bound MraY in 
enzymatic assays
47
. In 2004, Bouhss et al. described the high-level overexpression 
and purification of B. subtilis MraY. B. subtilis MraY was purified to homogeneity in 
milligram quantities with a specific activity of 1,900 units/mg of protein
94
. 
Initially, the activity of MraY was determined using a radiochemical assay which 
monitored the conversion of phospho-MurNAc-[
14
C]pentapeptide to [
14
C]lipid I by 
TLC or scintillation counter
102
. Alternatively, MraY activity can be determined using 
a fluorescence enhancement assay which monitors the conversion of fluorescently 
tagged UDP-MurNAc-pentapeptide to Lipid I
72,92
. UDP-MurNAc-pentapeptide is 
fluorescently tagged with a dansyl group at m-DAP or L-Lys at position 3. In this 
assay a fluorescence enhancement of 1.5-2 fold
71
 is observed upon conversion to 
Lipid I. This change in fluorescence is a direct response to the insertion of the dansyl 
group from an aqueous environment to the hydrophobic membrane. The 
radiochemical assay and the fluorescence enhancement will be discussed in more 
detail in Chapter 3.  
 
1.5.1 MraY Inhibitors 
 
 
MraY is the target of various natural products including tunicamycin, mureidomycin 
A, liposidamycin B and muraymycin. The potencies of these peptidyl nucleoside 
antibiotics have sparked the scientific community with great interest in investigating 
the structure-activity relationships of nucleoside antibiotics as MraY inhibitors 
(Chapter 4)
72,103-17
.  
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Mureidomycin A, isolated from Streptomyces flavidovirens SANK 60486
104
, consists 
of a 3’-deoxyuridine nucleoside linked to a modified peptide chain via an enamide 
linkage (Figure 1.28b)
103
. Mureidomycin A prevents peptidoglycan biosynthesis by 
selectively inhibiting MraY. Mureidomycin A was not found to inhibit mammalian 
glycoprotein biosynthesis and is therefore non-toxic
105
. 
Tunicamycin, isolated from Streptomyces lysosuperificus, is a fatty acyl nucleoside 
which reversibly inhibits MraY (Figure 1.28a)
72
.  Tunicamycin has been reported to 
also inhibit eukaryotic GlcNAc-1-P-transferase, preventing mammalian glycoprotein 
biosynthesis
106
.  GlcNAc-1-P-transferase is analogous to bacterial glycosyltransferase 
MurG.  Tunicamycin has antibacterial activity against Gram-positive bacteria with 
MIC values ranging from 0.2-50μg/mL107. A concise synthesis of tunicamycin and 
some analogues were reported in 1994
108
.  
 
Figure 1.28: Structure of Tunicamycin and Mureidomycin A 
 
Liposidomycin B, isolated from Streptomyces griseosporus
109
, is a nucleoside 
antibiotic containing a uracil, fatty acid, sulfated amino sugar and a 7-membered 
heterocycle (Figure 1.29). Liposidomycin B is a strong inhibitor of MraY (IC50 
0.03μg/mL) and MurG (IC50 ~1μg/mL)
110
. Unlike tunicamycin, liposidomycin does 
not stimulate a toxic response in mice at 180mg/kg
111
. 
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Muraymycin, produced by Streptomyces sp. NRRL 30471, is a potent inhibitor of in 
vitro MraY (IC50 0.027μg/mL)
112
. Muraymycin is an uridyl lipopeptide antibiotic 
whose activity is highly influenced by the nature of its lipophilic side chain (Figure 
1.29)
73,113
 McDonald et al (2002) reported antibacterial activity against S. aureus 
(MIC 2-16μg/mL), Enterococci (MIC 16–64 μg/mL) and Gram-negative bacteria 
(MIC 16–64 μg/mL)112. A previous report found that some members of the 
muraymycin family are able to protect mice from S. aureus infections (ED50 
1.1mg/kg), the highest in vivo activity of this group of compounds
47
.  
 
Figure 1.29: Structure of Liposidomycin B and Muraymycin A1/A3 
 
  
1.6 Bacteriophage Protein E 
 
 
In 2000 whilst investigating the different strategies of bacteriophage host cell lysis, 
Young et al came upon an interesting interaction between viral protein E and E. coli. 
In the case of Bacteriophage ΦX174, lytic protein E was found to cause host cell lysis 
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via inhibition of peptidoglycan
64,114
. Bacteriophage ΦX174 is a 5386bp phage that 
infects E coli. After replication of viral DNA, lysis of the E. coli host pursues via lytic 
proteins including protein E. 
Viral protein E has had a major role in the history of molecular biology. It was the 
first gene to be subjected to site-directed mutagenesis
115
, which is a critical and 
common procedure in research. It was also the first gene discovered to be overlapped 
within another gene in a different reading frame
116
. The complete DNA sequence of 
bacteriophage ΦX174 was determined in 1978 using the plus-and-minus method and 
the terminator method
116
. Gene E encodes a 91-amino-acid protein which activates 
endogenous autolytic membrane processes in E. coli
114
. No enzymatic activity has 
been observed for protein E itself
117
. Protein E is believed to be localised in the 
cytoplasmic membrane by its putative N-terminal transmembrane domain
118
. In 1997, 
Witte et al confirmed this by fusing protein E with a streptavidin moiety to produce 
hybrid protein E-FXa-StrpA. This hybrid protein was then recognised by α-
streptavidin antibodies in membrane fractions
119
.   
The mechanism of E-mediated lysis is controversial and many models have been 
proposed to explain its function.  
E-mediated lysis was observed to be strikingly similar to penicillin-mediated lysis
120
. 
This was confirmed by light and electron microscopy which revealed that lysis by 
protein E and penicillin both result in lesions at the cell septum
121-122-123
. These 
observations suggested that protein E targets and inhibits cell wall biosynthesis. 
Unlike the holin-endolysin system which systematically digests peptidoglycan after a 
programmed amount of time
124
, protein E has not been associated with cell wall 
degrading activity,
64
 instead it has been proposed to target a host protein causing cell 
lysis. Two proteins have been implicated as protein E targets, SlyD and MraY
125
.  
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1.6.1 SlyD and Protein E 
 
 
In 1985, Maratea et al isolated recessive mutations in the host gene slyD which blocks 
the lytic effects of protein E. Fusion experiments were conducted to determine if slyD 
mutants conferred resistance to protein E by preventing expression of gene E. 
Interestingly enough EΦlacZ fusions were still able to lyse slyD mutants, suggesting 
that these E fusions bypassed the step in which the wild-type slyD participates in E-
mediated lysis
126
. Maratea et al concluded that the slyD gene product may potentially 
serve as an initial recognition target, not the final lysis target. Bernhardt et al 
supported this hypothesis and suggested that lysis prevention by slyD mutants is 
associated with the inability of E to accumulate in the membrane due to improper 
folding
120
.    
In 1997, Hottenrott et al identified SlyD as a cytoplasmic metal ion-regulated 
peptidyl-prolyl cis/trans isomerase (PPIase) with chaperone-like properties
127
. 
Chaperones assist in protein folding by binding to hydrophobic patches of polypeptide 
chains, preventing aggregation
128
.  Proteomic analysis of E. coli BL21 showed an 
increase in the levels of SlyD after heat shock or membrane protein overexpression, 
implicating its role in protein folding
129-130
.   
The crystal structure of Thermus thermophiles SlyD (TtSlyD) was solved by Löw et 
al in 2010. The PPIase domain of TtSlyD has over 50% sequence similarity to E. coli 
SlyD and was co-crystallised with a prolyl-containing peptide structure (Figure 1.30). 
The active site is rich in hydrophobic residues which are believed to assist in binding 
and folding of polypeptides. Given the presence of multiple proline residues in the 
sequence of E peptide, it is plausible that SlyD assists in folding of the E protein.  
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Figure 1.30: Crystal Structure of TtSlyD co-crystallized with a prolyl-containing peptide 
substrate (PDB: 3LUO). Electrostatic map (left) shows the hydrophobic centre (white). Active site 
residues (green) are located in the hydrophobic pocket. The substrates proline is oriented in the centre 
of the active site where cis/trans isomerisation can occur.  
 
 
Further evidence that SlyD is not the lethal target for E-mediated lysis was reported 
by Bernhardt et al (2000). An Epos mutant of the E gene which contains two point 
mutation, R3H and L19F, was isolated on a slyD-null lawn
120
. This Epos mutant was 
found to be bacteriolytic in the absence of SlyD, suggesting that SlyD is an accessory 
protein in cell lysis, not the ultimate target
125
. It is possible SlyD may serve as a 
transport vessel, shielding protein E’s hydrophobic residues and protecting it from 
proteolysis until it reaches its membrane bound target
125
 (Figure 1.31).  
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Figure 1.31: SlyD as a protein E transport vessel. SlyD may serve as a transport vessel, shielding 
protein E’s hydrophobic residues and protecting it from proteolysis until it reaches its membrane bound 
target. 
 
 
1.6.2 MraY and Protein E 
 
 
To identify the final target of protein E, host mutants conferring resistance to Epos, 
slyD and WT phage infections were isolated by Bernhardt et al. High-frequency 
recombination (Hfr) and P1 mapping localised the mutations to minute 2 on the E. 
coli chromosome map
120
. As previously mentioned, this is the location of the mraY 
gene. Sequence analysis revealed that the surviving mraY mutants contained mutation 
F288L which is located at the predicted transmembrane helix 9
120
 (Figure 1.25). 
Further experimental analysis showed that in the presence of epitope-tagged Emyc 
protein, the activity of MraY was found to decrease by 75% with an accumulation of 
the UDPMurNAc-pentapeptide precursor
64
.  
These findings have motivated the TDHB research group at the University of 
Warwick to probe the structural and chemical properties of protein E in the hope of 
identifying a novel antimicrobial site. 
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Gene fusion experiments have shown that only 35 amino acids are necessary for lysis. 
This was further confirmed by the isolation of E amber mutants which were able to 
produce the wild-type phage within the host cell but could not activate lysis
131
. These 
35 amino acids are believed to encompass the putative transmembrane domain and 
will be referred to as Epep in this text
114,132
. The protein sequence of Epep is shown in 
Figure 1.32 
 
Figure 1.32: Sequence of Lytic E peptide. Shaded green are residues predicted to interact with 
MraY. Shaded yellow are residues located in the transmembrane region 
 
 
Epep was found to inhibit particulate E. coli MraY (IC50 = 0.8μM), but no inhibition 
of solubilised MraY was observed
125
. This suggests that rigidity, provided by the 
membrane, is important for the interaction of protein E with MraY. These 
experiments led to the hypothesis that protein E inhibits MraY via a protein-protein 
interaction in the membrane, which prevents interaction of MraY with other cell 
division proteins.   
 
1.7 Putative interaction between MraY and lytic E protein 
 
To determine the site of interaction between two proteins, structural and mutational 
studies are necessary.  In the case of MraY and protein E, genetic studies have shown 
that MraY mutation F288L causes resistance to protein E suggesting that Phe-288 is 
involved in binding protein E
120,133
. Utilising this information, we have constructed an 
α-helical model for the predicted transmembrane interactions between protein E and 
MraY, shown in Figure 1.33.  
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Figure 1.33: Predicted transmembrane interactions between Protein E and MraY translocase. 
The ten transmembrane helices, four periplasmic loops and five cytoplasmic sequences of MraY 
are shown. F288 in transmembrane helix 9 interacts with protein E in the transmembrane region 
 
 
Optimal protein interaction can occur between Phe-288 of helix 9 and Trp-4 and Trp-
7 of protein E, in which favourable aromatic interactions can be formed. Trp-4 and 
Trp-7 of protein E can participate in π-π stacking with Phe-288.  π-π stacking is an 
attractive interaction that occurs between the π-clouds of aromatics in a parallel 
orientation
134. π- π stacking interactions are prevalent in proteins and have been 
detected in the complexes of medicinal drugs and the targeted enzymes
135
. The 
parallel displaced orientation, in particular, is the most stable and energetically 
favourable orientation in proteins
135,136,137
. In this proposed model, it is plausible to 
form either a parallel-displaced orientation or a parallel-sandwich orientation (Figure 
1.34).  
Cytoplasm 
Periplasmic Space 
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Figure 1.34: Parallel π-π stacking orientations 
 
 
A salt bridge can also be formed between MraY’s Glu-287 and Arg-3 of protein E.  A 
salt bridge is a combination of hydrogen bonding and electrostatic interactions which 
can be formed between the carboxylate of glutamic acid and the cationic ammonium 
from arginine
137
. Salt bridges have been previously shown to contribute greatly to 
protein stability, folding and binding
138
.  Through this salt bridge it is possible for 
protein E and MraY to bind more tightly.   
Several protein X-ray crystal structures have shown a consistent pattern of salt bridges 
or charged residues stacked over aromatic interactions
139
. This structural motif has 
been termed cation-π interactions or SACA (Stacked Arrangement of Carboxylates 
over Aromatics)
139
. Cation–π interactions have been shown to be important for 
membrane insertion, substrate binding, catalysis and ion channel activity
140
. Entry 
into the transmembrane region is particularly difficult for charged amino acids such as 
arginine. However by associating with tryptophan, arginine can shield its positively 
charged side chain from the hydrophobic bilayer upon entry
141-142
. In the case of 
protein E, Trp-4 can shield Arg-3 during membrane diffusion. Once Arg-3 reaches the 
periplasmic side of the membrane, the combination of cation-π interactions and van 
der Waals forces can be used to align arginine’s side chain to bind MraY via a salt 
bridge with Glu-287
140,143
. Together, these residues provide an Arg-Trp-X-X-Trp 
motif that could interact with MraY. 
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Within the transmembrane region there are also possible Leu-Ile and Leu-Val 
contacts, and a possible polar interaction between Ser-303 of MraY and Ser-17/Ser-22 
of Epep. This model provides a good basis for a detailed study of the Protein E-MraY 
interaction. 
 
1.7.1 Mutational Studies on Protein E 
 
A variety of genetic studies on protein E have identified several mutations which are 
unable to cause lysis
119,133,144-145
.  Mutational studies conducted by Witte et al, showed 
that mutations P29G, P29S, P29V and P65G, P65S and P65V delayed lysis by 10-15 
minutes while mutations P21G, P21A, P21S and P21V completely abolished lysis
119
. 
The importance of P21 in vivo was further confirmed by Yu et al, Zheng et al and 
Tanaka and Clemons
133,144-145
. P21 is located in the membrane near the cytosolic 
surface and may be important for creating a helical kink. Helical kinks mediated by 
proline residues have been previously shown to allow for tightly packed structures in 
transmembrane helices
146-147
. Alternatively, P21 may be important for protein folding 
by SlyD. However, none of these studies have used SlyD mutants to confirm this.  
In 2012, Tanaka and Clemons demonstrated that in addition to Pro21, Trp7 was also 
essential for E-mediated lysis. Mutation W7A inhibited lysis in a similar manner to 
mutation P21A
133(Fig S2A)
.   W7A corresponds to the 2
nd
 Trp residue of the RWXXW 
motif that we hypothesise is important for interaction with MraY.  
 
1.7.2 Known antimicrobial peptides containing the RWXXW motif 
 
 
The RWXXW motif is very peculiar as it involves two of the bulkiest natural amino 
acids; one being very polar and basic and the other being the most hydrophobic. 
Cherkasov et al (2008) used Quantitative Structure Activity Relationship (QSAR) to 
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relate the structural characteristics of a molecule to biological activity. Interestingly 
enough, arginine and tryptophan were recorded to be prevalent amino acids in 
antimicrobial peptides
148
 (Figure 1.35). The physical properties of Arg and Trp side-
chains are expected to contribute greatly to this finding
149
.  
 
Figure 1.35: Occurrence of amino acids in QSAR data 
sets
148
. Set A and B have antimicrobial activity. Q1-Q4 are 
samples predicted to have activity. 
 
Remarkably, the RWXXW motif is also present in several known cationic peptides 
including Indolicidin
150
 and CP-11
151
 which show antibacterial activity against S. 
aureus and E. coli. The protein sequence of several antimicrobial peptides in 
comparison to protein E is given in Table 1.1. The sequence of indolicidin, isolated 
from bovine neutrophils
152
, contains RWPWW starting at position 2 relative to the C-
terminus. Derivatives of indolicidin such as Kai26 also contain the RWXXW motif. 
The N-terminal sequence of cecropin A contains the related KWKSF in which Lys-1 
and Phe-5 replace chemically equivalent Arg-1 and Trp-5 of the RWXXW motif, 
respectively. It is documented that the Trp-2 residue in this sequence is essential for 
activity
153
. Similarly, the C-terminal sequence of tritrpticin also contains a related 
sequence, RFPWW
154
. Lactoferricin B contains RWQW starting at position 5. It has 
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been demonstrated that Trp-6 and Trp-8 of this peptide are both essential for 
antimicrobial activity
155
. 
 
Table 1.1: Amino acid sequence alignment of ΦX174 E protein with other known antimicrobial 
peptides 
Antimicrobial 
peptides 
Sequence PDB file Ref 
E peptide N-MVRWTLWDTLAFLLL-C  114 
MX226 N-ILRWPWPWRRK-C 
C-KRRWPWPWRLI-N 
 
150
  
Kai26 C-KRWKWWRFKWKIF-N  150 
Indolicidin C-RRWPWWPWKWPLI-N 1G89, 
1G8C 
150
 
CP-11 C-KRRWPWWPWKKLI-N 1QXQ 151 
CycloCP-11  C-KC1RRWPWWPWKKLC1I-N 1QX9 
156
 
Sub6 N-RWWKIWVIRWWR-C  150 
Kai50 N-ILRWKWRWWRWWRR-C  150 
HHC-10 N-KRWWKWIRW-C  148 
HHC-36 N-KRWWKWWR-C  148 
HHC-8 C-RKRWWWWIK-N  150 
HHC-45 C-RWKKWWRKW-N  150 
Lactoferricin 
B 
N-EKCRRWQWRMKKLG-C 1LFC 
155-157 
Cecropin A N-KWKLFKKI….-C 1D9J 
153, 158 
Tritrpticin N-VRRFPWWWPFLRR-C 1D6X 154 
1002 N-VQRWLIVWRIRK-C  150 
1020 N-VRLRIRWWVLRK-C  150 
 
 
Although cationic antimicrobial peptides are known to insert and form pores in 
bacterial membranes (Chapter 1.2), they are thought to have multiple cellular targets, 
so the appearance of the same motif suggests a possible link with the protein E 
mechanism of bacterial cell lysis. 
 
1.7.3 Protein E analogues across ΦX174-like bacteriophages 
 
 
There are three groups of ΦX174-like bacteriophages159-160 which contain variations 
on the RWXXW motif. In group 1, of which ΦX174 is the principal member, the 
RWXXW motif is well conserved (though not entirely) in protein E homologues. In 
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group 2 (type field by phage α3) and group 3 (type field by phage G4), an additional 
Glu-2 residue is conserved and in some cases Arg-3 is often replaced by His (Figure 
1.36).   
Like arginine, histidine is a very polar amino acid that is commonly involved in the 
active sites or binding sites of proteins.  In addition, histidine has a pKa near to the 
physiological pH which allows its side chain to alternate between a neutral and 
positive charge
161
. Given its similarities, it is plausible that histidine can interact in a 
similar manner to arginine to form similar interactions as we proposed WT protein E 
forms with MraY. 
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Figure 1.36: Sequence of protein E homologues across various bacteriophages 
Group 1: X174-Like 
X174 MVRWTLWDTLAFLLLLSLLLPSLLIMFIPSTF 
s13   MVRWTLWDTLAFLLLLSLLLPSLLIMFIPSTF 
NC51  MVRWTLWDTLAFLLLLSLLLPSLLIMFIPSTF 
WA10  MVRWTLWDTLAFLLLLSLLLPSLLIMFIPSTF 
ID34  MVRWTLWDTLAFLLLLSLLLPSLLIMFIPSTF 
NC1   MVRWTLWDTLAFLLLLSLLLPSLLIMFIPSTF 
NC11  MVRWTLWDTLAFLLLLSLLLPSLLIMFIPSTF 
ID45  MVRWTLWDTLAFLLLLSLLLPSLLIMFIPSTF 
NC16  MVRWTLWDTLAFLLLLSLLLPSLLIMFIPSTF 
NC37  MVRWTLWDTLAFLLLLSLLLPSLLIMFIPSTF 
NC41  MVRWTLWDTLAFLLLLSLLLPSLLIMFIPSTF 
NC5   MVRWTLWDTLAFLLLLSLLLPSLLIMFIPSTF 
NC56  MVRWTLWDTLAFLLLLSLLLPSLLIMFIPSTF 
NC7   MVRWTLWDTLAFLLLLSLLLPSLLIMFIPSTF 
ID1   MVRWTLWDILAFLLLLSLLLPSLLIMFIPSTF 
WA4   MVRWTLWDTLAFLLLLSLLLPSLLIMFIPSTF 
WA14  MEHWTLSAILAFLLLLSLLLPSLLIMFIPLTF 
ID2   MVHWTLSDTLAFLLLLSLLLPSLLIMFIPLTS 
ID18  MELWTLWDTLAFLLLLSLLLPSLLIMFIPLTF 
ID22  MVLWTLLDTLAFLLLLSLLLPSLLIMFIPSTF 
WA11  MALWTLWDTLAFLLLLSLLLPSLLIMFIPSTF 
Group 2: 3-Like 
3    MERWTLLDILAFLLLLSLLLPSLLIMFIPSMY 
ID32  MERWTLWDTLAFLLLLSLLLPSLLIMFIPSTF 
ID62  MERWTLWDTLAFLLLLSLLLPSLLIMFIPSIF 
NC3   MERWTLWDTLAFLLLLSLLLPSLLIMFIPSTF 
NC35  MERWTLWDTLAFLLLLSLLLPSLLIMFIPSTF 
WA45  MERWTLWDTLAFLLLLSLLLPSLLIMFIPSTF 
NC28  MERWTLLDTLAFLLLLSLLLPSLLIMFIPSTF 
NC29  MERWTLLDTLAFLLLLSLLLPSLLIMFIPSTF 
WA13  MEHWTLWDTLAFLLLLSLLLPSLLIMFIPSTF 
ID21  MGHWTLSGILAFLLLLSLLLPSLLIMFIPLTF 
K    MERWTLSAILAFLLLLSLLLPSLLIMFIPSTF 
st1   MERWTLSAILAFLLLLSLLLPSLLIMFIPSTF 
 
Group 3: G4-Like 
G4    MEHWTLSGILAFLLLLSLFLPSLLITFIPLTS 
WA2   MEHWTLSGILAFLLLLSLLLPSLLIMFIPLTS 
ID8   MEHWTLSGILAFLLLLSLLLPSLLIMFIPLTS 
WA3   MEHWTLSGILAFLLLLSLLLPSLLIMFIPLTS 
ID12  MEHWTLSGILAFLLLLSLLLPSLLIMFIPLTS 
NC10  MEHWTLSGILAFLLLLSLLLPSLLIMFIPLTS 
WA6   MEHWTLSGILAFLLLLSLLLPSLLIMFIPLTS 
ID52  MERWTLSGILAFLLLLSLLLPSLLIMFIPSTF 
NC6   MERWTLSGILAFLLLLSLLLPSLLIMFIPSTF 
ID11  MEHWTLSGILAFLLLLSLLLPSLLIMFIPLTF 
ID41  MEHWTLSGILAFLLLLSLLLPSLLIMFIPLTF 
NC13  MEHWTLSGILAFLLLLSLLLPSLLIMFIPLTF 
NC19  MEHWTLSGILAFLLLLSLLLPSLLIMFIPSTF 
NC2   MEHWTLSGILAFLLLLSLLLPSLLIMFIPLTF 
WA5   MEHWTLSGILAFLLLLSLLLPSLLIMFIPLTF 
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1.8 Aims of the Project 
 
 
In this project, we hypothesise that the RWXXW motif of protein E inhibits MraY by 
interacting with Phe288. In order to investigate this hypothesis, synthetic peptide 
analogues of the RWXXW motif have been synthesised and tested against the activity 
of membrane bound MraY. 
Initially, Arg-Trp dipeptide derivatives were prepared containing hydrophobic octyl 
substituents at either N- or C- terminus, designed to anchor the peptide in the 
membrane. 
 
1.8.1 Compounds of Interest 
 
 
 
 
 
Figure 1.37: Arg-Trp dipeptide derivatives 
 
 
[1] 
[2] [3] 
48 
 
 To determine which interaction (electrostatic or π- π stacking) is most critical for the 
interaction between protein E and MraY, arginine and tryptophan were replaced with 
glycine (Figure 1.38). 
 
 
Figure 1.38: Gly-Trp and Arg-Gly dipeptide derivatives 
 
Pentapeptide analogues of the RWXXW motif were also designed. For ease of 
synthesis, and since Thr-5 does not appear to interact with MraY according to our 
predicted structural model (Figure 1.33), Thr-5 was replaced with Leu.  In ΦX174-
like bacteriophages (Group 1), Thr-5 is also commonly replaced by Leu (Figure 1.36), 
so RWGLW was considered the native sequence. To determine the binding efficiency 
[4] 
[5] [6] 
[7] 
[8] [9] 
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of individual amino acids in the RWXXW motif, each amino acid was replaced with 
glycine (Figure 1.39). 
 
Figure 1.39: RWXXW pentapeptide analogues 
 
 
Across various bacteriophages, the RWXXW motif is conserved (Figure 1.36). In 
group 2 and group 3 bacteriophages, a conserved Glu-2 residue precedes the 
RWXXW motif. Following our predicted structural model, this additional Glu-2 may 
interact with the Gln286 residue located on the MraY helix 8-helix 9 loop via 
hydrogen bonding. In group 3 bacteriophages, Arg-3 is often replaced by His which 
has similar chemical properties to Arg (Figure 1.36). Analogues of group 2 and group 
[10] 
[11] [12] 
[13] [14] 
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3 protein E were therefore also synthesised and examined for activity against MraY 
(Figure 1.40). 
 
Figure 1.40: G4-like and α3-like protein E analogues 
 
 
Table 1.2: RWXXW analogues synthesised within the scope of this research 
 Compound Formula Mass (g/mol) 
[1] H2N-RW-OMe C18H26N6O3 374.207 
[2] Octyl-RW-OMe C26H40N6O4 500.311 
[3] H2N-RW-Oct C25H40N6O3 472.316 
[4] H2N-GW-OMe C14H17N3O3 275.127 
[5] Octyl-GW-OMe C22H31N3O4 401.231 
[6] H2N-GW-Oct C21H31N3O3 373.237 
[7] H2N-RG-OH C8H17N5O3 231.133 
[8] Octyl-RG-OH C16H31N5O4 357.238 
[9] H2N-RG-Oct C16H33N5O3 343.258 
[10] H2N-RWGLW-OH C36H48N10O6 716.376 
[11] H2N-RGGLW-OH C27H41N9O6 587.318 
[12] H2N-GWGLW-OH C32H39N7O6 617.296 
[13] H2N-RWGGW-OH C32H40N10O6 660.313 
[14] H2N-RWGLG-OH C27H41N9O6 587.318 
[15] H2N-EHWGGG-OH C28H35N9O9 641.256 
[16] H2N-ERWGGW-OH C37H47N11O9 789.356 
 
[15] 
[16] 
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Chapter 2:   Synthesis of Peptides  
 
 
2.1 Steps in Peptide Synthesis 
 
 
The aim of this research project was to develop novel inhibitors of MraY. Exploiting 
the predicted structure-activity relationship of lytic E and MraY, 16 short RWXXW 
analogues were synthesised via manual SPPS and solution peptide synthesis.  
Efficient peptide synthesis required careful utilization of the following four steps: 
protection, activation, coupling and deprotection
162,163,164
. 
 
2.1.1 Protection 
 
 
Strategic protection of the carboxyl (COOH) and amino (NH2) functional groups was 
crucial; otherwise undesired products could form upon peptide coupling. A peptide 
bond or amide bond is a covalent chemical bond that is formed between the carboxyl 
group of one amino acid with the amino group of another amino acid
164
.  
If an amino acid is left unprotected at both termini, it can react with itself and form a 
variety of dipeptides, tripeptides and other polymers. If two different amino acids are 
left unprotected, there are four possible dipeptide products that can form. In the case 
of unprotected arginine and tryptophan, dipeptides H2N-Arg-Arg-OH, H2N-Arg-Trp-
OH, H2N-Trp-Arg-OH and H2N-Trp-Trp-OH can be formed.  
To maximize the yield and purity of the desired dipeptide, the N-terminus of one 
amino acid and the C-terminus of the other amino acid must be protected. Protecting 
groups vary according to protocol. In SPPS, the N-terminus is typically protected by 
Fluorenylmethyloxycarbonyl (Fmoc). The advantage of the Fmoc protecting group is 
that it is cleaved under very mild basic conditions (e.g. piperidine), but stable under 
acidic conditions
165
.  
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In SPPS, the C-terminus is protected by a polymeric resin particle. The first polymeric 
support was the Merrifield resin which was developed by Robert Merrifield in 
1963
166
. The Merrifield resin is composed of polystyrene cross-linked with 
chloromethylstyrene and divinylbenzene (<5%) (Figure 2.1)
167
.  
 
 
Figure 2.1: Merrifield Resin 
 
 
Originally the Merrifield resin was considered a permanent protecting group to aid in 
peptide coupling and purification
168
.  However, isolation of peptides from the 
Merrifield resin required vigorous treatment with anhydrous HF which consequently 
caused degradation
169
.  Modern resins such as the Wang resin and 2-chlorotrityl 
chloride resin are modified Merrifield resins. The Wang resin has a p-hydroxybenzyl 
alcohol linker and 2-chlorotrityl chloride resin has a trityl chloride linker ( 
Figure 2.2)
168,170
. The addition of these linkers enhances reactivity and allows 
cleavage with milder reagents such as TFA and H2O
171-172
. 
 
 
Figure 2.2: Modified Merrifield resins 
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In solution peptide synthesis, the C-terminus and the N-terminus can be protected by 
any soluble R group such as Boc or tBu.   
In addition to protecting the termini, many amino acids also have reactive side chain 
groups which need to be protected. Reactive side chain groups can interact with free 
termini or other side chain groups during synthesis
162
. If unprotected, side chain 
groups can negatively influence the yield and purity of a reaction; this is the case for 
histidine and lysine which have reactive amine groups. The guanidinium side chain 
group of arginine is not very reactive and therefore does not need a side chain 
protecting group. However, in the absence of a side chain protecting group, Fmoc-
Arginine-OH exists as an unmanageable paste which complicates peptide coupling 
and yield determination. To overcome this issue, an acid labile side chain protecting 
group such as PMC or the HCl salt of Fmoc-Arg-OH is necessary.  The structure of a 
fully protected arginine amino acid is given in  
Figure 2.3.  
 
 
 
 
Figure 2.3: Structure of a Fmoc-Arg(PMC)-OH (21). The N-terminus is protected by base labile 
Fmoc. The side chain is protected by acid labile 2,2,5,7,8 - pentamethyl - chroman - 6 – sulfonyl 
(PMC). 
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2.1.2 Activation 
 
 
Activation of the C-terminus is energetically necessary to form a peptide bond. The 
activation energy involved in the formation of an amide bond from a carboxylic acid 
and an amine is too high to overcome under normal conditions (Figure 2.4)
173
. To 
overcome such high activation energy and to avoid the formation of ammonium 
carboxylate salts, chemical modification of the carboxylic acid is necessary. 
In order for an amine to nucleophilically attack another compound, the target must be 
electrophilic and contain a good leaving group ‘X’. The hydroxyl group of a 
carboxylic acid is a poor leaving group, as it is electron donating. If ‘X’ were a good 
leaving group and electron withdrawing, it would enhance the electrophilicity of the 
carbonyl by inducing a partial positive charge. Modification of amino acid leaving 
groups is accomplished by the use of coupling agents. 
 
 
 
Figure 2.4: Energy changes in the formation of a peptide bond. The carboxylic acid (RCOOH) has 
a very low free energy. The carboxylic acid derivative (RCOX) has a higher energy, which allows it to 
overcome the high activation energy with greater ease than the carboxylic acid. 
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There are many commercially available coupling agents that are designed to activate 
amino acids. In this research project, N,N'-Dicyclohexylcarbodiimide (DCC), N,N′-
Diisopropylcarbodiimide (DIC), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDCI) and 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HATU) was used to synthesize Arg-Trp containing peptides 
(Figure 2.5). The order of reactivity/efficiency of these coupling agents is: 
DCC≈DIC≈EDCI<HATU162. 
 
 
Figure 2.5: Structures of coupling agents employed in RW peptide synthesis 
In order of reactivity: HATU> PyBOP>EDCI≈DIC≈ DCC 
 
 
The carbodiimide class (DCC, DIC, EDCI) of coupling agents are the standard choice 
for most synthetic chemists due to their mild conditions and affordability.
174
 The 
mechanism for carbodiimide mediated peptide coupling is given in Figure 2.6
175
.  
 
 
 
Figure 2.6: Mechanism of peptide coupling using carbodiimides 
 
 
The difference between DCC, EDCI, and DIC lies in the solubility of its urea by-
product. The by-product of DCC, N,N’-Dicyclohexylurea, is insoluble and 
precipitates from the reaction mixture as the reaction progresses
176
. DCC is not an 
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appropriate coupling agent for SPPS, as it would be very difficult to isolate the N,N´-
dicyclohexylurea from the insoluble resin beads
177
. DCC is typically used in solution 
peptide synthesis, as the insoluble urea can be removed by filtration. However, in 
practice the insoluble urea seems to continuously precipitate out, complicating 
purification and yield determination.  For these reasons, DIC and EDCI were the 
preferred choice of carbodiimides. The DIC urea byproduct, NN’-diisopropylurea, is 
soluble in many organic solvents
162
. The solubility of N,N’-diisopropylurea is 5.2g/L 
in CH2Cl2 compared 1.5g/L for N,N’-dicyclohexylurea
176
. The fishy smelling EDCI 
produces a water soluble urea by-product which can be easily removed by aqueous 
extraction in solution peptide synthesis or removed with successive washes in SPPS. 
The biggest challenges of carbodiimide-mediated peptide coupling are the evolution 
of unreactive by-products and racemisation. The nucleophilic centre of the O-acyl-
isourea intermediate competes with the incoming amino acid for its intramolecular 
acyl residue and forms an unreactive N-acylurea
164
 (Figure 2.7).   The formation of N-
acylurea effectively deactivates the carboxylic acid and makes it unavailable to form a 
peptide bond with the incoming amino acid.  
 
 
Figure 2.7: Formation of unreactive N-acylureas 
 
 
Racemisation of activated amino acids can occur in carbodiimide-mediated peptide 
coupling via formation of a cyclic oxazolone intermediate
176
. The electron-
withdrawing effect of the N-protecting group, Fmoc, extends to the α-carbon and 
promotes abstraction of the hydrogen atom by a base (Figure 2.8)
164
. Proton 
abstraction from the α-carbon yields a resonance stabilized ion. Since racemisation is 
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base catalysed, a sterically hindered base is often used during peptide coupling. The 
tertiary amine, N,N-Diisopropylethylamine (DIPEA) for example, cannot efficiently 
approach the chiral center of the reactive amino acid intermediate and therefore 
hinders racemisation.  
 
 
Figure 2.8: Mechanism of racemisation 
 
 
Both racemization and N-acylurea formation can be minimized by the addition of 
auxiliary nucleophiles such as 1-hydroxybenzotriazole (HOBt). This auxiliary 
nucleophile binds to the electrophilic carbonyl group, reducing the concentration and 
shortening the lifetime of the over activated O-acyl-isourea
164
 (Figure 2.9).  The 
incoming amino acid can then easily pick up the acyl residue without experiencing 
racemisation.  
 
Figure 2.9: Sequestration of O-acyl-isourea by HOBt 
 
 
In 2005, HOBt was reclassified by the United Nations as a desensitized explosive 
under the category UN3880
178
. This made it illegal to ship HOBt by air or sea and 
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made land shipment very expensive. Due to a very limited supply of HOBt available 
in the research group, only a few reactions were carried out with this racemisation 
agent.  Fortunately, in 2009 a non-explosive alternative of HOBt was developed
179
. 
Merck chemicals Ltd. tested this new compound and found that Oxyma Pure was 
similar to HOBt in reactivity, effectiveness and even in its physical properties (Figure 
2.10)
180
.  
 
Figure 2.10: Structure of Oxyma Pure 
 
 
In recent years, uronium based and phosphonium based coupling agents have become 
the preferred tool for carboxyl activation
162
.  In the presence of a tertiary base, PyBOP 
and HATU smoothly convert protected amino acids into active species without 
compromising optical activity
174
.  The phosphonium based agent, PyBOP, produces 
an amino acid OBt ester. The uronium based agent, HATU, produces a more reactive 
OAt ester (Figure 2.11). OAt esters are more reactive than OBt esters owing to the 
lower pKa of HOAt
174
.  HATU is regarded as the most effective coupling agent. 
However due to its cost it is usually only employed for very difficult and unusual 
couplings involving bulky and charged amino acids such as tryptophan and arginine.  
 
Figure 2.11: Active esters of PyBOP and HATU, respectively 
 
 
Once the carboxyl group was activated using the mentioned coupling agents, the 
protected amino acids can be coupled.  
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2.1.3 Coupling 
 
 
Once the amino acids have been protected and activated, coupling can occur.  4-
Dimethylaminopyridine (DMAP) was found to be useful in the enhancement of 
peptide coupling reactions mediated by carbodiimides
181
.  For phosphonium and 
uronium based coupling agents, N,N-Diisopropylethylamine (DIPEA) and N-
Methylmorpholine (NMM) have been recorded to catalysed difficult couplings
174
. 
Due to their non-nucleophilic properties, these tertiary bases are particularly efficient 
in peptide synthesis
176
. In both cases, only a catalytic amount of these bases was 
needed to facilitate peptide coupling. 
 
2.1.4 Deprotection 
 
 
To isolate the desired peptide, bulky protecting groups such as Fmoc, PMC, Boc and 
the resin must be removed. To cleave the N-terminal protecting group, Fmoc, a mild 
base such as 20% piperidine in DMF is used
162
.  
The C-terminus and the side chain protecting groups are removed by treatment with 
TFA
182
. Certain amino acids have been shown to cause problems during TFA 
cleavage.  The indole ring of tryptophan is susceptible to oxidation and alkylation by 
other reactive side chains
183. Arginine’s side chain protecting group, PMC, is 
extremely reactive leading to reattachment or modification of other unprotected side 
chains, such as the O-sulfation of tyrosine, serine or threonine
184
. To reduce 
undesirable side reactions, scavengers such as phenol, water, thioanisole, EDT, 1-
dodecanethiol, TIPS, methanesulfonic acid, indole, DTT and TES are often 
introduced.   
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2.2 Synthesis of Amino Acid Precursors 
 
2.2.1 Synthesis of esters 
 
 
In hopes of aiding membrane insertion, dipeptide esters such as H2N-RW-Octyl ester 
[3] were synthesized. Unlike protein E, which is made inside the bacterial cell, these 
dipeptide analogues need to cross the membrane in order to reach MraY. The addition 
of long ester chains may assist in the localisation of these compounds in the 
membrane. Furthermore, esterification of amino acids provides protection of the C-
terminus during peptide coupling. 
The synthesis of tryptophan methyl ester [17] was accomplished by treatment of L-
tryptophan with freshly distilled TMSCl in MeOH. This produced a pure white solid 
with 90% yield. MeOH’s low boiling point allowed easy isolation of the ester without 
the assistance of distillation or flash chromatography.  
TMSCl was not effective in esterifying carboxylic acids with larger alcohols such as 
1-octanol. To esterify 1g of L-tryptophan with 10mL of 1-octanol (12.6 eq), excess 
H2SO4 was used. After 30 minutes, the reaction reached completion producing 
tryptophan octyl ester [18]. Due to the high boiling point of 194-195°C,
185
 excess 1-
octanol could not be removed in vacuo.  As a result, vacuum distillation and flash 
chromatography was utilized.  
The octyl ester was isolated by vacuum filtration at 116°C with 62% yield. However, 
trace amounts of the alcohol was still present in the ester sample.  Under vacuum, 1-
octanol was expected to be removed at 130°C which is only 14°C above the 
temperature the ester was found. This small difference in boiling point may have led 
to trace amounts of the alcohol being distilled with the ester ( 
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Figure 2.12). 
 
 
Figure 2.12:  Vacuum distillation of 1-octanol and tryptohan octyl ester. Between 116°C-130°C 
trace amounts of 1-octanol was distilled with tryptophan octyl ester. 
 
 
To isolate the ester by flash chromatography, the silica gel was first deactivated using 
5% TEA in EtOAc. This ensured that the free amine of trypothan octyl ester [18] was 
not trapped in the column. 1-octanol was found to have an Rf of 0.7 in 100% EtOAc. 
[18] was sequestered from the deactivated silica baseline by adding MeOH. With an 
86% yield, flash chromatography was the better method to isolate the ester from the 
alcohol. Flash chromatography was quicker and involved less equipment than vacuum 
distillation.  
In the case of glycine octyl ester [19], the Steglich and Hassner method of 
esterification was used 
186,187
. This method involved the treatment of Fmoc-glycine 
with 1-Octanol, EDCI and DMAP/DCM (Figure 2.13). 
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Figure 2.13: Synthesis of glycine octyl ester 
 
 
In the reaction mechanism, the carboxylic acid reacts with EDCI to form Fmoc-
glycyl-O-acyl-isourea. The nucleophilic catalyst DMAP (4-Dimethylaminopyridine) 
is then used to catalyse the Stelgich rearrangement via an acetylpyridium ion 
intermediate
188
 (Figure 2.14). 
 
Figure 2.14: Steglich and Hassner esterification. 
 
 
Using this method, Fmoc-glycine octyl ester was synthesized with 92% yield, in 
comparison to the reported maximum yield of 97% using this methodology
189
. 1-
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Octanol did not cause any conflicts in isolation as only the exact equivalence needed 
was used. The overall yield however, dropped to 60% as a result of deprotection with 
piperidine to form the final product, [19].  
 
2.2.2 Synthesis of N-acyl amino acids 
 
 
Modification of the N-terminus, e.g. octanoyl-glycine [20] and octanoyl-Arg(PMC)-
OH [22], was also desired as an alternative way to localise compounds in the 
membrane. Acylated amino acid precursors were prepared via the Schotten-Baumann 
acylation method
190
. 
The Schotten-Baumann acylation method involved dissolving the amino acid, glycine 
or H2N-Arg(PMC)-OH, in water with 1.6eq of NaHCO3. To this solution, octanoyl 
chloride in THF was added dropwise. The salt, NaHCO3, optimised the reaction by 
ensuring that the amine remained uncharged and deprotonated. This encouraged the 
addition-elimination reaction, pushing the equilibrium towards the formation of 
product (Figure 2.15). Extraction into water followed by acidification caused 
precipitation of the pure products [20] or [22].  
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Figure 2.15: Mechanism of Schotten-Baumann acylation of glycine 
 
[20] and [22] were synthesized with 81% and 67% yields, respectively. These yields 
were likely affected by the final separation step which involved separating a thick oil 
from an aqueous solution.  
2.3 Peptide Coupling 
 
 
Strategic protection of amino acids facilitated the success of peptide couplings. 
Peptides were synthesized in solution and via SPPS.  
 
2.3.1 Solution Peptide Synthesis 
 
 
Solution peptide synthesis was first approached in a similar manner as SPPS. Base 
labile N-protected amino acids were activated using a coupling agent (Figure 2.5) and 
coupled to the free amine of a C-protected amino acid in the presence of a base ( 
Figure 2.16). To isolate the dipeptide ester, the fully protected dipeptide was treated 
with 20% piperidine in DCM.  
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Figure 2.16: Base labile N-protected peptide couplings. Where A= activating agent such as HATU, 
EDCI, DIC, DCC, X=ester 
 
 
This scheme was attempted on 4 different dipeptides, but was only successful in 
coupling H2N-RW-Oct [3] with 46% overall yield. In every case, the fully protected 
dipeptide ester was observed by ESI-MS after two days of stirring. After treatment 
with piperidine, the dipeptide ester was not observed in either the aqueous or organic 
layer. Using a base labile N-protecting group isn’t common in solution peptide 
synthesis and may have caused undesirable side reactions to consume the dipeptide. 
Upon treatment with piperidine, ESI-MS revealed a common mass across all four 
dipeptide reactions, m/z 264.2 [M+H]
+
. This mass corresponded to the fmoc-
piperidine adduct which is released upon Fmoc-deprotection (Figure 2.17)
162
. This 
suggests that fmoc-deprotection by piperidine was successful and further reaction of 
the dipeptide ester must have occurred.   
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Figure 2.17: Mechanism of Fmoc-deprotection 
 
 
It is possible that during work-up the dipeptide ester may have undergone 
spontaneous cyclisation under the presence of a base (Figure 2.18)
164
. Na2CO3(sat) 
may have been too strong of a base for work-up, preventing the dipeptide ester’s 
amine from becoming positively charged. As a result, the amine may have been able 
to intramolecularly attack the ester carbonyl to form a stable 6-membered ring, 2,5-
diketopiperazine.  
 
Figure 2.18: Base-catalysed cyclisation of dipeptide esters to form 2,5-diketopiperazines 
 
 
In diketopiperazines, the amide hydrogen and the carbonyl oxygen are cis to each 
other. The conversion from the more stable trans confirmation to the less stable cis 
confirmation requires energy. The formation of the stable 6-membered ring 2,5-diketo 
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piperazine, provides the necessary driving force to induce this trans/cis 
isomerisation
176
.  This conformational change is further facilitated by the absence of a 
bulky side chain. Therefore, ring closure is particularly pronounced in peptides 
containing glycine
164
. Due to the bulkiness of arginine and tryptophan, conversion 
from the trans to cis confirmation may have required more energy than the 2,5-
diketopiperazine releases. As a result, H2N-RW-Oct [3] was able to escape 
spontaneous cyclisation.  
To avoid this side reaction, the remaining dipeptide esters were synthesized using an 
acid labile N-protecting group, such as Boc. N-acyl dipeptides did not require 
cleavage of the N-protecting group and were treated in a similar manner without TFA 
treatment.  
 
 
Figure 2.19:   Acid-labile N-protected peptide couplings. Where R=Boc for dipeptides esters, or 
Acyl for N-acyl dipeptides, X=ester. When R=Acyl, TFA cleavage is not necessary. 
 
Dipeptides coupled via this route were synthesized in rather low yields ranging from 
20-44% (Table 2.1). These low yields are primarily due to the difficulty of coupling 
arginine and tryptophan which are both very bulky. In addition, side reactions and 
impurities, which are common in peptide couplings, furthered limited the success of 
these reactions.  
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Table 2.1: Dipeptide couplings 
Dipeptides  Amino acid precursors Coupling 
Agent 
% 
yield 
[1] H2N-RW-OMe  
     
Boc-Arg-OH, H2N-Trp-OMe HATU 30 
[2] Octanoyl-RW-
OMe    
Octyl-Arg(PMC)-OH, H2N-Trp-
OMe 
HATU 22 
[3] H2N-RW-Oct Fmoc-Arg(PMC)-OH, H2N-Trp-
Oct 
HATU 42 
[4] H2N-GW-OMe   
   
Boc-Gly-OH, H2N-Trp-OMe HATU 33 
[5] Octanoyl-GW-
OMe    
Octyl-Gly-OH, H2N-Trp-OMe HATU 20 
[6] H2N-GW-Oct    
     
Boc-Gly-OH, H2N-Trp-Oct EDCI 44 
[7] H2N-RG-OH        Fmoc-Arg(PMC)-OH, Fmoc-Gly-
OH 
DIC via 
SPPS 
35 
[8] Octanoyl-RG-OH       Octyl-Arg(PMC)-OH, H2N-Gly-
OtBu 
DCC 40 
[9] H2N-RG-Oct    
      
Boc-Arg-OH, H2N-Trp-Oct EDCI 38 
 
By-products were sometimes observed from side reactions. In the synthesis of 
octanoyl-glycine [20] (Chapter 2.2.2), a small excess of octanoyl chloride formed 
some octanoic anhydride [21] (Figure 2.20). Due to similarities in chemical shift, this 
side product went undetected by 
1
H-NMR.  
 
Figure 2.20: Synthesis of octanoic ahydride. Addition-elimination reaction of octanoyl chloride and 
octanoic acid. Octanoic acid originates from the reaction of octanoyl chloride with water.   
 
 
Upon reaction of the octanoyl-glycine/octanoic anhydride mixture with H2N-Trp-
OMe [17], two different products formed. The two products were isolated and 
purified by flash chromatography. ESI-MS identified the major species to have an m/z 
of 343.2 [M+H]
+
 and the minor species to have an m/z of 401.2[M+H]
+
 - a difference 
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of 58 Da. 
1
H-NMR revealed that the major species was missing one of its α-protons. 
NMR and mass spectroscopy data revealed that Octanoyl-Trp-OMe [23] was the 
major product and Octanoyl-GW-OMe [5] was the minor product.  
[23] resulted from the reaction of [21] with [17]. The free amine of H2N-Trp-OMe 
[17] nucleophilically attacked the anhydride [21] to form the shorter peptide product 
and caprylic acid (common name for octanoic acid) (Figure 2.21). This product lacked 
C2H3NO which has a molar mass of 57 Da. Octanoic anhydride [21] is expected to be 
more reactive than octanoyl-glycine [20],
191
 which is why this shorter peptide was the 
major species. It is clear from this example, that it is vital to properly characterize and 
purify all intermediates in multi-step reactions.  
 
Figure 2.21: Reaction of octanoic anhydride with H2N-Trp-OMe 
 
 
Another peculiar reaction involved the synthesis of H2N-RW-OMe [1] using an acid 
labile N-protecting group. Boc-Arg-OH was treated with HATU in minimum dried 
DCM. L-tryptophan methyl ester hydrochloride was added to the stirred solution and 
cooled to 0°C. TEA was added and the reaction was stirred for 3 days. After work-up, 
the organic layer was dried with MgSO4 and concentrated in vacuo. In order to 
characterize the compound by ESI-MS, MeOH was added. The addition of MeOH 
caused a white precipitate to form. ESI-MS identified the liquid to be the desired 
intermediate, Boc-RW-OMe [24]. The precipitate was insoluble in most solvents with 
the exception of acetone, where it was partially soluble. With permission from the 
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NMR technicians at the University of Warwick, an NMR experiment was conducted 
on the partially soluble product. 
1
H-NMR produced a spectrum that was interpreted as 
Boc-RW-OH [25]. It is possible that ester linkage of [24] may have partially 
hydrolysed during acid extraction to form Boc-RW-OH•HCl. Boc-RW-OH•HCl may 
have then formed an insoluble quaternary ammonium salt with TEA via a process 
called quaternisation
192
. The formation of this insoluble product caused a dramatic 
loss in the yield of [24]. [24] was then treated with 7:3 TFA/DCM to isolate the 
desired product, [1].     
Carbodiimides such as DCC or DIC generally gave very low yields for Arg-Trp 
dipeptide couplings, indicating that they are sensitive to steric hindrance. In practice 
they were only able to tolerate one bulky amino acid per coupling, not two. As a 
result, Octanoyl-RG-OH [8], H2N-RG-Oct [9] and H2N-GW-Oct [6] were the only 
compounds synthesised using carbodiimides (Table 2.1). The remaining bulky amino 
acids required treatment with more reactive coupling agents such as HATU.  
Racemisation did not occur when 1-2eq of Oxyma pure or HOBt was used in 
carbodiimide couplings, as judged by 
1
H-NMR. As expected, HATU couplings did 
not experience racemisation.  
In conclusion, due to the difficulties of coupling Arg- and Trp- amino acid 
derivatives, solution peptide synthesis was not the optimal method for the synthesis of 
most of the desired dipeptides. Side reactions and impurities significantly affected the 
yield of these dipeptide derivatives. These reactions were not optimised, as only a 
small amount of product was needed for biological testing.   
The remaining peptides were synthesised via manual SPPS, which proved to be the 
more reliable and superior coupling procedure. 
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2.3.2 Solid Phase Peptide Synthesis 
 
 
Lytic E RWXXW peptide analogues were synthesized on a fritted-filtered reaction 
vessel using a standard Fmoc SPPS procedure
162
 (Figure 2.22).  
 
 
Figure 2.22: Scheme for SPPS 
 
 
Similar to solution peptide synthesis, SPPS requires activation of the C-terminus to 
assist in peptide couplings. In a dried RBF Fmoc-protected amino acids (2-4eq) were 
dissolved in minimum dried DMF/DCM.  Following the addition of a coupling agent 
(2-4eq) and a catalytic base such as DMAP or DIPEA (1-2.5eq), the mixture was 
immediately added to 1eq. of swollen resin and agitated gently with N2 gas for 1-2 
days. To cap any remaining unloaded resin beads, anhydrous MeOH was later added 
to the resin and agitated under N2 gas for 1 hour.  
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Upon several washes with dried DMF and DCM, Fmoc-protecting groups were 
removed by treatment with 20-30% piperidine in DMF for 2 hours. Following another 
series of washes, activated amino acids were added to the loaded resin in a similar 
manner to the first step. 
Total isolation of dipeptides involved Fmoc-deprotection followed by treatment with 
TFA/H2O. Loaded resins were dried under vacuum for 30 minutes and transferred to a 
dried RBF in preparation for resin cleavage. The dried resin was treated with 
19:1/TFA:H2O (1mL per 100mg of loaded resin), flushed with N2 gas, and stirred 
gently overnight. The resin was removed by filtration under reduced pressure using a 
sintered glass funnel. The resin was washed twice with neat TFA to assist in the 
removal of any loosely bound peptide product. Filtrates were combined and TFA was 
evaporated using a CO2/acetone rotary evaporator.  Cold ether was used to precipitate 
the oligopeptides. The product was isolated and dried further with a high vacuum 
pump. The dried product was then dissolved in water and lyophilized overnight.  
Due to its affordability and mild treatment conditions, Wang resin is the standard 
resin used in Fmoc chemistry for C-terminus acids.
193
 H2N-RG-OH [7] was 
synthesised on the Wang resin using 4 eq. DIC, 4 eq. Oxyma Pure and 1 eq. DMAP in 
minimum dried DMF. This product was purified via HPLC with 25% yield relative to 
resin loading (Table 2.1). A range of different coupling agents, solvents and reaction 
times were explored in the hopes of synthesising H2N-GW-OMe [5] and H2N-RW-
OMe [1], but none of these products could be synthesised using the Wang resin.  
One common experimental error in manual SPPS is insufficient swelling time. The 
nucleophilic linkers of resins are located in small cavities inside the resin beads. 
Peptide coupling takes place inside these cavities and not on the surface of the 
resin
194
. If the resin is not properly swelled with DCM these cavities remain very tight 
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and narrow, preventing amino acids from entering.
195
 With swelling times over 1.5 
hours, triple the recommended time
162
, it is unlikely that the resin was not properly 
swelled. Other factors such as steric hindrance, lack of fluidity and poor reactivity are 
the most probable reasons for experimental failure.  
Attachment of the first amino acid is the most critical step in SPPS. This step involves 
a nucleophilic attack on the carbonyl of a protected and activated amino acid by the 
Wang resin’s linker (Figure 2.23). The activating group and the side chain protecting 
group of Fmoc-Trp(Boc)-O-acyl-isourea sterically hinders the carbonyl. Typically, 
this can be compensated by solvent fluidity which increases the probability of contact 
between two chemical species. However, in manual SPPS the nucleophile is 
stationary and only minimal stirring can be achieved via N2 gas. Steric hindrance as 
well as the weak reactivity of an SN
2
 reaction severely limited the attachment of the 
first amino acid. As a result, only Fmoc-glycine-O-acyl-isourea was able to 
successfully attach to the Wang resin and produce H2N-RG-OH [7].   
 
 
Figure 2.23:  Attachment of first amino acid to the Wang resin. Nucleophilic attack on the carbonyl 
of Fmoc-Trp(Boc)-O-acyl-isourea. 
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To determine the level of attachment, a spectrophotometer was utilized. Using 20% 
piperidine/DMF as a blank, this experiment measured the loss of piperidine during 
deprotection to form the Fmoc-piperidine adduct (Figure 2.17). Amino acid loading 
was determined using Equation 2.1. This value was then compared to the actual resin 
loading determined by the manufacturer, Merck Novabiochem. The final yield for 
H2N-RG-OH [7] was calculated relative to the resin loading determined from the 
spectrophotometer.  
Equation 2.1 
Loading (mmol/g) = (Abs290nm)/(mg of sample x 1.75)*  
* = Based on a molar absorptivity (ε) = 5253M-1cm-1  
 
Given the problems experienced with the Wang resin, alternative resins were 
investigated to synthesise the remaining peptides. 2-Chlorotrityl chloride resin was 
found to be an effective alternative to the Wang resin using the same SPPS procedure 
(Figure 2.22)
168
. Although more expensive than the Wang resin, this resin only 
required 2 eq. of Fmoc-amino acid compared to the 4 eq. needed by the Wang resin. 
The advantage of using 2-chlorotrityl resin over the standard Wang resin lies in its 
ability to attack a free carboxylic acid in an SN
1
 fashion (Figure 2.24). As a result, 
activation of the first incoming amino acid is not necessary allowing attachment of 
bulkier amino acids such as Fmoc-Trp(boc)-OH.  
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Figure 2.24: Attachment of the first amino acid to 2-chlorotrityl chloride resin 
 
 
Using 2-chlorotrityl chloride resin RWGLW [10], RGGLW [11], GWGLW [12], 
RWGGW [13], RWGLG [14], EHWGGG [15] and ERWGGW [16] were 
successfully prepared in yields ranging from 24%-87% on a 6.1x10
-4
 mol scale (Table 
2.2).  Pentapeptides and hexapeptides were primarily synthesised using 2 eq. of 
HATU as the coupling agent. DIC (2 eq) and Oxyma pure (2 eq) was used when 
coupling consecutive glycines in compounds such as RGGLW [11], EHWGGG [15], 
ERWGGW [16] and RWGGW [13]. Using DIC at these specific steps lowered the 
overall cost of SPPS.  
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Table 2.2: Pentapeptide and hexapeptide couplings using 2-Chlorotrityl chloride resin 
Peptides  Coupling Agent(s) Coupling time 
(days) 
% yield Cleavage 
(hrs) 
[10] RWGLW HATU 8  87 24 
[11] RGGLW DIC/HATU 7  24 6 
[12] GWGLW HATU 7  50 12 
[13] RWGGW DIC/HATU 8  28 6 
[14] RWGLG HATU 7  36 6 
[15] EHWGGG DIC/HATU 9 75 18 
[16] ERWGGW DIC/HATU 10 69 18 
 
 
Coupling times varied based on the number of adjacent bulky amino acids. Peptide 
couplings which involved two bulky amino acids such as Arg-Trp required two days 
of coupling. Peptide couplings which involved only one bulky amino acid such as 
Gly-Trp required only one day of coupling.   
The use of a fritted-filtered reaction vessel also greatly affected the coupling time and 
success of peptide couplings. This reaction vessel hindered peptide couplings as it 
was unable to control reaction conditions and allowed moisture to collect. Unlike 
automated systems, which have short reaction times (<5min) and can regulate the 
temperature, partial pressure and other factors according to the type of coupling,
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this reaction vessel only allowed couplings at room temperature and at atmospheric 
pressure, which resulted in multi-day experiments. 
 
Figure 2.25: Manual SPPS fritted-filtered reaction vessel. 
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The yields of these compounds were heavily affected by TFA cleavage time. 
Compounds cleaved over 24 hours were isolated with yields between 87%-96% 
(Table 2.2). Compounds cleaved within 6 hours resulted in poor yields. To isolate any 
remaining bound peptides, resins were re-cleaved for an additional 18 hours.  
TFA/H2O was removed by a CO2/acetone rotary evaporator followed by precipitation 
with cold ether. Unfortunately, the blue precipitate was insoluble and therefore could 
not be analysed by ESI-MS or NMR. It appeared that storage of loaded resins 
followed by re-cleavage may have caused degradation of the resin and/or peptide.  
The use of scavengers such as phenol, water, thioanisole and EDT did not greatly 
affect the yield or purity of peptides upon TFA cleavage. These TFA cocktails had to 
be prepared anew before each use
162
. The lengthy preparation of these cocktails was 
found to be an unfavourable use of time, given that the yield or purity was not 
enhanced by its use. 19:1/TFA:water was found to be a simple and suitable TFA 
cocktail.  This cocktail was effective at isolating the peptides whilst scavenging Boc, 
iBu and PMC/Pbf.
197
  
 
2.4 HPLC Purification 
 
 
Purification of the RWXXW analogues via HPLC was accomplished in the three 
steps: (I) optimisation of the gradient, (II) collection of the desired peak and (III) 
analysis by HPLC and high resolution ESI-MS.  
An Agilent Technologies series 6130 Quadrupole LC/MS instrument equipped with a 
C18 reverse phase column was initially used to determine the %B at which the desired 
peptide elutes. This employed a binary mixture of eluents A (H2O with 0.1%TFA) 
and B (MeOH with 0.1%TFA) and a standard linear gradient of 5% to 100%B in 60 
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minutes at a flow rate of 1 mL/min. By identifying the %B the peptide eluted at, the 
gradient was able to be optimised before purification on a preparative HPLC.  
Purification was conducted on an Agilent Technologies series 1200 Preparative HPLC 
instrument equipped with an Agilent Xorbax XDB-C18 preparative column (P/No: 
970150-902, size: 21.2x150mm 5micron). Depending on the tryptophan content, 
compounds were monitored at either 220nm or 280nm for compounds with multiple 
tryptophan residues. In the case of H2N-GW-Oct [6] (Figure 2.26), the product was 
found to have a retention time of 12.2 minutes using a linear gradient of 50%-100%B 
over 20 minutes at 220nm. 
 
Figure 2.26: Preparative HPLC chromatograph of H2N-GW-Oct [6] 
 
 
To ensure purification was successful, the purified compound was re-injected to the 
preparative HPLC column using the same gradient but at a wavelength of 210nm. If 
the chromatograph contained multiple peaks, isolation of the desired peak was 
repeated. The chromatograph of the pure H2N-GW-Oct [6] is given in Figure 2.27. 
The compound was found to be pure (>98%) with the exception of a small amount of 
simple salts which commonly elute instantly. A slight change in the retention time 
was also observed and may have resulted from the presence of an air bubble in the 
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column. 
1
H-NMR, 
13
C-NMR, and high resolution mass spectroscopy was also used to 
confirm purity. 
 
Figure 2.27: Re-injection of pure H2N-GW-Oct to a preparative HPLC column at 210nm. 
 
 
2.5 Conclusion 
 
 
Synthesis of the desired Arg-Trp containing peptides was found to be more difficult 
than anticipated. Both Arg and Trp are relatively bulky amino acids, which meant 
there were relatively difficult peptides to synthesise
198
.  
In solution peptide synthesis, many side reactions occurred which limited the yield 
and purity of reactions. When using a base labile N-protecting group, spontaneous 
cyclisation of dipeptides esters often occurred upon work-up. The cyclised products, 
2,5-diketopiperazines, were not readily observed by ESI-MS and could not be 
identified with confidence by 
1
H-NMR.  However, identification of the Fmoc-
piperidine adduct by ESI-MS suggested that Fmoc-deprotection was successful and 
that further reaction of the dipeptide ester must have occurred.  
In the synthesis of amino acid precursors it was very important to use precise amounts 
of reagents. Excess acyl chloride led to the production of anhydrides which are more 
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reactive than N-acyl amino acids. As a result, a shorter peptide product evolved upon 
treatment with a C-protected amino acid. It is clear from this example, that it is vital 
to properly characterize and purify all intermediates in multi-step reactions.  
The acid labile Boc N-protected group was the most reliable protecting group in 
solution peptide synthesis. This allowed all protecting groups to be removed 
simultaneously via acid treatment. However, poor yields were still reported using this 
route which led to adaptation of SPPS.  
SPPS proved to be the superior method for the synthesis of bulky amino acids. The 
standard Wang resin was found to only accept small, unhindered amino acid for the 
initial attachment. 2-Chlorotrityl chloride resin was able to tolerate the attachment of 
bulky amino acids. This was facilitated by the more reactive SN
1
 reaction involved in 
the attachment of the first amino acid. 
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Chapter 3:   In vitro Assays for MraY Activity 
 
 
3.1 Fluorescence Enhancement Assay  
 
 
A major goal of this project was to examine and characterise the inhibition of MraY 
by synthetic analogues of protein E which contain the RWXXW motif. In 1977, 
Weppner and Neuhaus reported that S. aureus MraY could accept substrate analogues 
with a fluorescent tag
199-200
. Certain fluorescent reporters such as dansyl chloride and 
fluorescein have been previously shown to exhibit polarity-dependent fluorescence 
which is especially pronounced upon entry into the membrane
201
. Utilising this 
polarity-dependent fluorescence, Weppner and Neuhaus were able to monitor the 
MraY reaction.  
To generate the fluorescently tagged substrate, Weppner and Neuhaus treated 0.5μmol 
UDP-MurNAc-pentapeptide with 21μmol of 5-(dimethylamino)naphthalene-1-
sulfonyl chloride (dansyl chloride) in 50% acetone and 0.25M NaHCO3
199
. This led to 
the attachment of a dansyl functional group to the ε-amino of L-Lys or m-DAP of 
UDP-MurNAc-pentapeptide (Figure 3.1). 
 
Figure 3.1: MraY catalysed reaction of UDP-MurNAc-(N
ε
-Dns)pentapeptide with C55-P to form 
dansyl-Lipid I 
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In the presence of UDP-MurNAc-(N
ε
-Dns)pentapeptide Weppner and Neuhaus 
observed a 30nm blue shift in the fluorescence emission spectrum of the MraY 
reaction
199
. This shift corresponded to the incorporation of the dansyl moiety into the 
hydrophobic membrane to form dansyl-lipid I (Figure 3.1). Phospho-MurNAc-(N
ε
-
Dns)pentapeptide, which is not a substrate for MraY, could not be incorporated in the 
membrane and therefore a shift in fluorescence was not observed
199
.   
Incorporation of the fluorescently tagged substrate into the membrane as dansyl-lipid 
I was confirmed by quenching studies which utilised nitroxyl stearate derivatives. 
Nitroxyl stearates are known to partition the fluid hydrocarbon region of the 
membrane
202
. Using various nitroxyl stearate derivatives which differ with respect to 
the depth of the nitroxide in the membrane, Weppner and Neuhaus demonstrated that 
dansyl-lipid I was embedded near the membrane surface
200
.   
Based on the work of Weppner and Neuhaus, Brandish (1995) developed a rapid 
continuous assay methodology
111-72
 which has recently been used for inhibitor 
screening by PhD candidate Agnes Mihalyi (unpublished, 2013). This assay was used 
to test the inhibitory activity of synthetic RWXXW analogues against membrane 
bound MraY. 
 
3.1.1 Isolation of membranes containing overexpressed MraY enzymes 
 
Previous studies on the inhibition of MraY by Epep were carried out using 
membranes containing overexpressed E. coli MraY. It was also of interest to assay 
against MraY enzymes from other bacterial strains in which residue Phe288 is not 
conserved. Protein E is known to not be active against B. subtilis MraY
64
, which lacks 
Phe288, so this enzyme was of interest as a negative control. Antimicrobial peptides 
containing Arg-Trp are known to be active against P. aeruginosa and S. aureus, 
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which lack Phe288 but contain Phe residues nearby in transmembrane helix 9 (Bugg, 
unpublished).  
In this research project, MraY was used to determine the inhibitory activity of 
RWXXW analogues. These various strains of MraY were of interest due to the 
presence and/or location of aromatic residue Phe288 (Table 3.1), which was 
previously shown to cause resistance to protein E in E. coli (Chapter 1.6).  
 
Table 3.1: Alignment of various strains of MraY relative to Phe288 of E. coli MraY 
MraY strains Sequence 
E. coli AVLLRQEFLLVIMGGVFVVE 
P. aeruginosa AVIVRQEIVLFIMGGVFVME 
S. aureus SIMLNQELSLIFIGLVFVIE 
B. subtilis AILTKLEILLVIIGGVFVIE 
M. flavus AIFTRTEILVAVLAGLMVAI 
 
 
In P. aeruginosa MraY, a Phe residue is present at position 291, 0.83 turns down the 
helix with respect to E. coli MraY (Figure 3.2). In S. aureus MraY, a Phe residue is 
present at position 292, 1.1 turns down the helix with respect to E. coli MraY. In B 
subtilis and M. flavus MraY, there are no aromatic residues in this region. Across 
these five strains of MraY, E. coli residue Glu287 is conserved. Using these various 
membranes, it will be possible to speculate on the importance and the flexibility in the 
interactions between protein E and E. coli MraY relative to residues Phe288 and 
Glu287. 
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Figure 3.2: Predicted secondary structure of MraY helix 9 relative to E. coli Phe288.  
 
 
Mihalyi overexpressed E. coli and P. aeruginosa membrane-bound MraY from a 
pJfy3c vector in E. coli DH5α cells.  Strep-tagged B. subtilis and S. aureus MraY was 
cloned by MOAC project student Amy O’Reilly on to a pET52b plasmid and 
overexpressed in E. coli C43 cells. These overexpressed membrane bound MraY’s 
were used in this project in the fluorescence assays.  Although the membranes will 
contain some endogenous E. coli MraY, the abundance of the WT enzyme is very low 
and control assay using the corresponding empty vector showed >40 fold reduced 
activity in each case.  
The total protein concentration of overexpressed membranes was determined using 
the Bradford assay. The total protein concentration of membranes is given in Table 
3.2. These values correspond to the total protein concentration which includes 
overexpressed MraY and endogenous membrane proteins. 
 
Table 3.2: Total protein concentrations in MraY membranes 
 mg/mL 
E. coli MraY 7.3 
P. aeruginosa MraY 1.3 
B. subtilis MraY 11 
S. aureus MraY 3.3 
M. flavus MraY 3.3 
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The fluorescent MraY substrate UDP-MurNAc-(N
ε
-Dns)pentapeptide was provided 
by Mihalyi who utilised methods from Lugtenberg et al, Fluoret et al and Weppner 
Neuhas
92,203,204
. 
Lipid carriers, C55-P and C35-P were purchased from Laroden AB.  Heptaprenyl 
phosphate (C35-P), a simple isoprenoid composed of 35 carbon units was reported to 
produce similar results in vitro as C55-P (Mihalyi, unpublished 2013). As a result, C35-
P was frequently used in this research project. 
 
3.2 Plate reader assay 
 
 
A Tecan GENios plate reader was used to determine the inhibitory activity of 
synthetic RWXXW analogues. To a 96 well plate, 10μL of overexpressed MraY 
membranes was added to 85μL of master mix and 5μL of the inhibitor (final 
concentration 100μg/mL). The master mix contained 21.μM UDP-MurNAc-(Nε-
Dns)pentapeptide and 47.2 μM of C55-P or 70.6 μM of C35-P in a buffer solution 
containing 100mM Tris base, pH 7.5 and 25mM MgCl2. The final protein 
concentrations in E. coli and P. aeruginosa MraY membranes were 0.7 mg/mL and 
0.13 mg/mL, respectively. The MraY catalysed reaction was monitored at an 
excitation wavelength of 340nm and an emission wavelength of 535nm. 
The production of dansyl-lipid I corresponded to an increase in fluorescence which 
was measured at 5 minute intervals in quadruplicates (Figure 3.3).  MeOH was used 
as the negative control.  Tunicamycin and Epep, at a final concentration of 100μg/mL, 
were used as the positive controls. Over time, compounds that did not inhibit the 
production of dansyl-lipid I were expected to cause an increase in fluorescence and 
behave similar to the negative control. Compounds that did inhibit the production of 
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dansyl-lipid I were expected to behave similar to the positive controls and retain a 
relatively constant fluorescence emission spectrum.  
 
Figure 3.3: Fluorescence emission of the E. coli MraY reaction in the presence of control 
inhibitors at 100μg/mL. Fluorescence units (FUs) was recorded before the addition of membrane 
bound MraY (t=0) and within 5 minutes and 10 minutes of its addition.  
 
 
Figure 3.4 shows the fluorescence emission spectrum of the E. coli MraY reaction in 
the presence of Arg-Trp dipeptide analogues at concentration 100μg/mL. The MraY 
reaction seemed to be inhibited by H2N-GW-Oct [6], indicative by a lower 
fluorescence emission after 10 minutes in comparison to the negative control. A few 
other inhibitors reduced the fluorescence emission of the MraY reaction (RW-OMe 
[1], GW-OMe [4], H2N-RG-OH [7]), but only 5-10% inhibition was observed at a 
concentration of 100μg/mL.  
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Figure 3.4: Fluorescence emission of E. coli MraY upon treatment with RWXXW dipeptide 
analogues at 100μg/mL. Fluorescence units (FUs) was recorded before the addition of membrane 
bound MraY (t=0) and within 5 minutes and 10 minutes of its addition. 
 
 
The inhibitory activity of these Arg-Trp dipeptide analogues were tested against P. 
aeruginosa MraY (Figure 3.5). Epep did not inhibit the reaction of P. aeruginosa 
MraY, apparent by an increase in the fluorescence emission of the MraY reaction. In 
this assay, H2N-GW-Oct [6], H2N-RG-OH [7] and Octyl-RG-OH [8] were found to 
limit the production of dansyl-lipid I by inhibiting P. aeruginosa MraY. 
It’s interesting that in both organisms, H2N-GW-Oct [6] was able to affect the 
production of dansyl-lipid I. Dipeptide H2N-RG-OH [7] was found to also inhibit P. 
aeruginosa MraY and E. coli MraY (though not extensively).  
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Figure 3.5: Fluorescence emission of P. aeruginosa MraY upon treatment with RWXXW 
dipeptide analogues at 250μg/mL. Fluorescence units (FUs) was recorded before the addition of 
membrane bound MraY (t=0) and within 5 minutes and 10 minutes of its addition. 
 
 
A few problems arose from this plate reader assay. The Tecan GENios plate reader 
measured the fluorescence of each well with respect to the entire row or column. If 
any particular compound had some intrinsic fluorescence it overshadowed the 
changes in fluorescence of other compounds. As a result, the assay was not as 
sensitive as anticipated. This is evident from the fluorescence measurements of Octyl-
RW-OMe [2] at time 0, before the addition of membrane bound MraY. At time 0, 
compound [2] had a higher fluorescence than the negative control (Figure 3.4; Figure 
3.5). The addition of membrane bound MraY to [2], led to a large increase in 
fluorescence over time. This large increase in fluorescence may have obscured the 
fluorescence effects from other compounds. As a result, it is difficult to conclude with 
confidence the inhibitory activities of these compounds via this method.  
In addition, this assay was only able to take fluorescence measurements at specific 
time intervals. It is possible that major and important changes in fluorescence may 
have occurred in the first 30seconds-1minute. If so, it would be necessary to take 
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various measurements within this time frame to obtain conclusive data. To overcome 
these issues it would be beneficial to use a continuous assay that can accurately and 
with sensitivity monitor the MraY reaction. A continuous assay would provide more 
conclusive information on the inhibitory activity of individual compounds relative to 
the controls. In addition, kinetic information such as the IC50 values can be 
determined.  
 
3.3 Continuous Fluorescence Assay for MraY Activity 
 
 
The continuous fluorescence assay developed by Brandish (1995) and later optimised 
by Mihalyi (2013) was the preferred method for the in vitro studies of protein E 
analogues against membrane-bound MraY. The MraY catalysed reaction was 
monitored by a Perkin Elmer fluorimeter at an excitation wavelength of 340nm and an 
emission wavelength of 530nm. To a Starna
®
 sub-micro fluorimeter cell, 15μL of 
membrane bound MraY was added to 150μL of master mix and 15μL of inhibitor. 
The master mix contained 21.μM UDP-MurNAc-(Nε-Dns)pentapeptide and 47.2 μM 
of C55-P or 70.6 μM of C35-P in a buffer solution containing 100mM Tris base, pH 7.5 
and 25mM MgCl2. The final protein concentrations of membranes containing 
overexpressed E. coli, P. aeruginosa, S. aureus, M. flavus and B. subtilis MraY in this 
continuous assay were 0.6, 0.1, 0.28, 0.3, 0.3 and 0.9 mg/mL, respectively.  
The continuous fluorescence assay revealed a rapid increase in fluorescence within 
the first two minutes of the MraY reaction, after which the assay was slightly non-
linear, as found by Brandish (1995). This is presumably due to the reaction reaching 
equilibrium (Figure 3.6). MeOH was used as the negative control in E. coli, B. 
subtilis, S. aureus and M. flavus MraY. Water was used as the negative control in the 
reactions of P. aeruginosa MraY, as MeOH enhanced the fluorescence of the P. 
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aeruginosa MraY reaction and generated false readings.  Tunicamycin, at a final 
concentration of 83μg/mL, was used as the positive control in all MraY strains. The 
addition of tunicamycin inhibited the production of dansyl-lipid I and as a result the 
fluorescence remained constant (Figure 3.6).  
 
 
Figure 3.6: The E. coli MraY reaction monitored via a continuous fluorescence assay 
 
 
3.3.1 Inhibition of E. coli MraY by Epep 
 
 
This continuous assay showed that Epep (83μg/mL) prohibited the production of 
dansyl-lipid I by inhibiting E. coli MraY. As expected, Epep did not inhibit B. 
subtilis, S. aureus, M. flavus or P. aeruginosa MraY. Three different concentrations of 
Epep were tested in order to determine the concentration necessary to inhibit the 
activity of E. coli MraY by half (IC50). As expected, an increase in fluorescence was 
observed in more dilute samples of Epep (Figure 3.7).  
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Figure 3.7: Inhibition of E. coli MraY by Epep 
 
 
3.3.2 IC50 determination 
 
 
Given that the greatest change in fluorescence occurred within the first 2 minutes, this 
region was further analysed to determine the IC50 value of each inhibitor.  The Perkin 
Elmer fluorimeter recorded the fluorescence of the MraY reaction every 0.1 seconds, 
allowing thorough analysis of the enzymatic reaction. In addition to qualitative 
duplicate measurements, these continuous measurements was treated as pseudo-
repetition and provided a method to calculate error. 
Utilising the software GenStat for Teaching and Learning, a linear regression was 
fitted to the first 500 data points. The slope of each line was then related to the percent 
activity of MraY in relation to the negative control; the negative control set to 
correspond to 100% enzyme activity. The percent activity of MraY was then plotted 
against the concentration of the inhibitor to produce an IC50 graph (Figure 3.8). With 
assistance from the Quantitative Biology Centre (QuBic), GenStat was programmed 
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to fit a smoothing spline function through the data points. This spline identified the 
concentration of the inhibitor which reduced the enzyme activity by 50%, IC50.  
To calculate error, GenStat factors in the standard error associated with each data 
point (determined from the linear regression) as well as the distance between the data 
points and the smoothing spline. An IC50 value of 30+/-3.5μg/mL was observed for 
Epep against E. coli MraY (Figure 3.8).  
 
Figure 3.8: IC50 of Epep against E. coli MraY 
 
The IC50 values of Arg-Trp dipeptide and peptapeptide analogues are given in Table 
3.3. From these values the continuous assay was found to contain between 5%-20% 
error. These IC50 values will be discussed in further detail in subsequent sections. 
 
Table 3.3: IC50 values of RWXXW against MraY 
μg/mL E. coli P. aeruginosa S. aureus M. flavus B. subtilis 
Epep 30 +/- 3.5 X X X X 
  [6] GW-Oct  294 +/-61 135 +/- 19 661 +/- 70 184 +/- 25 58 +/- 5.7 
  [4] GW-OMe X X X X 638 +/- 63 
[10] RWGLW 425 +/- 85 X 226 +/- 53 X 679 +/- 84 
[11] RGGLW 128 +/- 26 X X X 192 +/- 27 
[15]EHWGGG 298 +/- 17 218 +/- 23 281 +/- 26 112 +/- 11 X 
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3.3.3 Inhibition of MraY by Arg-Trp dipeptide analogues 
 
 
According to the fluorescence emission spectrum of dansyl-UDP-MurNAc 
pentapeptide, H2N-GW-Oct [6]  inhibited the production of dansyl lipid I in E. coli, B. 
subtilis, P. aeruginosa, S. aureus and M. flavus (Appendix 1.1-1.5). The IC50 value of 
this compound varied across MraY bacterial strains. Compound [6] was an especially 
strong inhibitor of B. subtilis, P. aeruginosa and M. flavus MraY with IC50 values of 
58.0, 135 and 184μg/mL, respectively (Table 3.3). A higher IC50 value of 294 and 
661μg/mL was observed against E. coli MraY and S. aureus MraY, respectively. 
Compound [6] may have participated in a π-π stacking interaction with a Phe residue 
in helix 9 of MraY. However, if this is the interaction responsible for inhibition, it is 
surprising that H2N-GW-Oct [6] inhibited M. flavus MraY which lacks aromatic 
residues in helix 9 (Table 3.1; Figure 3.2).  
Given the simplicity and similarity of compound [6] to the long hydrocarbon chains in 
household soaps, e.g. sodium octadecanoate (C17H35COONa), it could be possible that 
[6] is actually preventing the production of dansyl-lipid I by disturbing the membrane 
and forming micelles
205
. To rule out this possibility, analogues and intermediates of 
compound [6] were tested for in vitro activity against MraY via the continuous 
fluorescence assay. Intermediates H2N-Trp-octyl ester [18], H2N-Gly-octyl ester [19] 
and dipeptide ester H2N-RG-Oct [9]  were all tested for in vitro activity against E. 
coli, B. subtilis, P. aeruginosa  and M. flavus MraY, however none of these 
compounds were active inhibitors of these enzymes. Analogue H2N-GW-OMe [4] 
which contains a methyl ester hydrocarbon instead of an octyl ester hydrocarbon 
chain was unable to inhibit E. coli, P. aeruginosa, S. aureus and M. flavus MraY. 
Compound [4] did inhibit B. subtilis MraY but at a substantially high concentration, 
IC50 = 638μg/mL (Table 3.3, Appendix 1.6). Presumably, the octyl ester hydrocarbon 
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chain is important for localisation of the dipeptide in the membrane
206
. Interestingly, 
the location of the hydrocarbon chain appears to be important for the inhibition of 
MraY. None of the compounds which contain an N-octyl hydrocarbon chain was 
found to inhibit MraY.  
From these examples it is clear that the exact sequence of H2N-GW-Oct [6] is 
important for its inhibitory properties. In addition this compound was found to also 
have antibacterial activity against several strains of bacteria (Chapter 5).   
 
3.3.4 Inhibition of MraY by RWXXW pentapeptides 
 
 
Of the five synthetic peptides, three (GWGLW [12], RWGGW [13], RWGLG [14]) 
were found to show intrinsic fluorescence which interfered with the continuous 
fluorescence assay.  
RWGLW [10], which has the most sequence similarity to protein E at the predicted 
site of interaction (RWGTW), was found to have an IC50 value of 425μg/mL against 
E. coli MraY (Appendix 1.7), 226μg/mL against S. aureus MraY (Appendix 1.8) and 
679μg/mL against B. subtilis MraY (Appendix 1.9).  
Removal of the first tryptophan to form RGGLW [11] enhanced inhibition against E. 
coli and B. subtilis MraY (IC50 = 128 and 192μg/mL, respectively; Appendix 1.10-
1.11). Comparing the inhibitory activity of these two pentapeptides, it is possible that 
at certain orientations the first tryptophan residue hinders membrane insertion or 
association and therefore a higher concentration of RWGLW [10] is necessary to 
inhibit MraY. To circumvent this issue, Pro21 and Pro29 in native protein E may 
assist in kinking the helix to a position where the first tryptophan residue (Trp-4) does 
not interfere with cytoplasmic membrane insertion or association
146-147
. 
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These results suggest that the C-terminal tryptophan (Trp-7) may be more important 
than the tryptophan near the N-terminus (Trp-4), which is in agreement with reports 
from Tanaka and Clemons
133
. To confirm the importance of Trp-7, Mihalyi tested the 
inhibition of MraY by GWGLW [12], RWGGW [13] and RWGLG [14] using a 
radiochemical assay. The results of Mihalyi’s radiochemical assay will be discussed 
in section 3.4. 
 
3.3.5 Inhibition of MraY by α3-like and G4-like protein E homologues 
 
 
The fluorescence emission spectrum of the MraY reaction showed that changes in the 
RWXXW motif could be tolerated in the inhibition of E. coli, P. aeruginosa and M. 
flavus MraY (Table 3.3).  Compounds ERWGGW [16] and EHWGGG [15] were 
designed to test whether MraY can be inhibited by homologues of protein E. 
ERWGGW [16], an analogue of G4-like protein E, was found to have intrinsic 
fluorescence and therefore could not be tested via this continuous fluorescence assay. 
The results of Mihalyi’s radiochemical assay on this compound will be discussed in 
section 3.4.  
EHWGGG [15] was found to inhibit E. coli, P. aeruginosa, S. aureus and M. flavus 
MraY with IC50 values 298, 218, 281 and 112μg/mL, respectively (Table 3.3: 
Appendix 1.12-1.15). Glu287 is conserved in MraY and could potentially interact 
with the histidine residue of compound [15], in a similar manner as we predict Glu287 
interacts with Arg-3 of native protein E (ΦX174). The lack of activity against B. 
subtilis MraY, which contains the conserved Glu287 residue but lacks a Phe residue 
in the region of interest (Figure 3.2), suggests that a π-π stacking interaction may be 
more crucial for inhibition of the enzyme.  
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In E. coli, P. aeruginosa and S. aureus MraY a glutamine residue is conserved at 
position 286, above Glu287 (Table 3.1). Gln286 may interact with the glutamic acid 
of [15] via hydrogen bonding (Figure 3.9). This additional site of interaction may 
assist in membrane insertion and could also promote a tighter and more stable 
interaction between the inhibitor and the enzyme. Glu286 is not conserved in M. 
flavus and B. subtilis MraY. The absence of Glu286 in B. subtilis MraY may have 
further hindered the interaction between the enzyme and [15]. In M. flavus MraY, a 
threonine residue is present at position 286 and could participate in a hydrogen 
bonding interaction with the glutamic acid residue of [15] to enhance the interaction 
between the inhibitor and the enzyme. 
 
 
 
Figure 3.9: Interaction between glutamic acid residue of EHWGGG [15] with Gln286 of MraY 
 
The inhibitory activity of EHWGGG [15] suggests that MraY can be inhibited by 
other homologues of protein E. In addition it suggests that the presence of Arg-3 in 
protein E (ΦX174) is not critical for activity. This is further supported by the 
inhibitory activity of H2N-GW-Oct [6].  
 
3.4 Radiochemical Assay 
 
 
Compounds which contained intrinsic fluorescence could not be tested via the 
continuous fluorescence assay. These fluorescent compounds include GWGLW [12], 
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RWGGW [13], RWGLG [14] and ERWGGW [16]. These compounds were tested on 
an alternative radiochemical assay by Mihalyi. 
The radiochemical assay for MraY activity measures the transfer of [
14
C]-phospho-
MurNAc-pentapeptide to [
14
C]-lipid I. The carbon-14 labelled lipid I product is 
extracted with n-butanol and analysed on a scintillation counter. This method was 
based on the work of Tanaka et al
207
 and Brandish et al
111,71
 which was optimised by 
Mihalyi (2013).   
Mihalyi found that all four oligopeptides had similar inhibitory activity against E. coli 
MraY (Table 3.4; Appendix 2.1-2.4). 
 
Table 3.4: IC50 values found by Mihalyi via the radiochemical assay 
Pentapeptide  IC50 (μg/mL) 
[12] GWGLW 129+/-14 
[13] RWGGW 154+/-17 
[14] RWGLG 161+/-20 
[16] ERWGGW 238+/-20 
 
Tanaka and Clemons demonstrated the importance of the second tryptophan (Trp-7) 
in Epep for the inhibition of MraY
133
, therefore we expected [14] to have a higher 
IC50 value than RWGLW [10] (425μg/mL). The radiochemical assay revealed that 
[14] had a lower IC50 value (161μg/mL) than [10]. Via the continuous fluorescence 
assay, we showed that the first tryptophan is not critical for inhibition, evident by the 
low IC50 value of RGGLW [11] (128μg/mL). This could suggest that the location of 
tryptophan may not be as important as the number of tryptophans.  
It’s possible that these two methods of assays are not comparable. The continuous 
fluorescence assay measures the IC50 value during the first 2 minutes of the MraY 
reaction. The radiochemical assay measures the IC50 value after 30 minutes of 
reacting, by quantifying the radiolabelled lipid I product.  
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3.5 Inhibition Studies on Site-Directed mutants of E. coli MraY 
 
 
Testing the inhibitory activity of protein E analogues provided compelling 
information on the importance of protein E residues for inhibition of WT MraY. 
Similarly we wished to determine the importance of MraY residues relative to our 
protein E analogues, in order to provide a more conclusive picture on the interaction 
of protein E and MraY. Although some information was provided by assaying other 
bacterial MraY’s, these enzymes also contained many other point mutations, relative 
to E. coli. 
Following our predicted structural model for the interaction of MraY and protein E 
(Figure 1.32), Glu287 and Phe288 appear to be key players in E-mediated lysis. In 
hopes of testing our hypothesis, these residues were mutated using site-directed 
mutagenesis. Active inhibitors of WT MraY (Chapter 3.3), were tested for inhibitory 
activity against MraY mutants.  
MOAC project student Amy O’Reilly provided three E. coli MraY constructs with 
mutations F288A, F288L and E287A in a pET52b vector. These genes were cloned in 
with restriction enzymes SmaI and SacI. The pET52b vector has a T7 RNA 
Polymerase promoter and terminator which allowed transcription of the MraY gene 
upon IPTG induction. The pET52b vector confers ampicillin resistance which was 
especially useful in transformations.  These MraY constructs were fused with an N-
terminal Strep-tag II. Strep-tag II is composed of eight residues (Trp-Ser-His-Pro-
Gln-Phe-Glu-Lys) which exhibit intrinsic affinity toward streptavidin
208
. A plasmid 
map for these mutants is given in Figure 3.10. 
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Figure 3.10: Plasmid map of pET52b containing the mraY gene 
 
Mutants F288A, F288L and E287A were transformed into E. coli C43 competent cells 
in the presence of ampicillin (100μg/mL). Unlike DH5α, E. coli C43 cells carry the 
λDE3 lysogen which expresses T7 RNA polymerase from the lacUV5 promoter209. 
T7 RNA polymerase can then bind to the T7 RNA polymerase promoter on the 
pET52b vector, facilitating overexpression of the mraY gene.   
A single colony was isolated from a transformed plate and inoculated overnight in 
LB+Amp (100μg/mL). The start-up culture was then diluted 100-fold and allowed to 
grow to an OD600 of 0.6. The cells were then induced with IPTG (1mM) for 4 hours, 
spun down and lysed using a cell disruptor. The lysed cells were spun down in a 
centrifuge and the supernatant was concentrated in an ultracentrifuge producing a 
brown gel which corresponded to the MraY containing membranes.  
The presence and activity of MraY mutants was determined using the continuous 
fluorescence assay. Membrane-bound MraY mutants were diluted according to its 
fluorescence emission spectra in comparison to WT MraY. A Bradford assay was 
then utilised to determine the total protein concentration of these diluted membranes 
at 600nm. The standards for the Bradford assay contained 50μL of albumin (from egg 
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white) solution in 1.5mL of Bradford reagent at final concentrations of 0.25, 0.5, 1.0 
and 1.4 mg/mL. The Bradford assay revealed that F288A and E287A had a total 
protein concentration of 23mg/mL and F288L had a total protein concentration of 
13mg/mL. The total protein concentration of WT E. coli MraY membranes was found 
to be 7.3mg/mL (Table 3.2). Given that a higher concentration of mutant membranes 
is required to produce a similar fluorescence emission spectrum as WT MraY, it is 
plausible that MraY mutants have a lower specific activity than WT MraY. The 
addition of affinity tags like Strep II or His6 to MraY have been previously shown to 
reduce the specific activity of MraY in comparison to the native enzyme
71
 
 
3.5.1 Identification of MraY mutants 
 
 
To confirm the expression and identification of MraY mutants, two methods were 
explored. An empty pET52b vector was transformed in E. coli C43 cells. The 
corresponding membranes were isolated in a similar manner to the MraY mutants. 
These empty membranes contained only endogenous membrane proteins. Empty 
membranes were then diluted to 23mg/mL and 13mg/mL and compared to MraY 
mutants using the continuous fluorescence assay. In all three cases, the fluorescence 
emission spectrum showed that mutants F288A, F288L and E287A were 
overexpressed relative to the empty membranes (Figure 3.11). The reaction of F288L 
resulted in lower fluorescence relative to the other mutants; this is presumably due to 
the lower protein concentration.  
The activity of F288A, E287A and F288L MraY mutants were further confirmed by 
the addition of UMP.  Le Chateliers principle states that any change in a system at 
equilibrium will result in a shift of the equilibrium to counteract the change
210
.  Given 
that UMP is another product of the reversible MraY reaction, the addition of UMP 
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was expected to shift the equilibrium towards the formation of substrate. To the 
negative control, 15μL of UMP (final concentration 83μg/mL) was added to the MraY 
reaction. The addition of UMP resulted in a decrease in fluorescence indicative that 
dansyl-Lipid I is being converted back to UDP-MurNAc-(N
ε
-Dns)pentapeptide and 
exported out of the membrane. 
 
 
 
 
 
 
 
 
 
 
a) 
b) 
UMP 
UMP 
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Figure 3.11: Overexpression of MraY mutants relative to “empty” membranes. 
a) E287A MraY at a final concentration of 2mg/mL b) F288A MraY at a final concentration of 
1mg/mL c) F288L MraY at a final concentration of 2mg/mL. Given that UMP is another product of the 
reversible MraY reaction, the addition of UMP caused a decrease in fluorescence indicative that the 
equilibrium has shifted towards the reformation and exportation of the substrate out of the membrane.  
 
 
Another approach utilised to confirm the expression and identification of MraY 
mutants was Western blotting. There are very few examples of successful western 
blots in the characterisation of MraY. Lloyd et al characterised C-His6-tagged MraY 
in 2004 upon extraction from the membrane
71
. Ma et al (2011) characterised C-His6-
tagged MraY produced from cell-free expression techniques in the presence of 
artificial lipids and detergents
211
. In both studies, the MraY band ran lower than 
expected at 32kDa. 
A Western blot was performed on membrane-bound MraY mutants using Strep-Tactin 
Horse Radish Peroxidase (HRP) conjugate antibodies.  Unfortunately, no bands were 
observed for MraY mutants. This could be due to the use of membrane bound MraY. 
The extensive lipid environment may have hindered recognition by the Strep-Tactin 
c) 
UMP 
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HRP conjugated antibody. In addition, due the hydrophobic nature of membrane 
proteins like MraY, aggregation may have occurred upon denaturation
212
.   
Given the possibility that aggregation may have occurred preventing the protein from 
traveling down the SDS-gel and transferring correctly to a PVDF membrane, a Dot 
blot was performed. A dot blot is often used clinically in the detection of sexually 
transmitted diseases such as chlamydia and in the detection of antidiacyltrehalose 
antibodies in tuberculous patients
213
. A dot blot is a simple and quick technique for 
detecting and identifying proteins in the presence of antibodies. Unlike a Western 
blot, a dot blot cannot distinguish proteins by size; it is only able to confirm the 
presence of a tagged protein upon binding to an antibody
214
.  
To a nitrocellulose membrane paper, 5 and 20μL of membrane-bound MraY mutants 
(13 mg/mL) were spotted directly and allowed to air dry.  To prevent nonspecific 
binding, the membrane was treated with 5% Bovine Serum Albumin (BSA) in PBS 
for 1 hour at 4°C. Following three consecutive washes with PBS-Tween buffer, the 
membrane was treated with 20μL of diluted Strep-Tactin HRP conjugate in 10mL of 
PBS-Tween buffer for 1 hour at 25°C with gentle shaking. The membrane was 
washed twice with PBS-Tween and PBS. The membrane was finally treated with 
Novex® Electrochemiluminescence (ECL) reagents which contained an 
electrochemiluminescence substrate used for immunodetection of HRP (Figure 3.12). 
The dot blot was subsequently exposed to film and developed using an AGFA Curix 
60 processor.  
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Figure 3.12: Chemiluminescence reaction of Strep-Tactin HRP conjugate 
 
 
Incubation with ECL reagents for 30 seconds followed by 15 seconds exposure to 
film produced Figure 3.13a. ECL was able to detect the Strep-Tactin HRP conjugate 
antibody confirming the presence of Strep-tagged MraY in these samples. A small 
amount of nonspecific binding was observed in the negative control. Nonspecific 
binding commonly results from insufficiently blocking with BSA or an excessive 
concentration of the antibody
215
.   
Incubation with ECL reagents for 2 minutes followed by 60 seconds exposure to film 
produced Figure 3.13b. Prolonged incubation with ECL lead to the formation of halo 
like circles in the dot blot. These halos are often called ghost bands and are a result of 
high protein concentrations and long incubations times with ECL reagents
216
. A high 
concentration of protein results in a high concentration of the bound Strep-Tactin 
HRP conjugate. The addition of the ECL reagents resulted in a fast conversion of 
substrate to product. This led to a decrease in substrate concentration and therefore a 
decrease in the electrochemiluminescence reaction overtime. Because this reaction 
was not exposed to film quickly, the electrochemiluminescence reaction could not be 
accurately detected.  
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Figure 3.13: Dot Blot for MraY mutants.  
a) 30 seconds incubation with ECL followed by 15 seconds exposure to film b) 2 minutes incubation 
with ECL followed by 1 minute film exposure. Excess ECL exposure time led to a lack of HRP 
substrate upon film exposure. 
 
 
3.5.2 Continuous Fluorescence Assay using MraY mutants 
 
 
The activity of RWXXW analogues were tested against MraY mutants using the same 
procedure used for WT MraY (Chapter 3.2). The results from the continuous 
fluorescence assay using MraY mutants are given in Table 3.5.  
 
Table 3.5: Inhibitory activity of RWXXW analogues against MraY Mutants 
μg/mL E. coli E287A F288L F288A 
Epep 30 +/- 3.5 211 +/- 51 X X 
 [6] H2N-GW-Oct  294 +/-60.5 769 +/- 127 X X 
 [4] H2N-GW-OMe X X X X 
[10] RWGLW 425 +/- 85 X X X 
[11] RGGLW 128 +/- 26 X X X 
[15]EHWGGG 298 +/- 17 X X X 
 
 
3.5.2.1 Inhibition of F288L and F288A MraY 
 
 
Previous reports have shown that a mutation at Phe288 of E. coli MraY causes 
resistance to Epep.  Our predicted structural model elucidates a potential π-π stacking 
interaction between Phe288 and Trp-4 and Trp-7 of Epep. As a result, a mutation to 
Phe288 should cause a decrease or complete loss of inhibitory activity for Epep and 
other analogues which contain a tryptophan residue. The continuous fluorescence 
a) 
b) 
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assay confirmed these reports and showed that Epep was not an active inhibitor of 
F288L or F288A (Appendix 1.16-1.17)  
H2N-GW-Oct [6], which was found to be an active inhibitor of E. coli, P. aeruginosa, 
S. aureus, M. flavus and B. subtilis MraY in vitro (Table 3.3), was unable to inhibit 
MraY mutants F288L and F288A. We anticipated that the tryptophan residue in 
compound [6] would interact with Phe88 in a similar manner as Epep. The loss in 
inhibitory activity for compound [6] as well as RWGLW [10], RGGLW [11] and 
EHWGGG [15] against F288A and F288L MraY further strengthens our predicted 
structural model and the hypothesis that a π-π stacking interaction is involved in the 
inhibition of MraY by protein E.  
 
3.5.2.2 Inhibition of E287A MraY 
 
 
Our predicted structural model, illustrates a potential interaction between Glu287 of 
E. coli MraY and Epep. Mutation E287A caused a large increase in the IC50 of Epep 
(Appendix 1.18). Epep was found to have an IC50 value of 211μg/mL compared to the 
IC50 of 30μg/mL against WT E. coli MraY. Unlike native Epep which is produced by 
the host and transverses the membrane from the cytoplasm, in vitro studies require 
insertion of Epep from the periplasmic side of the membrane. In in vitro studies 
Glu287 could assist in membrane insertion via formation of a salt bridge with Arg-3 
(Figure 1.32).  
Mutation E287A completely abolished the inhibitory activity of pentapeptides 
RWGLW [10] and RGGLW [11]. In the absence of Glu287, the Arg residue in 
compounds [10] and [11] could not form an electrostatic interaction to assist in 
membrane insertion. This charged Arg residue therefore remained charged and 
exposed which may have complicated insertion into the hydrophobic membrane. 
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The α3-like protein E analogue EHWGGG [15] was also unable to inhibit MraY 
mutant E287A. Similar to compounds [10] and [11], the histidine residue of 
compound [15] could not form an electrostatic interaction with MraY in the absence 
of Glu287. The charged histidine residue may have subsequently hindered membrane 
insertion of EHWGGG [15] leading to a loss in inhibitory activity. These results 
further support our earlier findings, which suggested that MraY can be inhibited by 
protein E homologues of α3-like and G4-like bacteriophages (Chapter 3.3.5).     
H2N-GW-Oct [6] was found to have very minimal activity against E287A MraY, IC50 
= 769 +/- 127μg/mL (Appendix 1.19). The N-terminus of [6] could potentially form a 
similar electrostatic interaction as we predict Arg-3 of Epep forms with Glu287.  As a 
result a mutation to residue Glu287 could lead to a decrease in the inhibitory activity 
of [6]. Phe288, which has been previously shown to be critical for the inhibition of 
MraY, is still present in mutant E287A and therefore could bind to [6] once it 
transverses the membrane. 
 
3.6  Conclusion 
 
 
To determine the in vitro activity of membrane-bound MraY in the presence of 
RWXXW containing peptides, a continuous fluorescence assay was utilised. The 
continuous fluorescence assay monitored the conversion of fluorescently tagged 
MraY substrate UDP-MurNAc-(N
ε
-Dns)pentapeptide to membrane-bound dansyl-
lipid I. 
Initially a Tecan GENios plate reader was used to monitor the fluorescence of the 
MraY reaction. Assays that can be performed on a microtitre plate are highly 
desirable for large scale screening.  In practice, the application of this fluorescence 
assay to a microtitre plate resulted in a significant decrease in sensitivity. The Tecan 
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GENios plate reader measured the fluorescence of each reaction with respect to an 
entire row or column of the microtitre plate. If any particular compound had some 
intrinsic fluorescence it overshadowed the changes in fluorescence of other 
compounds. In addition, this assay was only able to take fluorescence measurements 
as specific time intervals. As a result, major fluorescence changes which occur within 
the first one minute of the reaction could not be observed.  
To overcome these issues a continuous assay was explored. The fluorescence 
continuous assay was optimised by Mihalyi and utilised a Perkin Elmer fluorimeter. 
The fluorimeter was found to be much more sensitive than the plate readers and was 
able to measure the fluorescence of the MraY reaction every 0.1 seconds, allowing 
thorough examination of the enzymatic reaction.  
The continuous fluorescence assay revealed that tryptophan may be important in the 
interaction between Epep and MraY. Compounds containing tryptophan residues were 
found to inhibit MraY while those that lack a tryptophan residue were not active 
inhibitors. We hypothesised that Trp-4 and Trp-7 of Epep interacts with MraY via a 
π-π stacking interaction with Phe288 of MraY. Mutation of Phe288 was found to 
cause resistance to Epep. This resistance may be due to the absence of the π-π 
stacking interaction. This pattern was also observed for RWXXW containing protein 
E analogues, which were unable to inhibit F288L and F288A MraY. 
According to our predicted structural model, MraY residue Glu287 could form an 
electrostatic interaction with Arg-3 of Epep. Therefore we hypothesised that 
analogues which lack an arginine residue would be unable to inhibit MraY. However, 
we found that compounds which lacked arginine or contained a chemically similar 
amino acid, like histidine, were still able to inhibit MraY.  H2N-GW-Oct [6] and 
EHWGGG [15] were active inhibitors of E. coli, P. aeruginosa, s. aureus and M. 
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flavus MraY. Mutation to MraY residue Glu287 abolished inhibitory activity for most 
RWXXW peptides with the exception of compound [6] and Epep which were still 
able to inhibit MraY but at a much higher IC50 value.  
These results confirmed the importance of MraY residues Phe288 and Glu287. 
Phe288 appeared to be especially critical for the inhibition of MraY. Following our 
predicted structural model, these results suggest that a π-π stacking interaction 
between MraY and Epep is indeed plausible and critical for inhibition. The proposed 
electrostatic interaction between Glu287 of MraY and Arg-3 of Epep appeared to 
assist in inhibition but was not essential. This was surprising as electrostatic 
interactions are known to be stronger than noncovalent interactions between aromatic 
rings
217
.  
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Chapter 4:  Antibacterial activity of synthetic Arg-
Trp containing peptides 
 
Having demonstrated that several synthetic Arg-Trp peptides were active inhibitors of 
the MraY reaction in the continuous fluorescence assay, we wished to test whether 
these peptides had antibacterial activity against E. coli and a range of Gram-negative 
and Gram-positive bacteria.  
The minimal inhibitory concentration (MIC) is defined as the lowest concentration of 
an antimicrobial that can visibly inhibit the growth of a microorganism
218
. A 
compound that generates a low MIC and IC50 value is especially desired in the 
development and quick approval of novel drugs. 
 
4.1 Kirby-Bauer Antibiotic Susceptibility test 
 
 
The antibacterial properties of RWXXW compounds were determined using 
qualitative and quantitative experiments. The Kirby-Bauer test for antibiotic 
susceptibility was initially used as a qualitative measure of antibacterial activity. The 
Kirby-Bauer test, first developed in 1966
219
 and standardised by the World Health 
Organization in 1971
220
, was established as a practical method of testing antibiotic 
susceptibility in clinical laboratories.  In this method inhibition of the organism is 
visualised on an LB plate and is evident by the appearance of zones of inhibition in 
which no growth has occurred.  
E. coli C43 and B. subtilis colonies were isolated from a standard agar plate and 
inoculated in 5mL of LB overnight at 37°C. 100μL of cultured bacteria was added to 
2mL of melted low percent agar containing 0.5% agar. The mixture was vortexed and 
spread evenly across an agar plate. Once solidified, antibacterial discs saturated with 
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25μL of RWXXW compounds (125μg/mL) were placed on top of the seeded agar 
plate and incubated overnight at 37°C. In this experiment, ampicillin (125μg/mL) and 
MeOH were used as the positive and negative controls, respectively. Compounds 
which have antibacterial properties prevented the growth of bacteria around the disc.  
The Kirby-Bauer test revealed that H2N-RW-Oct [3], Octyl-RW-OMe [2] and H2N-
GW-Oct [6] had some antibacterial activity against B subtilis. This was evident by the 
appearance of small zones of inhibition surrounding the antibacterial discs (Figure 
4.1). [3] appeared to be a better inhibitor of B. subtilis than [2] and [6], given that it 
produced a larger zone of inhibition.  
 
 
Figure 4.1: Inhibition of B. subtilis by RWXXW analogues via the Kirby-Bauer antibacterial 
susceptibility test. 25μL of ampicillin (100mg/mL) and 25μL MeOH was used as the positive and 
negative controls, respectively. Red circles highlight zones of growth inhibition.  
 
The Kirby-Bauer test confirmed the presence of antimicrobial activity in a limited 
number of compounds but could not provide information related to the MIC value. 
Some articles suggested measuring the diameter of the zones of inhibition in order to 
determine the MIC values relative to the positive control
221
. The observed zones of 
inhibition were too small to measure with confidence and therefore could not be 
analysed accurately. RWXXW analogues did not appear to have antibacterial 
properties against E. coli C43. However, this may be due to very small zones of 
inhibition which could not be properly detected. As a result, this experiment was 
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found to be an inappropriate high throughput screening method for the determination 
of antibacterial properties
222
. 
 
4.2 Microtitre Broth Dilution Technique 
 
 
To quantify the antibacterial properties of these compounds a microtitre broth dilution 
technique was utilised. The microtitre broth dilution technique has become an 
increasingly popular high throughput protocol that produces quantitative results 
(MIC)
223
.  This method utilises liquid media containing a defined number of bacterial 
cells to test the antibacterial properties of an inhibitor across various concentrations in 
a deep well microtitre plate
224
.  
E. coli, P. putida and B. subtilis colonies were isolated from an agar plate and 
inoculated in 5mL of LB broth overnight at 37°C.  A dilution series of the seeded LB 
was performed to get 10
-1
, 10
-2
, 10
-3
, 10
-4
, 10
-5
, 10
-6
, 10
-7
 and 10
-8
-fold dilutions.  
0.5mL of each dilution was poured onto an agar plate and incubated overnight at 
37°C.  The colonies were then counted and the dilution that gave 1000 colony 
forming units per mL (CFU/mL) was chosen for MIC calculations (Table 4.1). 
 
Table 4.1: Broth dilution that produces 10
3
 CFU/mL 
Bacterial Strain LB dilution that 
produced 10
3
 CFU/mL 
E. coli 1.8x10
-6
 
P. putida 3.9x10
-7
 
B. subtilis 8.9x10
-3
 
 
To a sterile deep well microtitre plate, 190μl of the seeded broth (CFU/mL = 103) was 
added to each well. 10μL of RWXXW peptide analogues were added to the 96 deep 
well plate to give a final volume of 200μL and final inhibitor concentrations 125, 
62.5, 31.25, 15.63, 7.82, 3.90, 1.95 and 0.97μg/mL, obtained by 2-fold serial 
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dilutions.  Each inhibitor concentration was tested in duplicates. 10μL of water was 
added to one of the wells to serve as a growth control. Normal LB was also used as a 
negative control. The microtitre plate was covered with a sterile adhesive film and 
incubated overnight at 37°C with shaking.  The solutions were then transferred to a 
standard 96 well plate for absorbance measurements (OD595). The inhibitor 
concentration which reduced the growth by at least 50% was considered the MIC of 
the compound. The MIC of RWXXW peptide analogues is provided in Table 4.2. 
 
Table 4.2: MIC (μg/mL) of RWXXW peptide analogues 
 (μg/mL) E. coli P. putida B. subtilis 
[2] Octyl-RW-OMe - - 125 
[3] H2N-RW-Oct 31 31 8 
[6] H2N-GW-Oct - - 16 
[13] RWGGW - - 125 
 
The microtitre broth dilution technique revealed that four RWXXW analogues had 
antibacterial activity against E. coli, P. putida, and B. subtilis with MIC as low as 
8μg/mL. Three of these compounds contained a hydrophobic chain which we 
anticipated could assist in membrane insertion. Dipeptide H2N-GW-Oct [6] which 
was found to be an inhibitor of E. coli, B. subtilis, S. aureus, P. aeruginosa and M. 
flavus MraY (Chapter 3.3) showed antibacterial activity only against B. subtilis. 
Pentapeptide RWGGW [13] which was found to be an inhibitor of E. coli MraY also 
showed weak antibacterial activity against B. subtilis. Peptides RWGLW [10], 
RGGLW [11] and EHWGGG [15] were not found to have antibacterial activity.  
Unexpectedly, Arg-Trp derivatives [2] and [3] showed antibacterial activity despite 
not showing in vitro activity against MraY. This raised the questions of whether these 
compounds inhibited the growth of bacteria by acting at a site other than MraY or 
perhaps by permeabilising the membrane in a similar manner to detergents
205
. 
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4.3 Antibacterial activity of H2N-RW-Oct [3] against Gram-negative bacteria  
 
 
We were especially intrigued by the antibacterial activity of H2N-RW-Oct [3]. 
Initially, we suspected that this compound would have the most antibacterial and 
antimicrobial activity as a result of its structure. Compound [3] is cationic, contains 
the desired arginine and tryptophan residues and has a long hydrophobic chain which 
could potentially assist in membrane insertion. The absence of in vitro activity 
suggests that this compound might act at a site other than MraY, or that it 
permeabilises the membrane. To determine if compound [3] permeabilises the 
membrane, a fluorometric assay testing for the permeabilisation of Gram-negative 
bacteria was performed. 
 
4.3.1  Use of the fluorescent probe 1-N-phenylnaphthylamine to investigate 
permeabilisation of Gram-negative bacteria by H2N-RW-Oct [3] 
 
The use of fluorescent probes is a well-documented tactic in structural biology to 
determine the structure and function of membranes
225,226,227
. The nonpolar fluorescent 
probe 1-N-phenylnaphthylamine (NPN) is a particularly useful probe to study the 
properties of biological membranes as it strongly fluoresces in phospholipid 
environments but only weakly in aqueous environments
228,229
. The structure of the 
uncharged lipophilic dye NPN is given in Figure 4.2
230
. 
 
 
Figure 4.2: Structure of fluorescent probe NPN 
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NPN was used in this research project to investigate if H2N-RW-Oct [3] permeabilises 
the outer membrane of Gram-negative bacteria. The outer membrane of Gram-
negative bacteria is rich in lipopolysaccharides (LPS) which are used to exclude 
external hydrophobic molecules from entering the cell
231
. The integrity and stability 
of the outer membrane can be compromised by permeabilising substances which can 
intercalate and release vital components of the outer membrane
232
. Once the 
membrane has been permeabilised, the phospholipid bilayer becomes exposed, 
facilitating the entry of hydrophobic agents such as NPN. The uptake of NPN into the 
hydrophobic membrane causes an increase in the fluorescences of NPN which can be 
measured.  
Using methods from Helander and Mattila-Sandholm (1999) an NPN uptake assay 
was adapted to a continuous fluorescence assay. A single colony of P. putida was 
isolated from a standard agar plate and inoculated in 5mL of LB overnight at 37°C 
with shaking. This start-up culture was diluted 100-fold with LB and allowed to grow 
to an OD600 of 0.5. The culture was then centrifuged for 10 minutes at 1000g at 25°C. 
The pellet was resuspended in half the volume of 5mM HEPES buffer, pH 7.2.  
Membrane permealisation of this bacterial suspension by [3] was determined on a 
Perkin Elmer fluorimeter at an excitation wavelength of 340nm and an emission 
wavelength of 435nm.  To a Starna
®
 sub-micro fluorimeter cell, 50μL of the bacterial 
suspension was added to 25μL of 40μM NPN and 25μL of the inhibitor. NPN and the 
inhibitors in question were dissolved in HEPES buffer, pH 7.2. The HEPES buffer 
solution was used as the negative control and EDTA (125μg/mL) was used as the 
positive control. EDTA is a known membrane permeabiliser that alters the outer 
membrane by releasing LPS
233
.   
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The effect of H2N-RW-Oct [3] on the membrane at various concentrations was 
monitored in duplicates. The results of this fluorometric assay are given in Figure 4.3.   
 
 
Figure 4.3: NPN membrane permeabilisation assay of P. putida in the presence of H2N-RW-Oct 
 
 
As expected, an increase in the fluorescence of NPN was observed after 500 seconds 
for cells treated with 125μg/mL EDTA. This indicated that EDTA successfully 
permeabilised the membrane and facilitated the entry of NPN molecules into the 
phospholipid bilayer. Cells treated with H2N-RW-Oct [3] only gave small changes in 
fluorescence, which were not concentration dependent. This suggests that the 
membrane was not successfully permeated by [3] and therefore NPN could not enter 
the phospholipid bilayer.  
The small increase in fluorescence observed for cells treated with compound [3] after 
10 minutes might be as a result of inhibition of MraY, since MraY inhibition would 
lead to cell lysis upon cell division allowing NPN to enter the phospholipid bilayer.  
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4.3.2 Overexpression of mraY protects the cells from H2N-RW-Oct mediated lysis  
 
 
To confirm that [3] does not permeabilise the membrane but instead inhibits MraY, a 
protection assay was performed. A protection assay was first performed by Zheng et 
al (2008) to confirm that MraY is the bacterial target of E-mediated lysis.  Zheng et al 
reported that overexpression of mraY on a pBAD30 plasmid protects E. coli from 
lysis by the ΦX174 E gene, expressed on a λ prophage, due to the formation of a 1:1 
protein complex. Since [3] shows antibacterial activity against E. coli, this method 
provided a method to test whether [3] interacted with MraY. If [3] forms a complex 
with MraY in vivo, then overexpression of mraY should protect E. coli from lysis by 
[3] and hence increase the MIC value.  
In this study, a pET52b vector containing WT mraY, F288L mraY or E287A mraY 
was used. The pET52b vector contained a T7 RNA polymerase promoter and 
terminator which allowed transcription of the genes of interest upon IPTG induction.  
The overexpression of integral membrane proteins has been recorded to be toxic to 
bacterial cells even at low levels of IPTG
234
, which could complicate the protection 
assay. Given that only a modest 1.5-2 fold increase in activity has been reported for 
the overexpression of MraY
71
, toxicity by MraY is not anticipated. Nevertheless, a 
growth experiment was conducted to determine the effect overexpression of integral 
membrane protein MraY has on bacterial growth.  
E. coli C43 cells, containing an empty pET52b vector, was induced with 0.5mM 
IPTG and was monitored every 30 minutes for 8.6 hours. To determine if the 
overexpression of MraY is toxic to bacterial cells, a similar experiment was 
conducted on E. coli C43 cells containing an additional copy of the mraY gene on a 
pET52b plasmid. The results of these growth experiments are given in Figure 4.4.  
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Figure 4.4: Effects of 0.5mM IPTG induction on bacterial growth 
 
 
According to Figure 4.4, the growth of bacterial cells was not affected by the addition 
of 0.5mM IPTG or the overexpression of MraY. As a result, 0.5mM IPTG was used 
to induce the overexpression of mraY genes in the protection assay.  
The protection assay utilised a microtitre plate to determine the MIC of [3] against 
cells overexpressing MraY. If [3] inhibits MraY, we would expect an increase in the 
MIC value at high concentrations of MraY. The excess MraY proteins will be able to 
overcompensate for the inhibition by [3] and continue producing peptidoglycan to 
avoid lysis. If [3] does not inhibit MraY, the MIC should not be affected by the 
overexpression of MraY.  
WT mraY and mraY mutants F288L and E287A were transformed into E. coli C43 
competent cells in the presence of ampicillin (100μg/mL). To serve as a negative 
control, an empty pET52b vector was transformed into E. coli C43 cells in the 
presence of ampicillin. A single colony was isolated from the transformed plate and 
inoculated in 5mL of LB+Amp (100μg/mL) overnight at 37°C with shaking.  Due to 
the low transformation efficiency of E. coli C43 competent cells, broth dilution was 
not required to identify the dilution that produced 1,000 CFUs/mL. The start-up 
culture was then diluted 100-fold with LB and induced with 0.5mM IPTG. Ampicillin 
was not added at this change in order to assure that the only effect measured was that 
of the inhibitor, H2N-RW-Oct [3].  
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To a sterile deep well microtitre plate, 190μl of the IPTG-induced seeded broth was 
added to each well. 10μL of H2N-RW-Oct [3] was added to the deep 96 well plate to 
give a final volume of 200μL and final inhibitor concentrations of 500, 450, 400, 350, 
300, 250, 125, 62.5, 31.25, 15.63, 7.82, 3.90, 1.95 and 0.98μg/mL, obtained by 2-fold 
serial dilutions.  Each inhibitor concentration was tested in duplicate. 10μL of water 
was added to one of the wells to serve as a growth control. Normal LB was also used 
as a negative control. The microtitre plate was covered with a sterile adhesive film 
and incubated at 37°C with shaking for 8 hours.  The solutions were then transferred 
to a standard 96 well plate for absorbance measurements (OD595). The inhibitor 
concentration which reduced the growth by 50% was considered the MIC of the 
compound. The MICs of compound [3] against E. coli cells overexpressed with MraY 
is provided in Table 4.3. 
 
Table 4.3: MIC of H2N-RW-Oct against E. coli cells overexpressed with MraY 
(μg/mL) WT  
E. coli 
(-) control 
Empty 
pET52b 
MraY F288L E287A 
[3] H2N RW-Oct 31 31 250 500 300 
 
The MIC of [3] against the negative control, which contained an empty pET52b 
vector, was found to be 31μg/mL. This is in agreement with the MIC value 
determined via the microtitre broth dilution technique. The MIC of [3] increased 8-
fold in cells overexpressing MraY and nearly 10-fold in cells overexpressing E287A 
MraY. These increases in MIC suggest that [3] interacts with MraY and induces lysis 
of the cell.    
The MIC of [3] increased 16-fold in cells overexpressing F288L MraY. This 
exceedingly high MIC may be due to a combination of two factors; (1) higher 
concentration of MraY and (2) weak binding interaction. We anticipated that H2N-
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RW-Oct [3] would interact with MraY via a π-π stacking interaction with Phe288. In 
the absence of Phe288 we would therefore expect a significant decrease in the 
inhibitory activity of [3]. In addition to there being an excess of F288L MraY proteins 
to overcompensate for the inhibition by [3], it is plausible that [3] was unable to bind 
as tightly to MraY in the absence of Phe288. As a result, this led to an MIC much 
higher than E. coli cells overexpressing WT MraY or E287A MraY.    
This protection assay further confirmed that H2N-RW-Oct does not permeabilise the 
membrane, in agreement with the results found via the NPN membrane 
permeabilisation assay. The protection assay also showed that [3] inhibits MraY in a 
similar manner as the E gene does from the experiments of Zheng et al. 
It is unclear why H2N-RW-Oct [3] did not have in vitro activity against membrane 
bound MraY via the continuous fluorescence assay. The presence of multiple Arg or 
Lys residues in cationic antimicrobial peptides is needed to bind to the surface of 
bacterial membranes, so this may be why H2N-RW-Oct [3] shows higher 
antimicrobial activity than H2N-GW-Oct [6]. 
 
4.3.2.1 Protection assay of known antimicrobial peptides against E. coli 
 
 
Known antimicrobial peptides, containing the RWXXW motif (Table 4.4), were 
provided by Professor Robert E.W. Hancock (UBC, Canada) and tested for activity 
against MraY using the protection assay. If the antimicrobial action of these peptides 
is via inhibition of MraY, then we would expect to observe an increase in the MIC 
against cells overexpressing MraY.  If these antimicrobial peptides do not inhibit 
MraY, the MIC should not be affected by the overexpression of MraY.   
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Table 4.4: Sequence of known antimicrobial peptides 
Antimicrobial 
peptide 
Labeled Terminus
a
 
MX226 N-ILRWPWPWRRK-C 
C-KRRWPWPWRLI-N 
Indolicidin C-RRWPWWPWKWPLI-N 
Kai47 C-KRWKWWRFKWKIF 
Kai50 C-RRWRWWRWKWRLI-N 
Sub6 C-RWWKIWVIRWWR-C 
1002 N-VQRWLIVWRIRK-C 
1020 N-VRLRIRWWVLRK-C 
 
Using the same protocol as the protection assay (Chapter 4.3.2), the MIC of known 
antimicrobial peptides was determined (Table 4.5). The protection assay revealed that 
these antimicrobial peptides had antibacterial activity against E. coli with MIC values 
ranging from 8-150μg/mL. Surprisingly, the MIC of these compounds decreased in 
cells overexpressing MraY. From radiochemical assays carried by Agnes Mihalyi, we 
know that these peptides do inhibit E. coli MraY, showing 30-60% inhibition at a 
concentration of 100μg/mL (unpublished, 2013). These decreasing MIC value can be 
as a result of inhibition at another site. Some of these antimicrobial peptides such as 
indolicidin are believed to target intracellular processes including DNA synthesis 
upon forming pores in the cytoplasmic membrane
46,235
. Due to the sequence similarity 
between these antimicrobial peptides and protein E, it is plausible that the interaction 
of these peptides with MraY assists in membrane insertion. If so, an increase in the 
concentration of MraY would facilitate the entry of these compounds into the cell and 
would increase the probability of inhibition to their intracellular targets. As a result, 
an increase in the concentration of MraY would lead to a decrease in the MIC.  
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Table 4.5: MIC of known antimicrobial peptides 
(μg/mL) (-) Control, pET52Bb MraY F288L E287A 
MX226 150 63 63 63 
Indolicidin 63 16 31 63 
Kai47 31 16 16 16 
Kai50 31 16 16 16 
Sub6 16 8 8 16 
1002 8 2 4 2 
1020 16 4 16 4 
 
 
4.4 Conclusion 
 
 
The antibacterial activity of RWXXW analogues was determined using the Kirby-
Bauer antibiotic susceptibility test and the microtitre broth dilution technique. The 
Kirby-Bauer test revealed that H2N-RW-Oct [3], Octyl-RW-OMe [2] and H2N-GW-
Oct [6] had some antibacterial activity against B. subtilis; this was evident by the 
appearance of small zones of inhibition surrounding the antibacterial discs. The 
observed zones of inhibition were too small to measure with confidence and therefore 
could not be analysed accurately to produce an MIC value. RWXXW analogues did 
not appear to have antibacterial properties against E. coli C43. However, this was due 
to very small zones of inhibition that could not be properly detected via this method. 
This experiment was able to qualitatively confirm antibacterial activity but could not 
provide meaningful information related to the MIC value. As a result this experiment 
was found to be an inappropriate high throughput method to screen the remaining 
compounds.  
To quantify the antibacterial properties of these compounds a microtitre broth dilution 
technique was performed. This method utilised liquid media containing a defined 
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number of bacterial cells to test the antibacterial properties of RWXXW compounds 
in a microtitre plate. The microtitre broth dilution technique revealed that 4 
compounds had antibacterial activity against E. coli, P. putida, and B. subtilis with 
MIC as low as 8μg/mL.  Among these compounds, H2N-GW-Oct [6] and RWGGW 
[13] which were found to inhibit the growth of B. subtilis (MIC = 16μg/mL and 
125μg/mL, respectively) were also active inhibitors of MraY in vitro. The agreement 
between the antibacterial and antimicrobial activity of [6] and [13] suggests that they 
interact with MraY, inhibiting peptidoglycan biosynthesis and as a result cause cell 
lysis.  
Unexpectedly, H2N-RW-Oct [3] had antibacterial activity but did not have in vitro 
activity. This suggests that either this compound inhibited the growth of bacteria by 
acting at a site other than MraY or by permeabilising the membrane in a similar 
manner to detergents
205
.  
An NPN membrane permeabilisation assay was conducted to determine if [3] 
permeabilised the membrane. In the presence of EDTA, a known membrane 
permeabiliser, the fluorescence of NPN increased, indicative that NPN entered the 
hydrophobic membrane. This pattern was not observed in the presence of [3], 
indicative that [3] does not permeabilse the membrane.  
In addition, a protection assay was conducted to determine if H2N-RW-Oct [3] 
inhibited the growth of bacteria via its interaction with MraY.  This assay showed that 
the MIC of [3] increased in cells overexpressing MraY, F288L MraY and E287A 
MraY. Given that an increase in the concentration of MraY caused a decrease in the 
inhibitory activity of [3], [3] is believe to inhibit the growth of bacteria by interacting 
with MraY. The MIC of [3] against F288L MraY was significantly higher 
(500μg/mL) and may be due to a weakened interaction with MraY. In the absence of 
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Phe288, H2N-RW-Oct [3] may not be able to effectively interact with MraY via a π-π 
interaction. The combination of this weakened interaction and an excess of MraY 
protein significantly reduced the inhibitory activity of [3]. 
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Chapter 5:   Uridine-Containing Peptides 
 
 
5.1 Introduction 
 
 
Modification of existing classes of antimicrobials is an increasingly popular tactic to 
combat resistance of bacteria to standard antibiotic therapies
236-237
. Much effort has 
been put forward in particular to the modification of natural products, Uridyl Peptide 
Antibiotics (UPA). UPAs such as pacidamycin, tunicamycin, mureidomycin A, 
liposidomycin B and muraymycin are known to inhibit the cell-wall biosynthetic 
enzyme MraY
109,72,238
. It is believed that UPAs act as transition state analogues of 
MraY substrate UDP-MurNAc-pentapeptide
239
. This is likely as prior reports have 
shown that the uridine motif is crucial for activity in vitro
240
.  As described in Chapter 
1.4.1, UPA’s have been reported to contain low levels or lack activity against human 
pathogens
241
, presumably due to their high hydrophilicity which may hinder passive 
diffusion across the cytoplasmic membrane. The in vitro potencies of these peptidyl 
nucleoside antibiotics have sparked the scientific community with great interest in 
investigating the structure-activity relationships of nucleoside antibiotics as MraY 
inhibitors and antibacterials
72,103-17
. 
In the course of the project, we noticed that members of the UPA class contained 
some structural features that are also found in the RWXXW motif. Muraymycin 
contains a cyclic amino acid analogue of arginine while the pacidamycins contain a 
tryptophan residue and an electron rich meta-tyrosine (Figure 5.1).  
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Figure 5.1: Structures of Muraymycin and Pacidamycin 1. In red is the crucial uridyl motif. Circled 
in blue are the common aromatic residues which are generally Trp, Phe or m-Tyr. In the case of 
muraymycin, aa2 (green) a cyclic arginine is observed.  
 
 
The presence of two aromatic residues and in some cases a cyclic arginine in UPAs 
bears a striking resemblance to the RWXXW motif we hypothesised is important for 
MraY inhibition. It therefore seemed possible that these UPAs form an initial 
interaction with MraY at the predicted protein E binding site in order to access the 
MraY active site from the exterior of the cell membrane. This is of particular interest 
as it is not known how these UPAs (≈800-1400kDa) cross the cell membrane. The 
two aromatic residues can form a π-π stacking interactions with Phe-288 of MraY in 
the same manner as protein E. m-Tyr in particular would be an excellent candidate for 
π-π stacking as it is more electron rich than a typical aromatic242.    
In 1996, previous members of our research group have shown that liposidomycin B 
and  mureidomycin A are slow binding inhibitors of MraY
72-238
. This mode of enzyme 
inhibition results from the reversible conversion of a loosely bound E•I complex into 
a more tightly bound E•I* complex (Figure 5.2). E•I* may represent either a 
conformational change or a reversible chemical reaction at the active site
243
. It is 
plausible that an initial interaction with MraY occurs at the protein E binding site to 
form E•I. This interaction may lead to a conformational change (E•I*) which may be 
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necessary to shuttle the large macromolecule to the MraY active site.  The hypothesis 
is further supported by previous reports which have shown that liposidomycin B is a 
non-competitive inhibitor of MraY, which might indicate initial binding to an 
allosteric site in MraY
244
.  
 
Figure 5.2: Kinetic Scheme for slow binding inhibition. kon and koff represent the unimolecular rate 
constants for the reversible conversion of EI to EI*
243
  
 
 
To test this hypothesis, a small collection of compounds containing a uridine motif 
and segments of the RWXXW motif were designed and synthesised (Figure 5.3). In 
order to mimic the spacing found in UPAs, a succinyl-Gly-Gly linker was inserted 
between uridine and Arg-Trp. Also, analogue [29] was designed, containing two Trp 
residues. These compounds were then tested for activity against MraY and MraY 
mutants F288L and E287A to determine if this initial interaction is occurring.  
 
 
 
 
 
[26] 
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Figure 5.3: UPA analogues containing Arg and/or Trp 
 
 
5.2 Synthesis of uridine derivatives 
 
 
To provide flexibility to these uridyl containing compounds an extension to the 5´ OH 
of the ribose ring was desired. To specifically esterify the 5´ OH, protection of the 
vicinal diols (2´OH and 3´OH) was required. Uridine protected at this site is 
commercially available as 2',3'-O-isopropylidene uridine [31] for £129 (5g). Given 
[27] 
[28] 
[29] 
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that a large quantity of [31] was needed to synthesise the desired uridyl containing 
oligopeptides, it was decided to synthesise [31].  
 
5.2.1 Formation of isopropylidene ketal 
 
 
Isopropylidene ketal or acetonide are the most common protecting groups of 1,2 and 
1,3-diols as they are stable to most experimental conditions except treatment with 
acids
245
. In carbohydrate chemistry, where 1,2 and 1,3 diols are both present, the 
formation of the desired acetonide is dependent on whether the reaction is under 
kinetic or thermodynamic control. The difference between these two reaction 
conditions lies in the activation energy. Reactions under kinetic control have lower 
activation energy than thermodynamic controlled reactions.  
 
Figure 5.4: Energy profile diagram comparing kinetic vs. thermodynamic controlled reaction for 
the protection of uridine diols 
 
 
Under kinetic control, 5-furan and 6-pyran ring systems exist in equilibrium (Figure 
5.5). The 1° alcohol of the furanose ring is more nucleophilic and sterically accessible 
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than the 2° alcohol towards the attack of the 1´ carbon.  As a result, the 6-pyranose 
form is the major isomer in solution (≈80%)246.  
 
Figure 5.5: Equilibrium conversion of furanose to pyranose 
 
 
Treatment of uridine with 2-methoxypropene under kinetic control, will therefore 
produce the undesired product, [30] (Figure 5.6). The activation energy of this 
reaction is much lower than 1,2-indol protection, and as result this reaction proceeds 
rather quickly
247
 (Figure 5.4). 
 
Figure 5.6: Product of kinetic controlled indol protection of uridine 
 
 
Following the method of J Tomasz (1978), a solution of uridine (1eq) and p-
toluenesulfonic acid (cat.) in CHCl3 was stirred under reflux and treated with 2.4 eq 
of 2-methoxypropene overnight. Removal of the solvent and the MeOH by-product in 
vacuo, followed by a standard work up and purification produced [31] at 71% yield. 
The addition of heat provided the energy to initiate 1,2-indol protection of the less 
stable furanose ring
248
 (Figure 5.7). However, a small amount of [30] did form which 
was removed by flash chromatography using 100% EtOAc. 
[30] 
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Figure 5.7: Thermally controlled mechanism of 1,2-indol protection of uridine using 2-
methoxypropene 
 
 
5.2.2 Elongation of 2',3'-O-isopropylidene uridine 
 
 
Previous work in the Bugg research group showed that [31] could be selectively 
acylated at C-5 with succinic anhydride
249
. This provided a convenient linker to 
couple to the amino terminus of a short peptide. 
Esterification of succinic anhydride (0.94eq) with the 1° alcohol of [31] (1eq) was 
accomplished by treatment with TEA (0.9eq) at 0°C overnight in anhydrous DCM. 
The solvent was removed in vacuo and the resulting residue was cooled to 0°C and re-
dissolved in Na2CO3(sat). Washing with Et2O removed the organic base, TEA. 
Protonation of the corresponding carboxylic acid with 2M HCl, extraction into DCM 
and purification of the product by flash chromatography produced [32] at 57% yield. 
 
Figure 5.8: 5'-succinyl-2', 3'-O-isopropylidene uridine [32] 
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5.2.3 Esterification of Fmoc-Aspartic Anhydride 
 
 
The synthesis of [29] was desired as it has the most sequence similarity to the natural 
product muraymycin. Product [29] required esterification of the aspartic acid side 
chain with 2', 3'-O-isopropylidene uridine [31]. In hopes of approaching this in a 
similar manner as [32], Fmoc-aspartic anhydride was first synthesised (Figure 5.9).    
  
Figure 5.9: Reaction scheme for the synthesis of Fmoc-aspartic anhydride[33] 
 
 
1 eq of Fmoc-OSu  in THF was added to a solution of aspartic acid (1eq) and Na2CO3 
(2.2 eq) in H2O. After stirring at room temperature overnight, the mixture was washed 
with Et2O. The aqueous layer was acidified to pH 2 and the desired intermediate 
Fmoc-aspartic acid was extracted into EtOAc. The organic phase was dried with 
MgSO4 and concentrated in vacuo. The residue was then re-dissolved in Ac2O with 
rapid heating and stirring (10 minutes) and immediately cooled to room temperature 
causing [33] to precipitate out at 96% yield.   
Esterification of [33] with the 1° alcohol of 2', 3'-O-isopropylidene uridine [31] (1eq) 
was accomplished by treatment with TEA (0.9eq) at 0°C overnight in dried DCM. 
Purification via flash chromatography using 100% EtOAc as the eluent isolated two 
products with Rf’s 0.5 and 0.3. ESI-MS revealed that both species had an m/z of 620.2 
[33] 
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[M-H]
-
. In addition, the 
1
H-NMR spectra of these two species was nearly identical.   It 
appeared that esterification of [33] with [31] was not regioselective and as a result a 
mixture of α and β esters were formed (Figure 5.10). Ibatullin and Stelivanov (2009) 
found that the regioselectivity of N-Fmoc-aspartic anhydride varied greatly depending 
on the polarity of the reaction media. In more polar solvents such as DMSO, acylation 
of the β carbonyl was the major product250. However, attempts to esterify [33] with 
[31] using DMSO as the solvent was unsuccessful.   
 
Figure 5.10: Products of the non-regioselective esterification reaction of [33] with [31] 
 
 
Attempts to grow crystals and distinguish the two products via X-ray crystallography 
were also unsuccessful. Higher resolution NMR experiments were conducted with 
help from the experimental NMR officer Dr. Ivan Prokes.  A two-dimensional 
Nuclear Overhauser Effect Spectroscopy (NOESY) experiment was conducted at 298 
K using an AVIII-600 spectrometer and DMSO-d6 as the solvent.  The result of the 
high resolution NMR experiment for [34b] is given in Figure 5.11.  
 
FAU-A [34a] FAU-B [34b] 
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Figure 5.11: NOESY spectra of [34b] in DMSO-d6. Long range coupling of H-16 with the H-2 of 
uracil and the H-7 and H-8 of the furanose ring suggests that [34b] has attached to the α-carboxyl of 
Fmoc-aspartic acid.   
135 
 
 
 
Figure 5.12: Zoomed in view of the NOESY spectra for [34b] highlighting interactions of interest. 
 
 
The NOESY spectra of [34b] showed that H-16 interacted with the H-7 and H-8 of 
the uridyl moiety and the sp
2
 hydrogen (H-2) of the uracil moiety. H-2 has a 
characteristically high chemical shift (≈7.2-7.8ppm) and in this spectrum appeared to 
have fused with an aromatic proton peak. The interaction of H-16 to H-2 is weak in 
comparison to the interaction with H-7 and H-8.  
With respect to [34a], an interaction was observed between H-9 and the H-7 and H-8 
of the furanose ring. We did not observed an interaction between H-9 and H-2 of the 
uracil moiety (Figure 5.13), suggesting that H-2 and H-9 protons are too far away in 
space to interact.  
From inspections of models, it appears that H-9 of [34a] has limited mobility in 
comparison to H-16 of [34b] which may hinder long range interactions with H-2. As a 
result, it seemed more likely that the NOESY spectra of Figure 5.11 corresponded to 
isomer [34b]. In both cases, the α-proton interacted with H-7 and H-8 but not H-2. No 
H-16 
H-16 
H-2 
H-2 
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other interaction was useful in distinguishing these two isomers. To distinguish with 
confidence X-ray crystallography would still be necessary.   
 
 
Figure 5.13: NOESY interactions of [34a] and [34b]. H-9 of [34b] was found to couple to H-7 and 
H-8 but not to H-2, presumably due to a greater distance in space and limited mobility. 
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5.3 SPPS 
 
UPA analogues were synthesized on a fritted-filtered reaction vessel using a standard 
Fmoc SPPS procedure
162
 (Figure 5.14). 
 
 
 
 
Figure 5.14: Scheme for SPPS of UPA analogues 
 
In a dried RBF, Fmoc-protected amino acids (2-4eq) were dissolved in minimum 
dried DCM.  Following the addition of a DIPEA (2.5eq), the mixture was 
immediately added to 1eq. of swollen 2-chlorotritylchloride resin and agitated gently 
with N2 gas for 1-2 days. To cap any remaining unloaded resin beads, anhydrous 
MeOH was later added to the resin and agitated under N2 gas for 1 hour.  
Upon several washes with dried DMF and DCM, Fmoc-protecting groups were 
removed by treatment with 20-30% piperidine in DMF for 2 hours. Following another 
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series of washes, activated amino acids were added to the loaded resin in a similar 
manner to the first step. Upon several washes with dried DMF and DCM, Fmoc-
protecting groups were removed as mentioned above.  
The addition of uridine derivatives [32], [34a] and [34b] to the peptide chain was 
achieved by activation with HATU (2eq) followed by treatment with DIPEA (2.5eq). 
The reaction mixture was immediately added to the loaded resin and agitated gently 
with N2 gas for 2 days. Compounds [34a] and [34b], which contained a free amino 
group (after fmoc-deprotection) was further coupled to other incoming amino acids to 
form [29a] and [29b]. The absence of an amino group in [32] prevented further 
peptide coupling and therefore was the terminal functional group in compounds [26], 
[27] and [28].  
Cleavage and total deprotection of uridine containing peptides involved treatment 
with 19:1 TFA/H2O overnight. The resin was removed by filtration under reduced 
pressure and washed twice with neat TFA to assist in the removal of any loosely 
bound peptide product. Filtrates were combined and TFA was evaporated using a 
CO2/acetone rotary evaporator.  Cold ether was used to precipitate the oligopeptides. 
The product was isolated and dried further with a high vacuum pump and lyophilised. 
TFA cleavage removed the side chain protecting groups, the diol protecting group and 
liberated the uridyl-oligopeptide from the resin. Products [26], [27], [28], [29a] and 
[29b] were purified by reverse phase HPLC at a flow rate of 20mL/min as described 
in Chapter 2.4. 64%, 96% and 91% of products [26], [27] and [28] was isolated, 
respectively.  Products [29a] and [29b] were isolated with very poor yields (<3%). 
Perhaps the acid treatment caused the product to degrade, cleaving the uridyl ester 
linkage. 
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5.4 Inhibition of MraY by uridyl oligopeptides determined by the continuous 
fluorescence assay 
 
The MraY catalysed reaction was monitored using the continuous fluorescence assay 
described in Chapter 3.3 at an excitation wavelength of 340nm and an emission 
wavelength of 530nm. The final protein concentrations of membranes containing 
overexpressed E. coli, P. aeruginosa, S. aureus, M. flavus and B. subtilis MraY in this 
continuous assay were 0.6, 0.1, 0.28, 0.3, 0.3 and 0.9 mg/mL, respectively. The 
results of the enzymatic assay are provided in Table 5.1.  
 
Table 5.1:  IC50 (μg/mL) values of uridine peptide analogues against MraY 
μg/mL E. coli E287A F288L P. aeruginosa S. aureus M. flavus B. subtilis 
[26] X X X X X X X 
[27] 71 +/- 13 X X 508 +/- 121 210 +/- 44 391 +/- 71 254 +/- 44 
[28] X X X X X X X 
[29a/b] X X X X X X X 
 
HOOC-RGGGsUr [27] was found to be an inhibitor of E. coli MraY with an IC50 of 
71μg/mL (Appendix 3.1). [27] was also found to inhibit P. aeruginosa, S. aureus, M. 
flavus and B. subtilis MraY with IC50 values of 508, 210, 391, and 254μg/mL, 
respectively (Appendix 3.2-3.5). In the case of [27], it is possible that an electrostatic 
interaction was initially formed between Glu287 and the arginine residue of [27]. This 
interaction may have assisted in the translocation of the molecule across the 
membrane bilayer in a similar manner to antimicrobial peptides (Chapter 1.2.1). Once 
across the membrane bilayer, [27] may have interacted with MraY at the active site 
via its uridyl moiety.  
None of the remaining uridyl oligopeptides were found to have activity against MraY. 
This was surprising since we hypothesised that the aromatic residues of these 
analogues may form an initial interaction with Phe288. In comparison to [27], the 
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remaining uridyl oligopeptides are bulky and rigid. It is possible that the small size 
and flexibility of the tripeptide glycyl motif of [27] facilitated translocation across the 
membrane and ultimately inhibition of MraY.  
 
5.4.1 Inhibition of E. coli MraY mutants by [27] 
 
 
To confirm if residues Glu287 and Phe288 are critical for the inhibition of MraY by 
[27], the activity of [27] against MraY mutants F288L and E287A was determined 
(Table 5.1). This provided a more conclusive picture on the interaction of this natural 
product analogue with MraY. 
Applying the same procedure used for WT MraY (Chapter 3.3), [27] was found to 
lose inhibitory activity against MraY mutants F288L and E287A. The lack of activity 
against E287A supports the hypothesis that [27] forms an initial electrostatic 
interaction with Glu287. The lack of activity against F288L was surprising given that 
[27] does not have an aromatic residue or any obvious motif that could interact with 
Phe288.  
 
5.5 Antibacterial activity of uridyl oligopeptides 
 
 
The antibacterial properties of these natural product analogues were determined via 
the microtitre broth dilution technique. Utilising the same procedure used for 
RWXXW analogues (Chapter 4.2), it was found that uridyl oligopeptides did not have 
antibacterial activity against E. coli, P. putida or B. subtilis. Though unfortunate, this 
was expected as most UPAs lack antibacterial activity against these organisms.   
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5.6 Inhibition of MraY by known UPAs determined by the continuous 
fluorescence assay 
 
The IC50 of known natural products against WT E. coli MraY and mutant MraY was 
determined using the continuous fluorescence assay. The structures of the UPAs 
tested, mureidomyin A, caprazamycin A, caprazamycin E, pacidamycin D and 
pacidamycin 1&2, are given in Figure 5.15. 
 
 
 
(a) 
(b) 
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Figure 5.15: Structures of UPAs (a) Caprazamycin (b) Pacidamycin (c) Mureidomycin A 
 
 
The continuous fluorescence assay confirmed previous reports that UPAs 
caprazamycin A, caprazamycin E, pacidamycin 1&2, pacidamycin D and 
mureidomycin A are inhibitors of the MraY reaction (Appendix 3.6-3.10). Utilising 
the software GenStat for Teaching and Learning, the IC50 value of each inhibitor was 
calculated (Table 5.2).   
 
Table 5.2: IC50 values of UPA against E. coli MraY 
UPAs IC50 (μg/ml) 
Mureidomycin A 0.60 +/- 0.10 
Caprazamycin A 0.25 +/- 0.03 
Caprazamycin E 0.16 +/- 0.03 
Pacidamycin D 0.16 +/- 0.03 
Pacidamycin 1&2 0.071 +/- 0.011 
 
These strikingly low IC50 values highlight the high potency of the UPA antibiotics. To 
test if these natural products interact with MraY at the protein E binding site before 
inhibiting at the active or another allosteric site, the activity of these natural products 
against MraY mutants was determined.   
 
 
 
 
 
(c) 
143 
 
5.6.1 Inhibition of F288L and E287A MraY by known natural products 
 
 
Due to the presence of aromatic residues, which we predict could form a π-π stacking 
interaction with Phe288 of MraY and the presence of a positively charged amino 
group, which could form an electrostatic interaction with Glu287, the inhibitory 
activity of known natural products against MraY mutants F288L and E287A was 
determined. The IC50 value of these UPAs were determined using the continuous 
fluorescence assay and the software GenStat for Teaching and Learning (Table 5.3; 
Appendix 3.11-3.20). 
Only a marginal 2-fold increase in the IC50 of mureidomycin A was observed when 
Glu287 or Phe288 was mutated. This suggests that theses residues may not be 
important in the inhibitory mechanism of mureidomycin A. Similarly, no significant 
change was observed in the IC50 values of caprazamycin A or E. 
 
Table 5.3: IC50 values of known nattural products against F288L and E287A MraY. Compounds 
whose increased in IC50 value relative to WT MraY is noted. 
 
IC50 E287A 
(μg/mL) 
Increase 
from WT 
IC50 F288L 
(μg/mL) 
Increase 
from WT 
Mureidomycin A 1.17 +/- 0.13 x2 1.05 +/- 0.3 x2 
Caprazamycin A 0.12 +/- 0.02 - 0.24 +/- 0.03 - 
Caprazamycin E 0.12 +/- 0.03 - 0.39 +/- 0.08 x2 
Pacidamycin D 0.48 +/- 0.07 x2 1.58 +/- 0.28 x10 
Pacidamycin 1&2 107 +/- 27 (ng/mL) - 0.97 +/- 0.18 x13 
 
No significant change in the IC50 values of Pacidamycin 1&2 or D was observed 
against MraY mutant E287A. A significant 10-13-fold increase was observed in the 
IC50 values of pacidamycin 1&2 and D against MraY mutant F288L.  This suggests 
that Phe288 is critical for the inhibition of MraY, presumably by assisting in the 
translocation of pacidamycin across the cell membrane. The aromatic residues of 
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pacidamycin could form a π-π stacking interaction with Phe-288 of MraY in the same 
manner as protein E (Figure 5.16). 
 
Figure 5.16: Predicted interaction between Pacidamycins and E. coli MraY at the anticipated 
protein E binding site. π-π stacking interactions can be formed between Phe-288 and the natural 
products aromatic residues. An electrostatic interaction can also be formed between Glu287 and the N-
terminus.  
 
 
5.7 Conclusion 
 
 
The effective and complex design of antibiotics by bacteria has sparked great interest 
in the modification of their natural products in the development of novel drugs. 
Modification of UPA is an increasingly interesting topic due to their potency in 
inhibiting peptidoglycan biosynthesis. Using a general template for the structure of 
natural product inhibitors of MraY, an interesting relationship was discovered 
between protein E and UPA. Similar to protein E, we hypothesised that UPAs bind to 
MraY at the protein E site. This initial interaction may cause a conformational change 
to the protein allowing the translocation of UPAs to the active site. This hypothesis is 
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supported by kinetic reports, which showed the UPAs are slow binding inhibitors of 
MraY
72
. Some UPAs were also found to be non-competitive inhibitors of MraY, 
further strengthening out hypothesis
238
.  
Synthesis of uridyl oligopeptide analogues was achieved by a mixture of solution and 
solid phase chemistry. Uridyl oligopeptide analogues required protection of the 
uridine 1,2-indol with 2-methoxypropene (71%). This was thermodynamically 
controlled in order to prevent indol protection of the pyranose isomer of uridine.  
In hopes of elongating and providing flexibility to these analogues, esterification at 
the 5’OH of 2',3'-O-isopropylidene uridine was performed. Esterification with fmoc-
aspartic anhydride was not regioselective and as a result esterification occurred at the 
α or β carbonyl. Esterification at both the carbonyls did not occur presumably due to 
steric hindrance. Upon inspection of models and NOESY spectrums, we were able to 
hypothesise on the identity of these isomers. However, to confirm with confidence, an 
X-ray crystal structure would still be necessary. Unfortunately, attempts to grow 
crystals were unsuccessful.  Esterification with succinic anhydride (57%) did not pose 
any problems as both carbonyls are equivalent.  
Following a general method for solid phase peptide synthesis, uridyl derivatives were 
effectively added to peptide chains with yields ranging from 64-96%, when the uridyl 
derivative was the last component added to the loaded resin. The addition of the 
uridyl derivative at the second step of peptide synthesis (RWAD(Ur)-W and 
RWAD(W)-Ur) lead to poor yields (2-3%). These exceedingly low yields may also be 
as a result of degradation upon TFA cleavage. 
The continuous fluorescence assay revealed that HOOC-RGGGsUr was an inhibitor 
of E. coli, B. subtilis, P. aeruginosa, S. aureus and M. flavus MraY. Mutation at 
Phe288 and Glu287 resulted in complete loss of inhibitory activity, suggesting that 
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these residues are important for binding. It’s plausible that Glu287 is important in 
forming an electrostatic interaction with the arginine of HOOC-RGGGsUr. It’s 
unclear the role or interaction of this inhibitor with Phe288.  
To determine if Phe288 and Glu287 interact with UPAs, the IC50 of mureidomyin A, 
caprazamycin A, caprazamycin E, pacidamycin D and pacidamycin 1&2 against WT 
MraY was compared to the IC50 of these natural products against MraY mutants 
F288L and E287A. A 10-13-fold increase in the IC50 of pacidamycin was observed 
against F288L. Pacidamycin may interact with Phe288 via a π-π stacking interaction. 
This interaction may facilitate the translocation of the 900kDa natural product across 
the cellular membrane and towards the active site of MraY.  
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Chapter 6:  Conclusion 
 
 
This research project was motivated by the increasing number of multidrug resistant 
bacteria. Resistance to commercially available antibiotics has increased so drastically 
that it is now considered an epidemic.  Much work has been invested in the 
development of new antimicrobials, yet in the past 40 years only three new classes of 
antibiotics have been developed.  This is primarily due to the difficulty in identifying 
new lead compounds from high-throughput screening and the rapid evolution and 
spread of resistance.   
Bacterial cell wall peptidoglycan biosynthesis is a well-established target for 
antibiotics. Many drugs have been developed to target various steps across the 
biosynthetic pathway of peptidoglycan with the exception of integral membrane 
protein MraY, which catalyses the first membrane bound step.  In nature, MraY is a 
popular and effective target of the uridyl peptide antibiotics which include natural 
products tunicamycin, muraymycin and pacidamycin. MraY is also the target of lysis 
protein E from bacteriophage ΦX174.  Previous research has shown that lysis protein 
E mediates cell lysis by an interaction with MraY at a site other than the active site. 
Genetic studies revealed that E-mediated lysis is dependent on the interaction between 
Phe288 of MraY and the transmembrane segment of protein E
120,133
.   
We have constructed an α-helical model for the predicted transmembrane interactions 
between protein E and MraY and shown that favourable interactions can be formed at 
the Phe288 site. Trp-4 and Trp-7 of protein E can participate in π-π stacking with Phe-
288, while Arg-3 can interact with Glu287 of MraY via an electrostatic interaction. 
Together, these residues provide an RWXXW motif which could interact with MraY 
via Phe288 and Glu287. In order to investigate this hypothesis, synthetic peptide 
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analogues of the RWXXW motif was synthesised and tested against membrane bound 
MraY and mutants F288L and E287A. 
Utilising a continuous fluorescence assay, developed by Brandish (1995) and 
optimised by Mihalyi (2013), the inhibitory activity of RWXXW analogues was 
determined.   This assay revealed that RWXXW analogues were able to inhibit MraY 
with IC50 values as low as 58μg/mL. Peptides which contained a tryptophan residue 
were especially good inhibitors of MraY presumably due to its interaction with 
Phe288. Mutation of Phe288 caused a dramatic decrease or complete loss to the 
inhibitory activity of peptides containing an aromatic residue. These findings support 
our hypothesis that a π-π stacking interaction may occur between Phe288 and the 
RWXXW motif of protein E.  
We hypothesised that MraY residue Glu287 could form an electrostatic interaction 
with Arg-3 of protein E. Therefore we expected compounds which lacked an arginine 
residue to be unable to inhibit MraY. However, we found that compounds which 
lacked arginine or contained a chemically similar amino acid, like histidine, were still 
able to inhibit MraY. It is possible that the N-terminus could interact with Glu287 via 
an electrostatic interaction. From these result it appeared that π-π stacking 
interaction is the crucial and dominant interaction in the inhibition of MraY.  
The presence of a hydrocarbon chain affected the inhibitory activity of peptides 
depending on which terminus it was acylated to.  Compounds which contained an 
octyl group on the C-terminus were good inhibitors of MraY (H2N-GW-Oct, 
IC50=58μg/mL) while compounds which contained an octyl group on the N-terminus 
did not contain any inhibitory activity. Analogues which were N-acylated and lacked 
an N-terminal arginine (e.g. Octyl-GW-OMe) would be unable to form an 
electrostatic interaction with Glu287. As a result, this may hinder proper insertion in 
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the membrane and prevent the formation of a π-π stacking interaction between the 
perspective aromatics. 
Given the potency and kinetics of uridyl peptide antibiotics, it was desired to design a 
compound which could interact with MraY at the protein E binding site in addition to 
the active site. Previous work in our research group has showed that natural products 
liposidomycin B and  mureidomycin A are slow binding inhibitors of MraY
72-238
. 
Kinetics studies revealed that a conformational change may be occurring prior to 
inhibition. We hypothesised that this conformational change may be a result of an 
initial binding at the predicted protein E binding site which allows the diffusion of the 
macromolecule across the membrane and to the active site. To test this hypothesis, we 
compared the inhibitory activity of some known natural products against WT MraY to 
that of MraY mutants F288L and E287A.  In the case of pacidamycin 1&2, which 
contains a tryptophan and a m-tyrosine residue, a 10-13 fold increase in the IC50 value 
was observed against MraY mutant F288L. This suggests that Phe288 plays some 
role in the inhibition of MraY by pacidamycin.  It is possible that the aromatic 
residues of pacidamycin were able to engage in a π-π stacking interaction with 
Phe288.  These observations support our hypothesis that uridyl peptide antibiotics 
interact with MraY at the protein E binding site before interacting at the active site. 
This is in agreement with the kinetics studies published by our research group in 
2006.  
To further test our hypothesis, a small collection of compounds containing a uridine 
motif and segments of the RWXXW motif were designed and synthesised. HOOC-
RGGGs-Ur was found to be a good inhibitor of WT MraY (IC50 = 71μg/mL) but not 
an inhibitor of F288L or E287A MraY. In the absence of Glu287, the arginine residue 
of HOOC-RGGGs-Ur would be unable to bind successfully to the protein which may 
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have hindered translocation across the membrane. The lack of activity against F288L 
was surprising given that HOOC-RGGGs-Ur does not have an aromatic residue or 
any obvious motif that could interact with Phe288.  
The antibacterial activity of all compounds was determined using the microtitre broth 
dilution technique. Some of these analogues contained antibacterial activity across 
multiple strains of bacteria including E. coli, B. subtilis and P. putida with MIC as 
low as 8μg/mL. To determine if inhibition of MraY is the mechanism of action which 
prevented the growth of bacteria further experimentation was necessary.  
A continuous fluorometric assay for the permeabilisation of Gram-negative bacteria 
was optimised and used to determine if a particular compound was a membrane 
permeabiliser instead of an enzyme inhibitor. With the use of 1-N-
phenylnaphthylamine which strongly fluoresces in permeabilised membranes, it was 
found that H2N-RW-Oct does not permeabilise the membrane in comparison to 
EDTA. To confirm if MraY was the target enzyme, E. coli cells overexpressing MraY 
were treated with an RWXXW analogue. The MIC of H2N-RW-Oct was found to 
increase 10 fold in cells overexpressing MraY and MraY mutant E287A. If MraY and 
the inhibitor form a 1:1 complex, overexpression of MraY would cause an increase in 
the MIC given that a higher concentration of the inhibitor would be necessary to 
inhibit the excess proteins. This experiment showed that the antibacterial activity of 
H2N-RW-Oct is strongly related to the inhibition of MraY.  
The MIC of H2N-RW-Oct increased 16-fold in cells overexpressing F288L MraY. 
This exceedingly high MIC may be as a result of a weakened binding affinity between 
the inhibitor and the protein. In the absence of Phe288, H2N-RW-Oct would be unable 
to participate in π-π stacking. As a result, this led to an MIC much higher than E. coli 
cells overexpressing WT MraY or E287A MraY. 
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This research project aimed to better understand the interaction between protein E and 
MraY. The results of this research project elucidated the importance of residues 
Phe288 and Glu287 of MraY and the RWXXW motif of protein E.  The inhibitory 
activity of these RWXXW analogues appeared to be site specific and rely on the 
presence of Phe288.  The antibacterial properties of these compounds were also found 
to be directly related to MraY. From this work, it appears that protein E binds to 
MraY at the site we hypothesised. Most importantly, this work identifies a promising 
target for the development of novel antimicrobial agents that is located on the outer 
face of the cytoplasmic membrane.     
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Chapter 7:  Experimental 
 
All chemicals used during this research project were purchased from Sigma Aldrich 
and Merck Novabiochem. Biological reagents C55-P and C35-P were purchased from 
Larodan Fine Chemicals. UDP-MurNAc pentapeptide was purchased from UK 
Bacterial Cell Wall Assembly Network (BaCWAN) and fluorescently tagged by PhD 
candidate Agnes Mihalyi. Natural products pacidamycin D and pacidamycin 1&2 
were provided by Dr. Rebecca Goss from the University of St. Andrews. Natural 
product mureidomycin A was provided from Dr. M. Inukai from Sankyo Ltd. Natural 
products caprazamycin A and caprazamycin E were provided by Dr. Bertolt Gust 
from Eberhard-Karls-Universität Tübingen.  
Water used during these experimental procedures was deionized and autoclaved when 
necessary. Deuterated methanol, chloroform and DMSO used for recording NMR 
spectra were purchased from Cambridge Isotope Labelling Inc. HPLC grade solvents 
were purchased from Fischer Scientific. Anhydrous solvents were only used when 
stated and were used as supplied. Solvents were evaporated using a Buchi Rotavapor 
R-114 equipped with a Buchi Vacuum pump V-700 and a Buchi Heating bath B-480.  
Flash column chromatography was conducted on Fluka Silica Gel (40-63μm, 60Å). 
Thin Layer Chromatograpy (TLC) was performed on aluminum backed plates pre-
coated with Merck TLC Silica Gel 60 F254 and were visualized under UV radiation. 
Semi-preparative HPLC purification was conducted on an Agilent Technologies 
series 1200 Preparative HPLC instrument equipped with an Agilent Xorbax XDB-
C18 preparative column (P/No: 970150-902, size: 21.2x150mm 5micron).  
Low resolution ESI mass spectra were recorded using a Bruker Esquire 2000 
electrospray ionization spectrometer. High resolution mass spectra were recorded on a 
Bruker Micro TOF spectrometer equipped with an electrospray ionization source. 
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Infra-red spectra were recorded using a Perkin-Elmer Paragon 1000 Fourier 
Transform spectrometer. Only selected absorptions are reported in units of 
wavenumbers (Vmax/cm
-1
) 
1
H-NMR spectra were recorded at 300, 400 or 600 MHz using Bruker DPX300, 
DPX400 or AV III-600 spectrometers, respectively. Chemical shifts (δH) are quoted in 
ppm with reference to the residual solvent peak. The data in parenthesis follow the 
order (i) multiplicity: s, singlet; d, doublet, t, triplet; q, quartet; m, multiplet (ii) 
number of equivalent protons (iii) coupling constant (J) in Hz (iv) assignment. COSY 
and NOESY were used in selected cases to aid in assignments. 
Specific rotation was determined using an Opitical Activity Ltd AA-10 Series 
Automatic Polarimeter.  
Fluorescence data was recorded using a Tecan GENios plate reader and a Perkin 
Elmer LS55 fluorescence spectrometer equipped with a PTP-1 peltier temperature 
programmer.  
Bacterial growth was monitored on a Thermo Electron UV-VIS spectrophotometer 
335908P-000. Bacterial cells were lysed using a Constant Systems Ltd. TS Series 
Cabinet cell disruptor. 
An AGFA Curix 60 processor were used to visualise proteins on a western blot and 
dot blot.  
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7.1 Synthesis of Amino Acid Precursors 
 
 
L-Tryptophan methyl ester Hydrochloride [17] 
251
 
 
 
 
L-Tryptophan (1.02 g, 5.0 x 10
-2 
mol, 1 eq) was stirred in 25mL of MeOH. Freshly 
distilled TMSCl (1.27 mL, 1.0 x 10
-2 
mol, 2 eq) was added dropwise to the solution 
and allowed stir overnight at room temperature. The reaction mixture was 
concentrated in vacuo. The resulting white powder was dried under high vacuum 
(0.99 g, 3.9 x 10
-3 
mol, 78%).  
Rf = 0.56 (8:2/EtOAc:MeOH) m.p. 218-222°C, lit m.p 218-220°C
252
; Fourier 
Transform Infrared, neat (vmax/cm
-1
) 3297.9 (m, -NH-) 1742.6 (s, C=O) 1578.9 (s, -
NH2) 1362.0 & 1350.6 (d, -COO-CH2-); 
1
H-NMR (300MHz, MeOD) δH: 3.40 (d, 
2H, J = 7.0Hz, H-3), 3.82 (s, 3H, H-1) 4.34 (t, 1H, J = 6.0Hz, H-2 ), 7.14 (m, 3H, H-4 
H-6 H-7), 7.41 (d, 1H, J = 8.0Hz, H-5), 7.56 (d, 1H, J = 8.0Hz, H-8) lit. δH
251
; 
HRMS: m/z (ESI) calculated for C12H15N2O2
+
: 219.1134 found: [M+H]
+
: 219.1128  
 
L-Tryptophan octyl ester [18] 
251
 
 
 
 
L-Tryptophan (1.02 g, 5.0 x 10
-3 
mol, 1 eq) was stirred in 1-octanol (10 mL, 6.3 x 10
-2 
mol, 12.6 eq) under reflux at 50°C. 5 mL of conc. H2SO4 was added to the reaction 
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mixture. Within 30 minutes of stirring, the maroon coloured reaction reached 
completion. The reaction mixture was taken up in EtOAc (25 mL) and washed with 
Na2CO3 (3 x 25 mL). The organic layer was isolated, dried with MgSO4 and 
concentrated in vacuo. Excess 1-octanol was removed from the product by reduced 
pressure distillation or flash chromatography using deactivated silica and 100% 
EtOAc as the eluent.  Procedure was modified from lit reference
253
; (6.8 g, 2.1 x 10
-2 
mol, 86 %).   
Rf = 0.78 (8:2/EtOAc:MeOH) Fourier Transform Infrared, neat (vmax/cm
-1
) 3320.6 
(m, -NH-) 1742.2 (s, C=O); 
1
H-NMR (300MHz, MeOD) δH: 0.80 (t, 3H, J=9.0Hz, H-
1), 1.20 (m, 10H, H-2 H-3 H-4 H-5 H-6) 1.42 (m, 2H, H-7 ), 3.44 (t, 2H, J=6.5Hz, H-
10), 3.66 (t, 1H, J=6.5Hz, H-9), 3.90 (t, 2H, J=6.0Hz, H-8), 6.93 (m, 3H, H-14 H-13 
H-11), 7.23 (d, J=8.0Hz, H-12), 7.42 (d, J=7.5Hz, H-15), lit. δH
254
; HRMS: m/z 
(ESI) calculated for C19H29N2O2
+
: 317.2224 [M+H]
+
. Found: [M+H]
+
: 317.2224 
 
Glycine octyl ester [19]
189
 
 
 
 
(i) A solution of Fmoc-Gly-OH (0.65 g, 2.2 x 10-3 mol, 1 eq), DMAP (0.13 g, 1.1 
x 10
-3 
mol, 0.5 eq) and 1-octanol (0.40 mL, 2.5 x 10
-3 
mol, 1.14 eq) in 8 mL of 
DCM was cooled with stirring in an ice bath.  N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (0.46 g, 2.4 x 10
-3 
mol, 1.1 eq) was added 
and the reaction mixture was stirred at 0°C for 2 hours. The reaction was then 
stirred at room temperature overnight.  
(ii) To the stirred solution, 20% piperidine in DMF was added and allowed to stir 
for 1 hour. The addition of the mild base caused the solution to become 
cloudy.  The reaction mixture was concentrated to dryness in vacuo and was 
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taken up in EtOAc (25 mL). The organic layer was washed with NaHCO3 (2 x 
15 mL) and water (2 x 15 mL). The organic layer was dried with MgSO4, 
concentrated in vacuo and dried further under high vacuum to produce a white 
thick oil (0.26 g, 1.37 x 10
-3 
mol, 62 %). Procedure was modified from lit 
reference
189
.  
Rf =  0.30 (8:2/EtOAc:MeOH)  Fourier Transform Infrared, neat (vmax/cm
-1
) 
1738.6 (s, C=O) 1567.6 (s, -NH2) 1433.7 & 1415.4 (d, -COO-CH2-); 
1
H-NMR 
(300MHz, MeOD) δH: 0.90 (t, 3H, J = 7.0Hz, H-1), 1.31 (m, 8H, H-2 H-3 H-4 H-5) 
1.52 (m, 2H, H-6 ), 1.70 (m, 2H, H-7), 3.84 (s, 2H, H-9), 4.24 (t, 2H, J = 6.5Hz, H-8) 
lit. δH
255
; HRMS: m/z (ESI) calculated for C10H22NO2
+
: 188.1606 [M+H]
+
, found: 
[M+H]
+
: 188.1645  
 
N-octanoyl glycine [20]
190
 
 
 
To a stirred solution of L-glycine (0.45 g, 6.04 x 10
-3 
mol, 1 eq) and NaHCO3 (0.76 g, 
9.06 x 10
-3 
mol, 1.5 eq) in water (20 mL), octanoyl chloride (1.03 mL, 6.04 x 10
-3 
mol, 
1 eq) in THF (10ml) was added dropwise. The cloudy reaction mixture was stirred at 
room temperature overnight. Acidification of the reaction mixture to pH1, using 2M 
HCl, induced the precipitation of a clear oil. The resulting oil was separated from the 
aqueous layer and left to dry under high vacuum overnight (0.98 g, 4.90 x 10
-3 
mol, 81 
%).  
Rf = 0.45 (8:2/EtOAc:Hex) Fourier Transform Infrared, neat (vmax/cm
-1
) 1738.1 (s, 
C=O) 1567.4 (s, -CONH-); 
1
H-NMR (300MHz, MeOD) δH: 0.90 (t, 3H, J = 7.0Hz, 
H-1), 1.31 (m, 8H, H-2 H-3 H-4 H-5) 1.60 (m, 2H, H-6 ), 2.27 (t, 2H, J = 7.5Hz, H-
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7), 3.90 (s, 2H, H-8) lit. δH 
256
; HRMS: m/z (ESI) calculated for C10H20NO3
+
: 
202.1398 [M+H]
+
, found: [M+H]
+
: 202.1434 
 
N-Octanoyl-NG-2,2,5,7,8-pentamethylchroman-6-sulfonyl-L-arginine; Octanoyl-
Arg(PMC)-OH [22] 
 
 
(i) Fmoc-Arg(PMC)-OH (9.94 g, 1.5 x 10-2 mol, 1 eq) was stirred in 40 mL of 
20% Piperidine in DCM for 3 hours.  The solution was concentrated to 
dryness in vacuo and dried further by high vacuum to produce a white paste 
corresponding to H2N-Arg(PMC)-OH.  
(ii) To a stirred solution of H2N-Arg(PMC)-OH and NaHCO3 (2.06 g, 2.45 x 10
-2 
mol, 1.6 eq) in H2O (50 mL), Octanoyl chloride (7.80 mL, 4.5 x 10
-2 
mol, 3 
eq) in THF (25 mL) was added dropwise. The cloudy reaction mixture was 
stirred at room temperature overnight. Acidification of the reaction mixture to 
pH 0.5, using 2M hydrochloric acid, induced the precipitation of a thick 
yellow oil. The resulting oil was separated from the aqueous layer and left to 
dry under high vacuum overnight. Procedure was modified from lit reference 
to produce the novel product
190
; (5.65 g, 9.9 x 10
-3 
mol, 67 %)  
Rf = 0.55 (8:2/EtOAc:MeOH)  Fourier Transform Infrared, neat (vmax/cm
-1
) 1611.8 
(s, NH-C=O) 1723.5 (s, C=O) 2925.9 (m, Ar, C-H); 
1
H-NMR (300MHz, MeOD) δH: 
0.80 (t, 3H, J=7.0Hz, H-1), 1.26 (s, 6H, H-15) 1.4-1.9 (m, 16H, H-2 H-3 H-4 H-5 H6 
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H-9 H-10 H-14) 2.04 (s, 3H, H-17), 2.26 (m, 5H, H-7 H-12)  2.48 (s, 6H, H-13 H-16), 
2.60 (t, 2H, J=6.5Hz, H-11), 4.57 (t, 1H, J=5.0Hz, H-8); HRMS: m/z (ESI) 
calculated for C28H47N4O6S
+
: 567.3216 [M+H]
+
. Found: [M+H]
+
: 567.3222 
 
7.2 Synthesis of Dipeptide Derivatives 
 
 
L-Arginyl-L-tryptophan methyl ester; H2N-RW-OMe [1]
257
  
 
 
 
To a 3-necked RBF equipped with a magnetic stir bar, Boc-L-Arg-OH (0.70 g, 2.5 x 
10
-3 
mol, 1 eq), HATU (0.95 g, 2.5 x 10
-3 
mol, 1 eq) and TEA (0.35 mL, 2.5 x 10
-3 
mol, 1 eq) was stirred in minimum dried DCM for 10 min. Upon the addition of [17] 
(0.64 g, 2.5 x 10
- 3
mol, 1 eq) and TEA (0.35 mL, 2.5 x 10
-3 
mol, 1 eq), the reaction 
was cooled to 0°C. The reaction mixture was allowed to slowly return to room 
temperature with stirring for 3 days. The yellow reaction mixture was washed with 
2M HCl (2 x 15 mL), water (15 mL) and 2M NaOH (2 x 15 mL). The organic layer 
was dried with MgSO4 and the solvent was evaporated in vacuo. The addition of 
MeOH caused a precipitate to form. LRMS revealed that the yellow MeOH solution 
contained the desired Boc-protected product. The MeOH solution was then 
concentrated in vacuo and treated with 7:3 TFA/DCM for 4 hours. TFA and DCM 
were evaporated using a CO2/acetone rotary evaporator. The remaining oil was re-
dissolved in MeOH, concentrated in vacuo and dried under high vacuum pump to 
produce a pale yellow oil. Procedure was modified from lit reference
257
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The novel product was purified by reverse phase HPLC at a flow rate of 20 mL/min 
producing a white solid (0.28 g, 7.4 x 10
-4 
mol, 30 %). The method employed a binary 
mixture of eluents A (H2O with 0.1 % TFA) and B (MeOH with 0.1 % TFA). HPLC 
gradient B: 5%-100%; 0-30 mins, 100%; 30-35mins, 100%-5%; 35-40, 5%; 40-
50mins. Retention time was found to be at 11.51mins. 
Rf =  0.46 (8:2/MeOH:EtOAc);  [α]
  
 
 = +14.0 (C=0.5, MeOH); 
1
H-NMR (400MHz, 
MeOD) δH: 1.61 (m, 2H, H-5) 1.80 (dt, 2H, J1=6.5Hz J2=14.0Hz, H-4) 3.21 (m, 4H, 
H-6 H-7) 3.60 (s, 3H, H-1) 3.80 (t, 1H, J=6.5Hz, H-3) 4.70 (t, 1H, J=3.5Hz, H-2) 6.93 
(t, 1H, J=7.0Hz, H-11) 7.03 (m, 2H, H-10 H-12) 7.23 (d, 1H, J=8.0Hz, H-8) 7.42 (d, 
1H, J=8.0Hz, H-9); 
13
C-NMR (100MHz, MeOD) δC: 19.2, 24.8, 29.8, 31.2, 46.1, 
51.0, 53.8, 112.3, 114.8, 119.7, 122.6, 124.9, 125.2, 128.8, 132.3, 169.9, 179.8; 
HRMS: m/z (ESI) calculated for C18H27N6O3
+
: 375.2145 [M+H]
+
. Found: [M+H]
+
: 
375.2153 
 
N-octanoyl-L-arginyl-L-tryptophan methyl ester; Octanoyl-RW-OMe [2]  
 
 
 
(i) To a 3-necked RBF equipped with a magnetic stir bar, [22] (1.42 g, 2.5 x 10-3 
mol, 1eq), HATU (0.95 g, 2.5 x 10
-3 
mol, 1eq) and DIPEA (0.25 mL, 1.25 x 
10
-3
 mol, 0.5 eq) were stirred in minimum dried DCM/DMF. The addition of 
[17] (0.64 g, 2.5 x 10
-3
 mol, 1eq) resulted in a yellow colour change. DIPEA 
(0.25 mL, 1.25 x 10
-3
 mol, 0.5eq) was added to the reaction mixture and 
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stirred for 2 days at room temperature. The yellow mixture was concentrated 
to dryness in vacuo and was taken up in EtOAc (100 mL). The yellow organic 
layer was washed with 10% citric acid (2 x 15 mL) and H2O (2 x 15 mL). The 
final organic layer was dried with MgSO4. The solvent was evaporated in 
vacuo and the product was dried further under high vacuum. 
(i) The dried product was treated with 9:1/TFA:DCM (10 mL), flushed with N2 
gas and stirred gently for 3 hours.  TFA was evaporated using a CO2/acetone 
rotary evaporator.  Cold Et2O was used to precipitate the auburn dipeptide. 
The ether layer was decanted and the auburn product was dried under high 
vacuum. Procedure was modified from lit references
258,259,193,182,260,162,261
 
The novel product was purified by reverse phase HPLC at a flow rate of 20 mL/min 
(0.28 g, 5.5 x 10
-4 
mol, 22 %). The method employed a binary mixture of eluents A 
(H2O with 0.1 % TFA) and B (MeOH with 0.1 % TFA). HPLC gradient B: 60%-65%; 
0-5 mins, 65%-75%; 5-20mins, 75%-100%; 20-25mins, 100%-60%; 25-30mins, 60%; 
30-35mins. Retention time was found to be at 6.49mins.  
Rf =  0.37 (1:1/MeOH:EtOAc); [α]
  
 
 = +40.0 (C=0.13, MeOH); 
1
H-NMR (300MHz, 
MeOD) δH: 0.88 (t, 3H, J=5.0Hz, H-1) 1.29 (m, 8H’s, H-2 H-3 H-4 H-5) 1.57 (m, 4H, 
H-6 H-12) 1.70 (m, 2H, H-11) 1.85 (m, 2H, H-7) 3.19 (m, 4H, H-13 H-14) 3.24 (s, 
3H, H-10) 4.37 (m, 1H, H-8) 4.75 (m, 1H, H-9) 6.98 (m, 1H, H-18) 7.53 (m, 2H, H-
16 H-17) 7.83 (dd, 1H, J1=7.5Hz, J2=14.0Hz, H-15) 8.09 (d, 1H, J=7.5Hz, H-19); 
13
C-NMR (100MHz, MeOD) δC: 9.4, 19.3, 25.1, 26.0, 28.2, 30.1, 30.8, 34.9, 40.3, 
53.2, 53.4, 55.2, 108.3, 111.2, 118.7, 119.1, 124.2, 127.0, 128.1, 139.9, 157.6, 166.5, 
173.1; HRMS: m/z (ESI) calculated for C26H41N6O4
+
: 501.3189 [M+H]
+
. Found: 
[M+H]
+
: 501.3184  
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L-Arginyl-L-tryptophan octyl ester; H2N-RW-Oct [3]  
 
 
 
(i) In a dried RBF, Fmoc-Arg(PMC)-OH (1.66 g, 2.5 x 10-3 mol, 1 eq) was 
dissolve in  neat TFA (6 mL), flushed with N2 gas and stirred gently overnight. 
TFA was evaporated using a CO2/acetone rotary evaporator. The side chain-
unprotected amino acid (Fmoc-Arg-OH) was precipitated with Et2O to 
produce a thick white paste. The ether layer was decanted and the product was 
dried by high vacuum for 2 hours. 
(ii) Fmoc-Arg-OH, HATU (0.95 g, 2.5 x 10-3 mol, 1 eq) and DIPEA (0.25 mL, 
1.25 x 10
-3
 mol, 0.5 eq) were stirred in minimum dried DCM/DMF. A solution 
of [18] (0.79 g, 2.5 x 10
-3 
mol, 1 eq) and DIPEA (0.25 mL, 1.25 x 10
-3
 mol, 0.5 
eq) in minimum dried DCM was added to the reaction mixture and stirred for 
4 days at room temperature. LRMS was used to monitor the reaction.  
(iii) 50% piperidine in DCM (10 mL) was added to the reaction mixture and stirred 
for 3 hours. The reaction mixture was concentrated to dryness in vacuo and 
was taken up in EtOAc (25 mL). The organic layer was washed with 
Na2CO3(sat) (2 x 15 mL) and H2O (2 x 15 mL) and dried with MgSO4. The 
solvent was evaporated in vacuo and the product was dried under high vacuum 
to produce a thick orange liquid. Procedure was modified from lit 
references
258,259,193,182,260,162,261
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The novel product was purified by reverse phase HPLC at a flow rate of 20 mL/min 
(0.54 g, 1.1 x 10
-3 
mol, 46 %). The method employed a binary mixture of eluents A 
(H2O with 0.1 % TFA) and B (MeOH with 0.1 % TFA). HPLC gradient B: 60%-
100%; 0-4mins, 100%-60%; 4-14mins, 60% 14-24mins. Retention time was found to 
be at 12.5mins.  
Rf =  0.49 (1:1/EtOAc:MeOH); [α]
  
 
 = +150.0 (C=0.1, MeOH); 
1
H-NMR (300MHz, 
MeOD) δH: 0.90 (t, 3H, J=7.0Hz, H-1) 1.25 (m, 8H, H-2 H-3 H-4 H-5) 1.47 (m, 2H, 
H-6) 1.57 (m, 2H, H-7) 1.77 (m, 2H, H-18) 1.91 (m, 2H, H-17) 3.22 (m, 2H, H-11) 
3.31 (m, 2H, H-8) 3.80 (m, 2H, H-19) 4.01 (t, 2H, J=6.0Hz, H-10) 4.76 (t, 1H, 
J=6.5Hz, H-9) 7.07 (m, 2H, H-13 H-15) 7.43 (m, 2H, H-12 H-14) 7.80 (m, 1H, H-
16); 
13
C-NMR (100MHz, MeOD) δC: 14.5, 26.3, 28.4, 28.9, 29.1, 30.0, 30.2, 31.7, 
32.0, 32.7, 42.2, 53.5, 55.1, 66.8, 112.8, 119.0, 120.0, 120.7, 121.8, 122.5, 124.3, 
136.2, 157.1, 166.5, 173.4; HRMS: m/z (ESI) calculated for C25H41N6O3
+
: 473.3235 
[M+H]
+
. Found: [M+H]
+
: 473.3237 
 
Glycyl-L-tryptophan methyl ester; H2N-GW-OMe [4]  
 
 
 
(i) In a dried RBF, Boc-Gly-OH (0.44 g, 2.5 x 10-3 mol, 1 eq), HATU (0.95 g, 2.5 
x 10
-3
 mol, 1 eq) and DIPEA (0.25 mL, 1.25 x 10
-3
 mol, 0.5 eq) were stirred in 
minimum dried DCM.  A solution of [17] (0.64 g, 2.5 x 10
-3
mol, 1  eq) and 
DIPEA (0.25 mL, 1.25 x 10
-3
 mol, 0.5 eq) in minimum dried DCM was added 
to the reaction mixture and stirred for 3 days. The yellow product was 
concentrated to dryness in vacuo and was taken up in EtOAc (100mL). The 
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organic layer was washed with 10% citric acid (2 x 15 mL) and water (2 x 15 
mL). The final organic layer was dried with MgSO4. The solvent was 
evaporated in vacuo. 
(ii) The dried product was treated with 9:1/TFA:DCM (10 mL), flushed with N2 
gas and stirred gently for 3 hours.  The TFA was evaporated using a 
CO2/acetone rotary evaporator. The auburn product was further dried under 
high vacuum. Procedure was modified from lit references
258,259,193,182,260,162,261
  
The novel product was purified by reverse phase HPLC at a flow rate of 20 mL/min 
(0.23 g, 8.3 x 10
-4 
mol, 33 %). The method employed a binary mixture of eluents A 
(H2O with 0.1 % TFA) and B (MeOH with 0.1 % TFA). HPLC gradient B: 0%-100%; 
0-15 mins, 100%-0%; 15-20mins, 0%; 20-30mins. Retention time was found to be at 
8.80mins.  
Rf = 0.40 (8:2/EtOAc:CHCl3); [α]
  
 
 = +120.0 (C=0.1, MeOH); 
1
H-NMR (300MHz, 
MeOD) δH: 3.0-3.7 (m, 7H, H-1 H-3 H-4) 4.72 (dd, 1H, J1=5.5Hz J2=8.0Hz, H-2) 
7.00 (m, 3H, H-7 H-8 H-9) 7.23 (d, 1H, J=8.0Hz, H-5) 7.41 (d, 1H, J=7.5Hz, H-6), 
lit. δH
262
. 
13
C-NMR (100MHz, MeOD) δC: 29.4, 41.9, 52.8, 54.7, 110.0, 112.2, 118.9, 
119.9, 122.3, 124.4, 128.2, 136.8, 166.9, 173.1; HRMS: m/z (ESI) calculated for 
C14H18N3O3
+
: 276.1348 [M+H]
+
. Found: [M+H]
+
: 276.1340 
 
N-octanoyl-L-glycyl-L-tryptophan methyl ester; Octanoyl-GW-OMe [5] 
 
 
 
To a dried RBF, [20] (0.5 g, 2.5 x 10
-3
mol, 1 eq), HATU (0.95 g, 2.5 x 10
-3
 mol, 1 eq) 
and DIPEA (0.25 mL, 1.25 x 10
-3 
mol, 0.5 eq) were dissolved in minimum dried 
DCM.  A solution of [17] (0.637 g, 2.5 x 10
-3
 mol, 1 eq) and DIPEA (0.25mL, 
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1.25x10
-3
mol, 0.5eq) in minimum dried DCM was added to the reaction mixture and 
stirred for 3 days. The yellow mixture was concentrated to dryness in vacuo and was 
taken up in EtOAc (100 mL). The yellow organic layer was washed with 10% citric 
acid (2 x 15 mL) and water (2 x 15 mL). The final organic layer was dried with 
MgSO4. The solvent was evaporated in vacuo and the product was dried further under 
high vacuum. The novel product was purified by flash chromatography using 
5:3:2/CHCl3:EtOAc:Pet ether as the eluent.  Procedure was modified from lit 
references
258,259,193,182,260,162,261
 (0.20 g, 5.0 x 10
-4 
mol, 20 %)  
Rf  = 0.43 (8:2/EtOAc:MeOH); [α]
  
 
 = +48.0 (C=0.5, MeOH); 
1
H-NMR (300MHz, 
MeOD) δH: 0.78 (t, 3H, J=7.0Hz, H-1) 0.9-1.4 (m, 8H, H-2 H-3 H-4 H-5) 1.47 (m, 
2H, H-6) 1.57 (m, 2H, H-7) 2.08 (m, 2H, H-11) 3.25 (s, 2H, H-8) 3.55 (s, 3H, H-10) 
4.65 (t, 1H, J=6.0Hz, H-9) 6.98 (m, 3H, H-16 H-15 H-14) 7.23 (d, 1H, J=8.0Hz, H-
12) 7.39 (d, 1H, J=8.0Hz, H-13); 
13
C-NMR (100MHz, MeOD) δC: 26.1, 26.8, 28.5, 
30.2, 30.4, 32.9, 34.8, 39.0, 43.4, 49.8, 54.8, 106.2, 110.3, 112.4, 119.2, 120.0, 122.6, 
124.7, 154.2, 173.9, 176.8, 181.3; HRMS: m/z (ESI) calculated for C22H31N3NaO4
+
: 
424.2212 [M+Na]
+
. Found:  424.2213 
 
Glycyl-L-tryptophan octyl ester; H2N-GW-Oct [6]
263
  
 
 
 
(i) To a 3-necked RBF equipped with a magnetic stir bar was added [18] (1.60 g, 
5 x 10
-3 
mol, 1 eq), EtOH (20 mL), NMM (1.20 mL, 11 x 10
-3 
mol, 2.2 eq), 
Boc-Gly-OH (0.89 g, 5 x 10
-3 
mol, 1 eq) and HOBt (0.10 g, 7.5 x 10
-4 
mol, 
0.15 eq, cat.). The mixture was cooled to 10°C and N-(3-
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Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (1.15 g, 6.0 x 10-3 
mol, 1.2 eq) was added. The reaction was stirred at 25°C for three days. Water 
(25 mL) was added to the reaction mixture and the noncrystalline product was 
extracted in DCM and dried with MgSO4. The solvent was evaporated in 
vacuo and dried under high vacuum to produce a pale yellow oil.  
(ii) The protected dipeptide product was treated with 7:3/TFA:DCM and stirred 
overnight under nitrogen. TFA was evaporated using a CO2/acetone rotary 
evaporator.  Cold Et2O was used to precipitate the brown dipeptide oil. The 
ether was decanted from the product. The wet product was dried further using 
a high vacuum pump to remove any residual ether. The dried product was then 
dissolved in water and lyophilised overnight to produce a deep maroon 
coloured oil.  
The novel product was purified by reverse phase HPLC at a flow rate of 20 mL/min 
(0.82 g, 2.2 x 10
-3 
mol, 44%). The method employed a binary mixture of eluents A 
(H2O with 0.1 % TFA) and B (MeOH with 0.1 % TFA). HPLC gradient B: 50%-
100%; 0-15 mins, 100%-50%; 15-20mins, 50%; 20-30mins. Retention time was 
found to be at 12.2mins.  
[α]  
 
 =  +50.6 (C=0.5, MeOH); 
1
H-NMR (400MHz, MeOD) δH: 0.81 (t, 3H, J=7.1Hz, 
H-1) 1.21 (m, 10H, H-2 H-3 H-4 H-5 H-6) 1.52 (m, 2H, H-7) 3.57 (s, 2H, H-10) 3.92 
(d, 2H, J=5.0Hz, H-11) 4.00 (t, 2H, J=7.0Hz, H-8)  4.68 (m, 1H, H-9) 6.92 (t, 1H, 
J=6.5Hz, H-15) 7.00 (t, 1H, J=8.0Hz, H-14) 7.23 (d, 1H, J=8.0Hz, H-13) 7.43 (d, 1H, 
J=8.0Hz, H-12) 7.63 (d, 1H, J=8.0Hz, H-16); 
13
C-NMR (100MHz, MeOD) δC: 14.4, 
16.7, 19.7, 28.6, 30.4, 31.7, 35.3, 35.5, 63.4, 67.6, 111.2, 115.1, 122.0, 124.5, 129.6, 
134.6, 135.1, 136.5, 137.7, 165.5, 168.7; HRMS: m/z (ESI) calculated for 
C21H32N3O3
+
: 374.2444 [M+H]
+
. Found: [M+H]
+
: 374.2439 
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N-octanoyl-L-arginyl-glycine; Octanoyl-RG-OH [8] 
 
 
 
(ii) A stirred solution of [22] (1.23 g, 2.2 x 10-3 mol, 1 eq), Oxyma Pure (0.31 g, 
2.2 x 10
-3 
mol, 1 eq), H2N-Gly-OtBu•AcOH (0.42 g, 2.2 x 10
-3 
mol, 1 eq) and 
DMAP (0.07 g, 5.5 x 10
-3 
mol, 0.25 eq) in minimum dried DCM was cooled to 
0°C. DCC (0.91 g, 4.4 x 10
-3 
mol, 2 eq) was added to the reaction mixture and 
stirred at room temperature for 3 days. The insoluble urea by-product was 
removed from the reaction mixture by filtration. The filtrate was concentrated 
to dryness in vacuo and was taken up in EtOAc (25 mL). The yellow organic 
layer was washed with 10% citric acid (2 x 15 mL) and water (2 x 15 mL) and 
was dried with MgSO4. The solvent was evaporated in vacuo and the resulting 
yellow liquid was dried further under high vacuum. 
(iii) The protected dipeptide, confirmed by LRMS, was treated with neat TFA (10 
mL), flushed with N2 gas, and stirred gently for 4 hours. The TFA was 
evaporated using a CO2/acetone rotary evaporator.  Cold ether was used to 
precipitate the greenish dipeptide. The ether layer was decanted and the green 
product was dried under high vacuum. Procedure was modified from lit 
references
258,259,193,182,260,162,261
 
The novel product was purified by reverse phase HPLC at a flow rate of 20 mL/min 
(0.31 g, 8.7 x 10
-4 
mol, 40 %). The method employed a binary mixture of eluents A 
(H2O with 0.1% TFA) and B (MeOH with 0.1% TFA). HPLC gradient B: 40%-100%; 
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0-10 mins, 100%-40%; 10-15mins, 40%; 15-25mins. Retention time was found to be 
at 5.02 minutes.  
Rf =  0.60 (1:1/MeOH:EtOAc); [α]
  
 
 =  +18.0 (C=0.25, MeOH); 
1
H-NMR (300MHz, 
MeOD) δH: 0.80 (m, 3H, H-1) 1.20 (m, 8H’s, H-2 H-3 H-4 H-5) 1.57 (m, 4H, H-6 H-
11) 1.80 (m, 2H, H-10) 2.17 (t, 2H, J=7.5Hz, H-7) 3.11 (t, 2H, J=7.0Hz, H-12) 4.32 
(m, 2H, H-8 H-9); 
13
C-NMR (100MHz, MeOD) δC: 14.2, 23.8, 26.2, 26.4, 26.9, 30.2, 
30.3, 32.9, 40.9, 41.8, 42.1, 54.2, 158.8, 172.9, 176.0, 174.4; HRMS: m/z (ESI) 
calculated for C16H32N5O4
+
: 358.2454 [M+H]
+
. Found: [M+H]
+
: 358.2449 
 
L-Arginyl-glycine octyl ester; H2N-RG-Oct [9]
263
  
 
 
 
To a 3-necked RBF equipped with a magnetic stir bar was added [19] (0.50 g, 2.5 x 
10
-3 
mol, 1 eq), EtOH (10 mL), NMM (0.60 mL, 5.5 x 10
-3 
mol, 2.2 eq), Boc-Arg-OH 
(0.69 g, 2.5 x 10
-3 
mol, 1 eq) and HOBt (0.06 g, 3.8 x 10
-4 
mol, 0.15 eq, cat.).  The 
mixture was cooled to 10°C and N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (0.466 g, 3.0 x 10
-3 
mol, 1.2 eq) was added. The reaction was stirred at 
25°C overnight followed by the addition of water (25 mL). The noncrystalline product 
water was extracted in DCM and dried with MgSO4. The solvent was evaporated in 
vacuo and dried under high vacuum to produce a pale yellow oil.  
The novel product was purified by reverse phase HPLC at a flow rate of 20 mL/min 
(0.33 g, 9.5 x 10
-4 
mol, 38 %). The method employed a binary mixture of eluents A 
(H2O with 0.1% TFA) and B (MeOH with 0.1% TFA). HPLC gradient B: 5%-100%; 
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0-30 mins, 100%; 30-35 mins, 100%-5%; 35-40mins, 5%; 40-50mins. Retention time 
was found to be at 16.8 minutes.  
Rf =  0.6 (1:1/MeOH:EtOAc); [α]
  
 
 =  +50.0 (C=0.25, MeOH); 
1
H-NMR (300MHz, 
MeOD) δH: 0.80 (t, 3H, J=7.0Hz, H-1) 1.56 (m, 8H’s, H-2 H-3 H-4 H-5 H-6) 1.86 
(m, 6H, H-7 H-11 H-12) 3.17 (m, 3H, H-10 H-13) 3.25 (s, 2H, H-9) 4.05 (t, 2H, 
J=6.5Hz, H-8); 
13
C-NMR (100MHz, MeOD) δC: 14.6, 23.7, 25.0, 25.5, 26.9, 28.6, 
29.6, 30.3, 33.1, 36.2, 37.6, 53.9, 65.1, 158.9, 171.2, 175.8; HRMS: m/z (ESI) 
calculated for C16H34N5O3+: 344.2662 [M+H]
+
. Found: [M+H]
+
: 344.2656 
 
Solid Phase Peptide Synthesis of L-Arginyl-glycine; H2N-RG-OH [7] 
 
 
 
Resin preparation 
In a fritted filtered funnel, dried Wang resin (0.5g, 0.55mmol loading, 1eq) was 
swollen with dried DCM (3x volume) for 30 minutes.  Vacuum was applied to 
remove DCM. Dried DMF (3x volume) was added to the resin, agitated for 1 minute 
with N2(g) and removed by vacuum. This washing process was repeated five times. 
 
Coupling/Deprotection 
 
 
Cycle I-Attachment of the first amino acid to the resin 
 
 
In a dried 3-necked RBF, equipped with a calcium chloride drying tube, Fmoc-Gly-
OH (0.65 g, 2.2 x 10
-3 
mol, 4 eq), Oxyma Pure (0.31 g, 2.2 x 10
-3 
mol, 4 eq) and DIC 
(0.35 mL, 3.4 x 10
-3 
mol, 6.2 eq) was dissolved in minimum dried DMF and stirred 
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for 10 minutes at 0°C. Following the addition of DMAP (0.07 g, 5.5 x 10
-4 
mol, 1 eq), 
the reaction mixture was immediately added to the swollen resin and agitated with 
N2(g) for 2 days.  
 
Estimation of first residue attachment 
 
A small sample of resin beads (Cycle I) was removed from the reaction vessel and 
dried by vacuum. The dried resin-bound amino acid was weighed and transferred to a 
10mm matched silica UV cell filled with 3mL of freshly prepared 20% piperidine in 
DMF. The resin suspension was agitated with a Pasteur pipette for 5 minutes. The 
absorption spectrophotometer was zeroed at 290nm using 20% piperidine in DMF. 
The absorbance of the UV cells containing settled resin was read at 290nm and 
averaged together. Loading was calculated using Equation 1, based on a molar 
absorptivity (ε) = 5253M-1cm-1. 
 
Equation 2.1 
Loading (mmol/g) = (Absaverage)/(mg of sample x 1.75) 
 
 
Utilizing an absorption spectrophotometer, 68% of Fmoc-Gly-OH was estimated to 
have attached to the Wang resin after 2 days of reacting. Vacuum was applied to 
remove the reaction mixture from the resin. To cap unloaded resin beads, Benzoic 
anhydride (0.62 g, 2.75 x 10
-3 
mol, 5 eq) and pyridine (0.04 mL, 5.5 x 10
-4 
mol, 1 eq) 
in DMF was added to the loaded resin and agitated for 30 min with N2(g). Vacuum 
was applied to remove the solution from the resin.  The resin was washed with DMF 
(5 x 10 mL) and DCM (5 x 10 mL).  
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Fmoc-deprotection 
 
To remove the Fmoc protecting group, the resin was treated with 20% piperidine in 
DMF (10mL) for 2 hours. Vacuum filtration was applied to remove this solution from 
the resin.  The resin was further washed with DMF (5 x 10 mL) and DCM (5 x 10 
mL). 
 
Cycle II  
 
 
In a dried 3-necked RBF, equipped with a calcium chloride drying tube, Fmoc-
Arg(PMC)-OH (1.46 g, 2.2 x 10
-3 
mol, 4 eq), Oxyma Pure (0.31 g, 2.2 x 10
-3 
mol, 4 
eq) and DIC (0.34 mL, 3.4 x 10
-3 
mol, 6.2 eq) was dissolved in minimum dried DMF 
and stirred for 10 minutes at 0°C. Following the addition of DMAP (0.07g, 5.5x10
-
4
mol, 1eq), the reaction mixture was immediately added to the loaded resin and 
agitated with N2(g) overnight. A Kaiser test (Ninhydrin test) was used to monitor the 
disappearance of resin-bound free amines from cycle I. The resin was washed with 
DMF (5x10mL) and DCM (5x10mL). Fmoc-deprotection using the above procedure 
was used.  
 
Kaiser Test 
 
A small sample of resin beads (Cycle II) was removed from the reaction vessel and 
washed several times with ethanol. The beads were transferred to a glass vial, and 
were treated with two drops of 5% Ninhydrin in EtOH, 80% phenol in EtOH and 2% 
0.001M KCN in pyridine. The resin solution was stirred manually and heated to 
110°C. Solutions which turned blue indicated that the reaction was not complete and 
resin-bound free amines were still present. Solutions which turned yellow in colour 
indicated that the peptide coupling reaction was complete. 
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Cleavage/Isolation 
 
The loaded resin was dried under vacuum for 30 minutes and transferred to a dried 
flask in preparation for resin cleavage. The dried resin was treated with 
19:1/TFA:H2O (1 mL per 100 mg of loaded resin), flushed with N2(g), and stirred 
gently overnight. The resin was removed by reduced pressure filtration through a 
sintered glass funnel. The resin was washed twice with neat TFA. Filtrates were 
combined and TFA was evaporated using a CO2/acetone rotary evaporator.  Cold 
Et2O was used to precipitate the dipeptide. The ether layer was decanted and the 
remaining dipeptide was dissolved in water and lypholised overnight. Procedure was 
modified from lit references
258,259,193,182,260,162,261
. 
The known product was purified by reverse phase HPLC at a flow rate of 20mL/min 
(0.032 g, 1.38 x 10
-4 
mol, 25 %). The method employed a binary mixture of eluents A 
(H2O with 0.1%TFA) and B (ACN with 0.1%TFA). HPLC gradient A: 100% A; 0-5 
mins, 100%-75%; 5-10mins, 75%-50%; 10-15mins, 50%-100%, 15-25mins. 
Retention factor was found to be at 6.90min.  
Rf = 0.29 (1:1/MeOH:EtOAc); 
1
H-NMR (300MHz, MeOD) δH: 1.76 (m, 3H, H-4) 
1.93 (m, 2H, H-3) 3.23 (t, 2H, J=7.0Hz, H-5), 3.92 (m, 1H, H-2) 4.06 (s, 2H, H-1); 
13
C-NMR (100MHz, MeOD) δC: 21.1, 29.7, 42.1, 42.1, 53.9, 158.3, 172.8, 179.9; 
HRMS: m/z (ESI) calculated for C8H18N5O3
+
: 232.1410 [M+H]
+
. Found: [M+H]
+
: 
232.1322  
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7.3 General Method for SPPS using 2-chlorotrityl chloride resin 
 
Resin preparation 
In a fritted filtered funnel, dried 2-chlorotrityl chloride resin (1.22 mmol/g loading) 
was swollen with DCM (3x volume) for 30 minutes.  Vacuum was applied to remove 
DCM. Dried DMF (3x volume) was added to the resin, agitated for 1 minute with 
N2(g) and removed by vacuum. This washing process was repeated five times 
 
Coupling/Deprotection 
Cycle I-Attachment of the first amino acid to the resin 
 
In a dried RBF, 2eq* of Fmoc-protected amino acid was dissolved in minimum dried 
DCM.  Following the addition of DIPEA (2.5eq)*, the reaction mixture was 
immediately added to the resin and agitated with N2(g) overnight (Fmoc-Trp(PMC)-
OH and Fmoc-Arg(PMC)-OH was agitated over two nights). To cap the unloaded 
resin beads, anhydrous MeOH (3x volume) was added to the resin and agitated under 
N2(g) for 1 hour. Vacuum filtration was applied to remove the solution from the resin.  
The resin was then washed with DCM (5 x 10 mL) and DMF (5 x 10 mL).  
 
Fmoc-deprotection 
 
To remove the Fmoc protecting group, the resin was treated with 20% piperidine in 
DMF (10 mL) for 2 hours. Vacuum was applied to remove this solution from the 
resin.  The resin was further washed with DMF (5 x 10 mL) and DCM (5 x 10 mL). 
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Cycle II-IV  
 
In a dried RBF, 2eq* of Fmoc-protected amino acids (Fmoc-Arg(PMC)-OH, Fmoc-
Trp(Boc)-OH, Fmoc-Gly-OH, Fmoc-Leu-OH, Fmoc-Ala-OH, Fmoc-His(Trt)-OH, 
Fmoc-Glu(OtBu)-OH)  or 2eq* of urdiyl- derivatives and HATU (2eq)* were 
dissolved in minimum dried DMF.  Following the addition of DIPEA (2.5eq)*, the 
reaction mixture was immediately added to the resin and agitated with N2(g) for 2 
days. When Fmoc-Gly-OH was used, HATU was substituted with DIC and only 1 day 
of agitation with N2(g) was required. Vacuum was applied to remove the solution from 
the resin.  The resin was then washed with DCM (5x10mL) and DMF (5x10mL). 
Fmoc-deprotection using the above procedure was used. 
 
Cleavage/Isolation 
 
The loaded resin was dried under vacuum for 30 minutes and transferred to a dried 
flask in preparation for resin cleavage. The dried resin was treated with 
19:1/TFA:H2O (1mL per 100mg of loaded resin), flushed with N(g), and stirred gently 
overnight. The resin was removed by reduced pressure filtration through a sintered 
glass funnel. The resin was washed twice with neat TFA. Filtrates were combined and 
TFA was evaporated using a CO2/acetone rotary evaporator.  Cold Et2O was used to 
precipitate the oligopeptide. The ether layer was decanted. The wet product was dried 
further with a high vacuum pump to remove any residual ether.  The dried product 
was then dissolved in water and lyophilized overnight. Procedure was modified from 
lit reference
168-264
. 
*relative to resin loading of 1.22mmol/g 
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L-Arginyl-L-tryptophyl-glycyl-L-leucinyl-L-tryptophan; RWGLW [10] 
 
 
 
The novel product was purified by reverse phase HPLC at a flow rate of 20 mL/min. 
The method employed a binary mixture of eluents A (H2O with 0.1 % TFA) and B 
(MeOH with 0.1 % TFA). HPLC gradient B: 5%-100%; 0-30 mins, 100%; 30-
35mins, 100%-5%; 35-40mins, 5% 40-50mins. Retention time was found to be at 
17.4mins (0.38 g, 5.3 x 10
-4 
mol, 87 %). 
1
H-NMR (300MHz, MeOD) δH: 0.77 (dd, 
6H, J1=6.0Hz J2=12.0Hz, H-17) 1.4-1.7 (m, 7H, H-6 H-7 H-15 H-16) 2.44 (d, 4H, 
J=5.0Hz, H-9 H-18) 2.53 (t, 2H , J=6.5Hz, H-8) 3.21 (t, 1H, J=2.0Hz, H-1)  3.25 (s, 
2H, H-3) 4.3-4.6 (m, 3H, H-2 H-4 H-5) 7.01 (m, 4H, H-12 H-13 H-21 H-22) 7.21 (m, 
4H , H-10 H-11 H-19 H-20) 7.45 (m, 2H, H-14 H-23); HRMS: m/z (ESI) calculated 
for C36H48N10O6
+
: 717.3837 [M+H]
+
. Found: [M+H]
+
: 717.3831 
 
L-Arginyl-glycyl-glycyl-L-leucinyl-L-tryptophan; RGGLW [11] 
 
 
 
The product was purified by reverse phase HPLC at a flow rate of 20 mL/min. The 
method employed a binary mixture of eluents A (H2O with 0.1 % TFA) and B (MeOH 
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with 0.1 % TFA). HPLC gradient B: 5%-35%; 0-10 mins, 35%-60%; 10-25mins, 
60%-100%; 25-30mins, 100% 30-35mins, 100%-5%; 35-40mins, 5% 40-50mins. 
Retention time was found to be at 17.6mins (0.09 g, 1.5 x 10
-4 
mol, 24 %). 
1
H-NMR 
(400MHz, MeOD) δH: 0.79 (dd, 6H, J1=6.5Hz J2=13.0Hz, H-11) 1.14 (t, 2H, 
J1=7.5Hz H-7) 1.20 (m, 1H, H-10) 1.44 (t, 2H, J=7.5Hz, H-9) 1.53 (m, 2H, H-6) 2.47 
(d, 2H, J=8.0Hz, H-12) 3.07 (m, 2H, H-8) 3.90 (s, 4H, H-2 H-3) 4.01 (m, 1H, H-5) 
4.37 (t, 1H, J=7.5Hz, H-4) 4.58 (m, 1H, H-1) 7.01 (m, 2H, H-15 H-16) 7.22 (d, 1H, 
J=8.0Hz, H-14) 7.45 (dd, 1H, J1=8.0Hz J2=18.0Hz, H-13) 7.90 (d, 1H, J=8.0Hz, H-
17); HRMS: m/z (ESI) calculated for C27H41N9NaO6
+
: 610.3077 [M+Na]
+
. Found: 
[M+H]
+
: 610.3072 
 
Glycyl-L-tryptophyl-glycyl-L-leucinyl-L-tryptophan; GWGLW [12] 
 
 
 
The product was purified by reverse phase HPLC at a flow rate of 20 mL/min. The 
method employed a binary mixture of eluents A (H2O with 0.1 % TFA) and B (MeOH 
with 0.1 % TFA). HPLC gradient B: 30%-100%; 0-30 mins, 100%; 30-35mins, 
100%-30%; 35-40mins, 30% 40-50mins. Retention time was found to be at 12.3mins 
(0.19g, 3.1x10
-4
mol, 50%). 
1
H-NMR (400MHz, MeOD) δH: 0.61 (d, 3H, J=6.5Hz, H-
14) 0.68 (d, 3H, J=6.5Hz, H-14) 1.2-1.8 (m, 3H, H-12 H-13) 3.00 (d, 2H, J=5.0Hz, H-
15) 3.18 (d, 2H, J=3.5Hz, H-6) 3.42 (s, 2H, H-3) 3.90 (s, 2H, H-1) 4.16 (m, 1H, H-4) 
4.30 (m, 1H, H-2) 4.60 (m, 1H, H-5) 6.75 (m, 2H, H-8 H-17) 6.9-7.6 (m, 4H, H-9 H-
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10 H-18 H-19) 7.90 (m, 2H, H-7 H-16) 8.30 (m, 2H, H-11 H-20); HRMS: m/z (ESI) 
calculated for C32H40N7O6
+
: 618.3040 [M+H]
+
. Found: [M+H]
+
: 618.3035 
 
L-Arginyl-L-tryptophyl-glycyl-glycyl-L-tryptophan; RWGGW [13] 
 
 
 
The product was purified by reverse phase HPLC at a flow rate of 20 mL/min. The 
method employed a binary mixture of eluents A (H2O with 0.1 % TFA) and B (MeOH 
with 0.1 % TFA). HPLC gradient B: 5%-100%; 0-30 mins, 100%; 30-35mins, 100%-
5%; 35-40mins, 5% 40-50mins. Retention time was found to be at 15.2mins (0.11g, 
1.7x10
-4
mol, 28%). 
1
H-NMR (400MHz, MeOD) δH: 1.59 (m, 2H, H-7) 1.77 (m, 2H, 
H-6) 2.45 (d, 4H, J=8.0Hz, H-9 H-15) 2.52 (t, 2H , J=7.0Hz, H-8) 3.55 (d, 4H, 
J=2.0Hz, H-3 H-4)  4.07 (t, 2H, J=7.0Hz, H-1) 4.54 (m, 1H, H-5) 4.61 (m, 1H, H-2) 
6.98 (m, 2H, H-11 H-17) 7.22 (m, 4H, H-12 H-13 H-18 H-19) 7.47 (m, 2H, H-10 H-
16) 7.89 (m, br, 2H, H-14 H-20); HRMS: m/z (ESI) calculated for C32H41N10O6
+
: 
661.3211 [M+H]
+
. Found: [M+H]
+
: 661.3218 
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L-Arginyl-L-tryptophyl-glycyl-L-leucinyl-glycine; RWGLG [14] 
 
 
 
The product was purified by reverse phase HPLC at a flow rate of 20 mL/min. The 
method employed a binary mixture of eluents A (H2O with 0.1 % TFA) and B (MeOH 
with 0.1 % TFA). HPLC gradient B: 5%-35%; 0-10 mins, 35%-60%; 10-25mins, 
60%-100%; 25-30mins, 100% 30-35mins, 100%-5%; 35-40mins, 5% 40-50mins. 
Retention time was found to be at 18.0mins (0.13 g, 2.2 x 10
-4 
mol, 36 %). 
1
H-NMR 
(300MHz, MeOD) δH: 0.80 (m, 6H, H-17) 1.21 (t, 2H, J=7.5Hz, H-8) 1.6-2.1 (m, 5H, 
H-6 H-15 H-16) 3.1-3.3 (m, 4H, H-7 H-9) 3.6-3.8 (m, 2H, H-1 H-4) 3.88 (s, 4H, H-3 
H-5)  4.40 (m, 1H, H-2) 7.00 (m, 2H, H-12 H-13) 7.23 (m, 1H, H-11) 7.48 (d, 1H, 
J=7.0Hz3, H-10) 7.64 (d, 1H, J=7.5Hz, H-14); HRMS: m/z (ESI) calculated for 
C27H42N9O6
+
: 588.3258 [M+H]
+
. Found: [M+H]
+
: 588.3253 
 
L-Glutamyl-L-histidyl-L-tryptophyl-glycyl-glycyl-glycine; EHWGGG [15] 
 
 
 
The product was purified by reverse phase HPLC at a flow rate of 20 mL/min. The 
method employed a binary mixture of eluents A (H2O with 0.1 % TFA) and B (MeOH 
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with 0.1 % TFA). HPLC gradient B: 5%-25%; 0-10 mins, 25%-60%; 10-25mins, 
60%-100%; 25-30mins, 100%-5%; 30-35mins, 5%; 35-45mins. Retention time was 
found to be at 12.6 mins (0.29 g, 4.6 x 10
-4 
mol, 75 %). 
1
H-NMR (400MHz, MeOD) 
δH: 1.95 (dt, 2H, J1=7.0Hz, J2=13.5Hz, H-7) 2.36 (t, 2H, J=7.5Hz, H-8) 3.10 (d, 2H, 
J=6.5Hz, H-12) 3.16 (d, 2H, J=7.5Hz, H-9) 3.80 (s, br, 6H, H-4 H-5 H-6) 3.88 (m, 
1H, H-1) 4.50 (t, 1H, J=7.0Hz, H-3) 4.63 (t, 1H, J=6.0Hz, H-2) 6.9-7.1 (m, 2H, H-10 
H-16) 7.24 (m, 2H, H-14 H-15) 7.50 (d, 1H, J=8.0Hz, H-13) 7.60 (d, 1H, J=8.0Hz, 
H-17) 8.59 (s, br, 1H, H-11); HRMS: m/z (ESI) calculated for C28H36N9O9
+
: 
642.2636 [M+H]
+
. Found: [M+H]
+
: 642.2631 
 
L-Glutamyl-L-arginyl-L-tryptophyl-glycyl-glycyl-L-tryptophan; ERWGGW [16] 
 
 
 
The product was purified by reverse phase HPLC at a flow rate of 20 mL/min. The 
method employed a binary mixture of eluents A (H2O with 0.1 % TFA) and B (MeOH 
with 0.1 % TFA). HPLC gradient B: 5%-35%; 0-10 mins, 35%-60%; 10-25mins, 
60%-100%; 25-30mins, 100%-5%; 30-35mins, 5%; 35-45mins. Retention time was 
found to be at 17.7 mins (0.33 g, 4.2 x 10
-4 
mol, 69 %). 
1
H-NMR (400MHz, MeOD) 
δH: 1.4-2.0 (m, 6H, H-7 H-9 H-10) 2.37 (t, 2H, J=7.5Hz, H-8) 3.0-3.3 (m, 6H, H-11 
H-12 H-18) 3.52 (s, 2H, H-5) 3.56 (s, 2H, H-4) 3.90 (t, 1H, J=6.0Hz, H-1) 4.30 (t, 1H, 
J=6.0Hz, H-2) 4.50 (m, 1H, H-3) 4.62 (m, 1H, H-6) 6.8-7.1 (m, 2H, H-14 H-20) 7.2-
7.6 (m, 4H, H-15 H-16 H-21 H-22) 8.25 (m, 2H, H-13 H-19) 8.37 (m, 1H, H-23) 8.47 
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(d, 1H, J=7.5Hz, H-17); HRMS: m/z (ESI) calculated for C37H48N11O9
+
: 790.3636 
[M+H]
+
. Found: [M+H]
+
: 790.3637 
 
7.4 Synthesis of Uridyl-containing Peptides 
 
2',3'-O-Isopropylidene uridine [31]
265
 
 
 
A suspension of uridine (3.50 g, 1.40 x 10
-2 
mol, 1 eq) and p-toluenesulfonic acid 
(0.14 g, cat) in CHCl3(350 mL) was treated with 2-methoxypropene (3.30 mL, 3.50 x 
10
-2 
mol, 2.4 eq). The mixture was heated to reflux and stirred overnight. The solvent 
was removed in vacuo to yield a purple foam.  The product was purified by flash 
chromatography using EtOAc as the eluent (3.10 g, 1.1 x 10
-2 
mol, 71 %)  
Rf =  0.42 (100% EtOAc); m.p. 163-166°C, lit m.p 163-166°C
266
; 
1
H-NMR 
(400MHz, DMSO-d
6
) δH: 1.29 (s, 3H, H-4) 1.49 (s, 3H, H-4) 3.5-3.6 (m, 2H, H-1) 
4.09 (m, 1H, H-2) 4.76 (dd, 1H, J1=3.5Hz J2=6.5Hz, H-3) 4.88 (dd, 1H, J1=3.0Hz 
J2=6.5Hz, H-5)  5.65 (d, 1H, J=6.5Hz, H-6) 5.85 (d, 1H, J=3.0Hz, H-8) 7.80 (d, 1H, 
J=8.0Hz, H-7); 
13
C-NMR (100MHz, CDCl3) δC: 25.8, 63.3, 80.5, 82.7, 82.7, 86.9, 
96.3, 103.0, 142.0, 175.4, 178.5; HRMS: m/z (ESI) calculated for C12H16N2NaO6
+
: 
307.0906 [M+Na]
+
. Found: [M+Na]
+
: 307.0901 
 
 
 
 
 
180 
 
5'-succinyl-2', 3'-O-isopropylidene uridine [32]
249
 
 
 
 
 
Succinic anhydride (1.03 g, 1.03 x 10
-2 
mol, 0.9 eq) was dissolved in dry DCM (100 
mL) and a solution of [31] (3.101 g, 1.1 x 10
-2 
mol, 1 eq) in dry DCM (110 mL) was 
added. The mixture was treated with TEA (1.01 g, 1.4 mL, 1.0 x 10
-2 
mol, 0.90 eq) 
and was cooled to 0°C overnight. The reaction was allowed to warm to room 
temperature. The solvent was removed in vacuo, and the resulting residue was cooled 
to 0°C and dissolved in Na2CO3(sat).  The aqueous layer was washed with Et2O (3 x 
100 mL), cooled to 0°C and acidified with 2M HCl to pH 1.6. The product was then 
extracted with DCM (4 x 50 mL) and dried with MgSO4. The solvent was removed in 
vacuo. The product was purified by flash chromatography using (8:2/EtOAc:CHCl3) 
as the eluent (2.260 g, 5.88 x 10
-3 
mol, 57.0 %).  m.p. 71-74°C Rf = 0.54 
(8:2/EtOAc:CHCl3);  
1
H-NMR (400MHz, DMSO-d
6
) δH: 1.34 (s, 3H, H-6) 1.54 (s, 
3H, H-6) 2.57 (m, 4H, H-1 H-2) 4.05 (m, 1H, H-4) 4.24 (d, 2H, J=5.0Hz, H-3) 4.81 
(dd, 1H, J1=4.0Hz J2=6.5Hz, H-5)  4.93 (dd, 1H, J1=3.0Hz J2=6.5Hz, H-7) 5.54 (d, 
1H, J=6.5Hz, H-8) 5.83 (d, 1H, J=4.0Hz, H-10) 7.62 (d, 1H, J=8.0Hz, H-9); 
13
C-
NMR (100MHz, CDCl3) δC: 25.5, 28.8, 28.9, 60.4, 64.0, 80.9, 84.6, 85.3, 94.9, 102.2, 
142.5, 160.0, 164.4, 172.0, 176.4; HRMS: m/z (ESI) calculated for C16H20N2NaO9
+
: 
407.1066 [M+Na]
+
. Found: [M+Na]
+
: 407.1061 
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5'-Succinyl-2',3'-O-isopropylideneuridyl-glycl-glycyl-L-tryptohyl-L-arginine [26] 
 
 
 
[26] was synthesised via SPPS following a general method using 2-chlorotrityl 
chloride resin (Chapter 7.3). The product was purified by reverse phase HPLC at a 
flow rate of 20 mL/min. The method employed a binary mixture of eluents A (H2O 
with 0.1 % TFA) and B (MeOH with 0.1 % TFA). HPLC gradient B: 50%-100%; 0-
15 mins, 100%-50%; 15-20mins, 50%; 20-30mins. Retention time was found to be at 
11.4mins (0.31 g, 3.9 x 10
-4 
mol, 64 %). 
1
H-NMR (400MHz, MeOD) δH: 1.85 (m, 
2H, H-21) 1.90 (m, 2H, H-20) 2.5-2.8 (m, 8H, H-8 H-9 H-14 H-22) 3.5-4.4 (m, 11H, 
H-4 H-5 H-6 H-7 H-10 H-11 H-12 H-13) 5.89 (d, 1H, J=3.5Hz, H-3)  5.91 (d, 1H, 
J=3.5Hz, H-1) 6.91 (t, 1H, J=6.0Hz, H-18) 6.98 (t, 1H, J=8.0Hz, H-17) 7.1-7.4 (m, 
2H, H-15 H-16) 7.56 (d, 1H, J=8.0Hz, H-2) 7.93 (d, 1H, J=8.0Hz, H-19); 
13
C-NMR 
(100MHz, MeOD) δC: 24.4, 30.3, 36.8, 41.6, 43.5, 44.4, 52.5, 53.4, 65.1, 65.7, 71.3, 
72.2, 75.3, 76.1, 79.5, 80.3, 82.8, 83.4, 91.8, 103.6, 112.6, 119.6, 120.2, 122.7, 142.7, 
169.6, 170.0, 171.9, 172.4, 190.1; HRMS: m/z (ESI) calculated for C34H46N10O13
+
: 
801.3162 [M+H]
+
. Found: [M+H]
+
: 801.3169 
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5'-Succinyl-2',3'-O-isopropylideneuridyl-glycl-glycyl-glycyl-L-arginine [27] 
 
 
 
[27] was synthesised via SPPS following a general method using 2-chlorotrityl 
chloride resin (Chapter 7.3). The product was purified by reverse phase HPLC at a 
flow rate of 20 mL/min. The method employed a binary mixture of eluents A (H2O 
with 0.1 % TFA) and B (MeOH with 0.1 % TFA). HPLC gradient B: 5%-50%; 0-15 
mins, 50%-100%; 15-20mins, 100%; 20-25mins, 100%-5%; 25-30mins, 5% 30-
40mins. Retention time was found to be at 9.8mins. (0.392 g, 5.8 x 10
-4 
mol, 96%)  
1
H-NMR (400MHz, MeOD) δH: 1.58 (m, 2H, H-15) 1.88 (m, 2H, H-14) 2.4-2.7 (m, 
4H, H-8 H-9) 3.13 (m, 2H, H-16) 3.67 (dd, 1H, J1=3.1Hz J2=3.1Hz, H-4) 3.80 (m, 
6H, H-7 H-11 H-12) 3.90 (s, 2H, H-10)  4.07 (m, 1H, H-13) 4.29 (dd, 1H, J1=2.8Hz 
J2=3.8Hz, H-5) 4.39 (q, 1H, J=4.6Hz, H-6) 5.63 (d, 1H, J=7.9Hz, H-3) 5.83 (d, 1H, 
J=4.5Hz, H-1) 7.91 (d, 1H, J=8.0Hz, H-2); 
13
C-NMR (100MHz, MeOD) δC: 24.9, 
28.4, 29.1, 32.0, 41.5, 41.8, 42.0, 44.0, 55.3, 62.9, 70.1, 71.8, 81.8, 98.5, 104.2, 150.1, 
157.0, 164.0, 170.8, 171.0, 171.6, 174.3, 172.8; HRMS: m/z (ESI) calculated for 
C25H38N9O13
+
: 672.2589 [M+H]
+
. Found: [M+H]
+
: 672.2584 
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5'-Succinyl-2',3'-O-isopropylideneuridyl-glycl-glycyl-L-tryptophyl-glycine [28] 
 
 
 
 
[28] was synthesised via SPPS following a general method using 2-chlorotrityl 
chloride resin (Chapter 7.3). The product was purified by reverse phase HPLC at a 
flow rate of 20 mL/min. The method employed a binary mixture of eluents A (H2O 
with 0.1 % TFA) and B (MeOH with 0.1 % TFA). HPLC gradient B: 5%-100%; 0-30 
mins, 100%; 30-35mins, 100%-5%; 35-40mins, 5% 40-50mins. Retention time was 
found to be at 11.3 mins. (0.270 g, 3.8 x 10
-4  
mol, 91 %)  
1
H-NMR (400MHz, 
MeOD) δH: 2.5 (m, 6H, H-8 H-9 H-14) 3.69 (s, 1H, H-10) 3.72 (s, 1H, H-13) 3.74 (s, 
1H, H-11) 3.81 (m, 1H, H-6) 4.01 (m, 1H, H-4) 4.23 (m, 3H, H-5 H-7)  4.61 (dd, 1H, 
J1=5.1Hz J2=5.0Hz, H-12) 5.63 (d, 1H, J=8.0Hz, H-3) 5.71 (d, 1H, J=8.0Hz, H-1) 
6.91 (t, 1H, J=7.5Hz, H-18) 7.00 (t, 1H, J=7.5Hz, H-17) 7.05 (d, 1H, J=5.5Hz, H-16) 
7.21 (d, 1H, J=8.0Hz, H-2) 7.50 (d, 1H, J=8.0Hz, H-15) 7.60 (d, 1H, J=8.5Hz, H-19); 
13
C-NMR (400MHz, MeOD) δC: 16.6, 289, 30.3, 31.5, 43.8, 44.4, 55.9, 65.1, 71.6, 
75.5, 83.4, 91.8, 103.3, 111.5, 112.6, 118.5, 119.6, 120.5, 123.0, 125.2, 129.2, 142.7, 
158.9, 161.7, 164.0, 167.9, 171.3, 173.3, 182.0; HRMS: m/z (ESI) calculated for 
C30H35N7NaO13
+
: 724.2185 [M+Na]
+
. Found: [M+Na]
+
: 724.2190 
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9H-fluoren-9-ylmethyl (2,5-dioxotetrahydrofuran-3-yl)carbamate; N-Fmoc-
aspartic anhydride [33]
250
 
 
A solution of Fmoc-OSu (2.55 g, 7.5 x 10
-3 
mol, 1 eq) in THF (20 mL) was added 
with stirring to a solution of aspartic acid (1.00 g, 7.5 x 10
-3 
mol, 1 eq) in H2O (15 
mL) containing Na2CO3 (1.75 g, 1.65 x 10
-2 
mol, 2.2 eq). After stirring at room 
temperature overnight, the mixture was washed with Et2O (2 x 20 mL). The aqueous 
layer was acidified with HCl to pH 2 and extracted with EtOAc (2 x 30 mL). The 
organic phase was dried with MgSO4 and the concentrated in vacuo. The residue was 
then dissolved in Ac2O (8 mL) with rapid heating and stirring (10 minutes). The 
reaction mixture was then cooled to room temperature causing traces of precipitate to 
crash out. To encourage crystallization the mixture was left overnight under an ice 
bath. The precipitate was filtered off, washed with dry Et2O and dried under high 
vacuum (2.330 g, 7.2 x 10
-3 
mol, 96 %).  
1
H-NMR (400MHz, DMSO-d6) δH: 2.90 
(dd, 2H, J1=6.5Hz, J2=12.5Hz, H-1) 3.33 (dd, 2H, J1=8.5Hz, J2=10Hz, H-1) 4.32 (t, 
1H, J=6.5Hz, H-5) 4.54 (m, 2H, H-4) 4.71 (m, 1H, H-2) 7.41 (t, 2H, J=7.5Hz, H-7) 
7.50 (t, 2H, J=7.5Hz, H-8) 7.73 (d, 2H, J=7.5Hz, H-6) 7.91 (d, 2H, J=7.5Hz, H-9) 
8.20 (d, 1H, J=7.5Hz, H-3); 
13
C-NMR (100MHz, DMSO-d6) δC: 34.7, 46.6, 50.4, 
66.0, 120.1, 120.2, 125.0, 125.1, 127.0, 127.1, 127.7, 140.8, 143.6, 155.9, 169.8, 
172.1; HRMS: m/z (ESI) calculated for C19H15NNaO5
+
: 360.0848 [M+Na]
+
. Found: 
[M+Na]
+
: 360.0842 
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N-(9-Fluorenylmethoxycarbonyl)-L-aspartic acid-β-2',3'-O-isopropylidine uridyl 
ester; FAU-A [34a] 
 
[33] (0.41 g, 1.25 x 10
-3 
mol, 1 eq) was dissolved in dry DCM (70 mL) and a solution 
of [31] (0.75 g, 1.25 x 10
-3 
mol, 1 eq) in dry DCM (110 mL) was added. The mixture 
was treated with TEA (0.4 mL, 2.5 x 10
-3 
mol, 2 eq) and was cooled to 0 °C. The 
reaction mixture was stirred at 0°C overnight and then allowed to warm to room 
temperature. The solvent was removed in vacuo, and the resulting residue was cooled 
to 0°C and dissolved in Na2CO3(sat).  The aqueous layer was washed with diethyl 
ether (3 x 100 mL), cooled to 0°C and acidified with 2M HCl to pH 1.6. The product 
was then extracted with DCM (4 x 50 mL) and dried with MgSO4. The solvent was 
removed in vacuo. The product was purified by flash chromatography using EtOAc as 
the eluent (0.231 g, 3.7 x 10
-4 
mol, 30 %). 
Rf =  0.5 (100% EtOAc); 
1
H-NMR (400MHz, DMSO-d6) δH: 1.40 (s, 6H, H-5) 1.52 
(s, 6H, H-5) 2.85 (m, 2H, H-9) 3.73 (dd, 1H, J1=3.5Hz, J2=12Hz, H-4) 3.97 (dd, 1H, 
J1=2.5Hz, J2=12Hz, H-6) 4.23 (m, 3H, H-7 H-8) 4.90 (m, 1H, H-10) 5.02 (m, 3H, H-
11 H-12) 5.53 (d, 1H, J=3.5Hz, H-3) 5.78 (d, 1H, J=8.0Hz, H-1) 6.91 (d, 2H, 
J=7.5Hz, H-14) 7.30 (d, 1H, J=8.0Hz, H-2) 7.25 (d, 2H, J=7.5Hz, H-15) 7.56 (m, 
2H, H-13) 7.72 (m, 2H, H-16); 
13
C-NMR (100MHz, DMSO-d6) δC: 25.6, 27.5, 31.2, 
47.0, 51.0, 60.2, 66.3, 81.0, 84.5, 87.0, 21.6, 102.3, 113,5, 120.6, 125.7, 127.5, 128.1, 
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141.2, 142.4, 144.2, 150.8, 156.3, 163.6, 170.4, 171.5, 172.0, 172.8   HRMS: m/z 
(ESI) calculated for C31H30N3O11
- 
: 620.1880 [M-H]
-
. Found: [M-H]
-
: 620.1878 
 
N-(9-Fluorenylmethoxycarbonyl)-L-aspartic acid- α -2',3'-O-isopropylidine 
uridyl ester; FAU-B [34b] 
 
 
[33] (0.41 g, 1.25 x 10
-3 
mol, 1 eq) was dissolved in dry DCM (70 mL) and a solution 
of [31] (0.75 g, 1.25 x 10
-3 
mol, 1 eq) in dry DCM (110 mL) was added. The mixture 
was treated with TEA (0.4 mL, 2.5 x 10
-3 
mol, 2 eq) and was cooled to 0 °C. The 
reaction mixture was stirred at 0 °C overnight and then allowed to warm to room 
temperature. The solvent was removed in vacuo, and the resulting residue was cooled 
to 0 °C and dissolved in Na2CO3(sat).  The aqueous layer was washed with diethyl 
ether (3 x 100 mL), cooled to 0 °C and acidified with 2M HCl to pH 1.6. The product 
was then extracted with DCM (4 x 50 mL) and dried with MgSO4. The solvent was 
removed in vacuo. The product was purified by flash chromatography using EtOAc as 
the eluent (0.163 g, 2.6 x 10
-4 
mol, 21 %). 
Rf =  0.3 (100% EtOAc); 
1
H-NMR (400MHz, DMSO-d6) δH: 1.39 (s, 6H, H-5) 1.51 
(s, 6H, H-5) 2.73 (m, 2H, H-16) 3.60 (m, 2H, H-4 H-6) 4.24 (m, 1H, H-7) 4.44 (m, 
2H, H-8) 4.87 (dd, 1H, J1=3.0Hz, J2=6.5Hz, H-9) 5.14 (dd, 1H, J1=2.5Hz, J2=6.5Hz, 
H-10 H-11) 5.72 (dd, 1H, J1=3.0Hz, J2=8.0Hz, H-3) 5.90 (d, 2H, J=2.5Hz, H-1) 7.46 
(m, 3H, H-2 H-14) 7.52 (t, 2H, J=7.5Hz, H-13) 7.80 (m, 2H, H-12) 7.91 (m, 2H, H-
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15); 
13
C-NMR (100MHz, DMSO-d6) δC: 25.6, 27.3, 47.0, 51.5, 64.3, 66.2, 80.9, 83.1, 
84.2, 92.2, 102.4, 113.8, 120.6, 125.7, 127.7, 141.2, 142.9, 144.3, 150.9, 156.2, 163.5, 
170.9, 172.9; LRMS m/z (ESI) 620.2 [M-H]
-
; HRMS: m/z (ESI) calculated for 
C31H30N3O11
- 
: 620.1880 [M-H]
-
. Found: [M-H]
-
: 620.1889 
 
L-Arginyl-L-tryptophyl-L-alanyl-L-aspartyl-α-tryptophyl-β-uridyl ester; 
RWAD(Ur)-W [29a] 
 
 
 
 
[29a] was synthesised via SPPS following the general SPPS method using 2-
chlorotrityl chloride resin, Fmoc-protected amino acids and [34a] (Chapter 7.3). Due 
to poor yields (10mg, 1x10
-5
mol, 3%), the product was unable to be characterised by 
NMR. HRMS: m/z (ESI) calculated for C31H30N3O11
- 
: 981.3826 [M+Na]
+
. Found: 
[M+Na]
+
: 981.3834 
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L-Arginyl-L-tryptophyl-L-alanyl-L-aspartyl-β-tryptophyl-α-uridyl ester; 
RWAD(W)-Ur [29b] 
 
 
 
[29b] was synthesised via SPPS following the general SPPS method using 2-
chlorotrityl chloride resin, fmoc-protected amino acids and [34b] (Chapter 7.3). Due 
to poor yields (8mg, 1x10
-5
mol, 2%), the product was unable to be characterised by 
NMR. HRMS: m/z (ESI) calculated for C31H30N3O11
- 
: 981.3826 [M+Na]
+
. Found: 
[M+Na]
+
: 981.3832 
 
7.5 Fluorescence Plate Reader Assay 
 
 
A Tecan GENios plate reader was used to determine the inhibitory activity of 
synthetic RWXXW analogues at an excitation wavelength of 340nm and emission 
wavelength of 535nm. To monitor the formation of dansyl-Lipid I, membrane bound 
MraY was treated with a master mix containing dansyl-tagged UDP-MurNAc 
pentapeptide and lipid carrier C55-P or C35-P. Dansyl-tagged UDP-MurNAc 
pentapeptide was provided by Agnes Mihalyi.  
C55-P and C35-P was purchased from Larodan Fine Chemicals in a 
chloroform/methanol (2:1) + 3 % (v/v) ammonia solution. 20 μl of the 10 mg/mL 
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stock solution (total 0.2 mg) was transferred to a small vial. The solvents were 
removed from this sample using a gentle stream of N2(g). Once the solution was 
completely dried it was redissolved in 2 mL of a buffer solution containing 50 mM 
Tris Base pH 7.5, 2 mM β-mercaptoethanol, 1mM MgCl2, 20 % glycerol and 0.5 % 
TritonX100.  The solution was vortexed and sonicated until the 100μg/mL solution 
became clear.  
 
Preparation of the Master Mix (MM) 
 
The master mix contained a mixture of buffer A, water, dansyl-UDP-MurNAc 
pentapeptide and lipid carrier C55-P or C35-P (Table 7.1).  Buffer A contained a final 
concentration of 100 mM Tris base, pH 7.5 and 25 mM MgCl2. The master mix 
contained 21.0 μM Dansyl-UDP-MurNAc pentapeptide and 47.2 μM C55-P or 70.6 
μM C35-P.  
 
Preparation of Membrane-bound MraY 
 
Agnes Mihalyi overexpressed E. coli and P. aeruginosa MraY in E. coli DH5α cells. 
Membrane isolates were dissolved in a membrane buffer containing 50 mM Tris pH 
7.5, 2 mM β-mercaptoethanol and 1 mM MgCl2. The final protein concentrations of 
membranes containing overexpressed E. coli and P. aeruginosa MraY in this plate 
reader assay were 0.72 and 0.13 mg/mL, respectively.  
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Table 7.1: Final concentrations in plate reader assay 
 Stock Volume Concentration in 
MM 
Concentration in 
each well 
Dansyl-UDP-
MurNAc 
pentapeptide 
(1427.20 g/mol) 
3.75 mg/mL 40 μL 21.0 μM 17.9 μM 
C55-P (847.28 
g/mol) 
  or 
C35-P (566.74 
g/mol) 
0.1 mg/mL 2 mL C55-P = 47.2 μM 
C35-P = 70.6 μM 
C55-P = 40.1 μM 
or 
C35-P = 60.0 μM 
Buffer A 200 mM Tris 
base pH 7.5 
50 mM 
MgCl2 
2.5 mL 100 mM Tris 
base, pH 7.5 
25 mM MgCl2 
85 mM Tris 
base, pH 7.5 
21.25 mM 
MgCl2 
Water  0.46mL   
 
Plate reader assay protocol 
 
To a 96 well plate, 10 μL of overexpressed MraY membranes was added to 85 μL of 
master mix and 5 μL of the inhibitor (final concentration 100 μg/mL in MeOH). 
MeOH was used as the negative control.  Tunicamycin and Epep, at a final 
concentration of 100 μg/mL in MeOH, were used as the positive controls. 
Fluorescence measurements were taken before the addition of membranes, t =0, then 
at 5 minute intervals for 20 minutes.  
 
7.6 Continuous Fluorescence Assay 
 
 
The MraY catalysed reaction was monitored by a Perkin Elmer LS55 fluorimeter at 
an excitation wavelength of 340nm and an emission wavelength of 530nm. . To 
monitor the formation of dansyl-Lipid I, membrane-bound MraY was treated with a 
master mix containing dansyl-UDP-MurNAc pentapeptide and lipid carrier C55-P or 
C35-P. Dansyl-tagged UDP-MurNAc pentapeptide was provided by Agnes Mihalyi.  
C55-P or C35-P was prepared as mentioned in Chapter 7.5.  
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Continuous assay protocol 
 
To a Starna
®
 sub-micro fluorimeter cell, 15 μL of membrane bound MraY was added 
to 150 μL of master mix and 15 μL of inhibitor.  The final protein concentrations of 
membranes containing overexpressed E. coli, P. aeruginosa, S. aureus, M. flavus and 
B. subtilis MraY in this continuous assay were 0.6, 0.1, 0.28, 0.3, 0.3 and 0.9 mg/mL, 
respectively. The final concentration of all reagents in the master mix and in the assay 
is given in Table 7.2.  
 
Table 7.2: Final concentrations in continuous fluorescence assay 
 Stock Volume Concentration in 
MM 
Concentration in 
cuvette 
Dansyl-UDP-
MurNAc pentapeptide 
(1427.20 g/mol) 
3.75 mg/mL 40 μL 21.0 μM 17.5 μM 
C55-P (847.28 g/mol) 
  or 
C35-P (566.74 g/mol) 
0.1mg/mL 2 mL C55-P = 47.2 μM 
C35-P = 70.6 μM 
C55-P = 39.3 μM 
or 
C35-P = 58.8 μM 
Buffer A 200 mM 
Tris base, 
pH 7.5 
50 mM 
MgCl2 
2.5 mL 100 mM Tris 
base, pH 7.5 
25 mM MgCl2 
83.3  mM Tris 
base, pH 7.5 
20.83 mM 
MgCl2 
Water  0.46mL   
 
7.7 IC50 determination 
 
 
The IC50 of novel MraY inhibitors were calculated using the statistical software 
GenStat for Teaching and Learning. A linear regression was fitted to the first 500 data 
points. The slope of each line was then related to the percent activity of MraY in 
relation to the negative control (Table 7.3). The negative control was assumed to 
correspond to 100 % MraY activity. 
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Table 7.3: Slope dependent inhibition by Epep. 
Epep 
[μg/mL] 
Slope Error in 
slope 
% Activity 
of MraY 
% Error 
0 0.112 0.002 100 1.35 
37 0.041 0.001 36 1.20 
62.5 0.037 0.001 32.5 1.17 
83 0.014 0.001 12 1.26 
 
The percent activity of MraY was plotted against the concentration of the inhibitor to 
produce an IC50 graph. With assistance from the Quantitatvie Biology Centre 
(QuBic), GenStat was programmed to fit a smoothing spline function through the data 
points.  A smoothing spline gently angulates between data points minimising the 
distance between the points and the line. The function of a spline is similar to an 
exponential function and has equation 3.1. 
                                                                         [7.1] 
Where: 
A: % activity of MraY 
B: rate of decrease  
C: concentration 
 
Using this equation the concentration of the inhibitor that reduces the activity of the 
enzyme by 50 % can be determined.   
 
 
 
 
  ln   
   
  = C                                                               [7.2] 
 
To calculate error, GenStat factors in the standard error associated with each data 
point (determined from the linear regression) as well as the distance between the data 
points and the smoothing spline. The error generated by this graph is relative to the 
concentration of the inhibitor. 
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7.8 Overexpression and Isolation of MraY mutants 
 
 
Transformation into E. coli C43 
 
MOAC summer project student Amy O’Reilly provided three E. coli mraY constructs 
with mutations F288A, F288L and E287A in a pET52b vector. 5 μL of these MraY 
containing vector DNA were added to 50 μL of E. coli C43 competent cells and 
incubated over ice for 30 minutes. The samples were incubated at 42 °C in a water 
bath for 45 seconds and immediately transferred to ice for 3 minutes. 300 μL of LB 
was added to each sample and incubated at 37°C with shaking (180 rpm) for 1 hour.  
100 μL of the seeded LB was poured to a standard agar plate. An L-shaped cell 
spreader was used to assure the mixture was evenly distributed across the plate. The 
agar plate was incubated overnight at 37 °C.   
 
Isolation of E. coli membranes 
 
A single colony was isolated from the transformed plate and inoculated in 5 mL of 
LB+Amp (100 μg/mL) overnight at 37 °C with shaking. This start-up culture was 
diluted 100-fold with LB+Amp (100 μg/mL) and allowed to grow to an OD600 of 0.6. 
The cells were then induced with IPTG (1 mM) and allowed to grow for 4 hours at 37 
°C with shaking. The cells were spun down at 4,400 g for 15 minutes at 4 °C. The 
pellet was transferred to a pre-weighed falcon tube and resuspended in membrane 
buffer (3 mL/gram of pellet). Typically 1-2 grams of pellet was isolated. The 
membrane buffer contained 50 mM Tris pH 7.5, 2 mM β-mercaptoethanol and 1 mM 
MgCl2. 2.5 mg of Lysozyme (from egg white) and 25 μg of DNAse I (from bovine 
pancreas) was added to each 1mL of membrane buffer.   The cells were then lysed 
using a Constant Systems Ltd. TS Series Cabinet cell disruptor. The lysed cells were 
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spun down at 24,000 g for 20 minutes at 4 °C. The supernatant was then isolated and 
spun down at 40,000 rpm for 1 hour at 4 °C using an ultracentrifuge. The membrane 
pellet was homogenised in minimum membrane buffer (<2 mL) and flash frozen with 
liquid N2 in 300 μL aliquots.  
 
7.9 Protocol for Western Blot 
 
 
SDS-PAGE protocol 
 
Membrane-bound MraY mutant samples were determined by discontinuous-dodecyl-
sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
267
. The running gel was 
composed of 1.252 mL of 1.5 M Tris, pH 8.8, 2.025 mL of 29.1% (w/v) acrylamide, 
1.678 mL of dH2O, 51.2 μL of 10% SDS, 51.2 μL of 10 % APS and 4.45 μL of 
TEMED.   The mixture was poured between two glass plates to solidify. The stacking 
gel was composed of 500 μL of 0.5M Tris, pH 6.5, 200 μL of 29.1% (w/v) 
acrylamide, 1.3mL of dH2O, 20 μL of 10% SDS, 30 μL of 10% APS and 3 μL of 
TEMED. The stacking gel was poured over the solidified running gel, and a 10-well 
comb was inserted. While the gel solidified, protein samples were prepared. To 25 μg 
of membrane-bound MraY in a membrane buffer composed of 50 mM Tris pH 7.5, 2 
mM β-mercaptoethanol and 1 mM MgCl2, 5 μL of SDS dye was added and boiled at 
60 °C for 10 minutes. Prestained molecular weight and strep tag markers were used in 
the gel. The gel was run for 55 minutes at room temperature at 180 volts and 400mA. 
 
Transfer process 
 
To analyse the molecular weight of the MraY proteins, the proteins were transferred 
from the SDS-PAGE gel to a PVDF membrane. The transfer buffer was composed of 
2.9 g of glycine powder, 5.8 g of TRIS base powder, 200 mL of MeOH and dH2O 
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(total volume of 1L). 2 sponges and 2 pieces of filter paper were soaked in the transfer 
buffer before being using in the transfer sandwich.  The PVDF membranes were cut 
and activated in 20 mL of 100 % MeOH.  
The transfer sandwich was prepared in the following order; sponge, filter paper, SDS-
PAGE gel, activated PVDF membrane, filter paper and a sponge. Air bubbles were 
removed by evenly and firmly rolling a 50mL falcon tube over the sandwich. The 
transfer sandwich was clamped and placed in the transfer tank. The transfer process 
was run for up to 3 hours at 4 °C at 110v and 170mA in the transfer buffer.  
 
Blocking the membranes 
 
The PVDF membrane was blocked with 50 mL of blocking buffer at 4 °C for 1 hour. 
The blocking buffer was composed of 5 % albumin (from Marvel powdered milk) in 
50 mL of PBS. The blocking buffer was decanted from the membrane and the 
membrane was washed 3 times with 20mL PBS-Tween buffer for 5 minutes with 
gentle shaking at room temperature.  
 
Antibody HRP-Conjugate binding 
 
10 mL of PBS-Tween buffer was added to the membrane. 10 μL of 0.1 % Strep-
Tactin HRP-conjugate in PBS-Tween was added and incubated at room temperature 
for 1 hour with gentle shaking. The membrane was washed twice with PBS-Tween 
buffer and twice with PBS buffer for 1 minute at room temperature. 
 
Chemoluminescence 
 
The membrane was treated with 2 mL of Novex® Electrochemiluminescence (ECL) 
reagents A and B (1:1) for up to 2 minutes with gentle shaking. The membrane was 
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then transferred to a developing cassette and blotted onto film in a dark room.  An 
AGFA Curix 60 processor was used to develop the film and visualise protein bands.  
 
7.10 Protocol for Dot Blot 
 
 
A dot blot was performed to confirm the presence of Strep-tagged proteins. 
Nitrocellulose membrane paper was cut into strips and spotted directly with 5 and 20 
μL of membrane-bound MraY mutants (13 mg/mL in membrane buffer). The spots 
were air dried (≈ 1 hour).   
 
Blocking the membranes 
 
The loaded nitrocellulose membrane strips were blocked with 50 mL of blocking 
buffer at 4 °C for 1 hour. The blocking buffer was composed of 5 % albumin (from 
Marvel powdered milk) in 50 mL of PBS. The blocking buffer was decanted from the 
membrane strips.  The membrane strips were then washed 3 times with 20 mL PBS-
Tween buffer for 5 minutes with gentle shaking at room temperature.  
 
Antibody HRP-Conjugate binding 
 
10mL of PBS-Tween buffer was added to the membrane strips. 20 μL of 0.1 % Strep-
Tactin HRP-conjugate in PBS-Tween was added and incubated at room temperature 
for 1 hour with gentle shaking. The membrane was washed twice with PBS-Tween 
buffer and twice with PBS buffer for 1 minute at room temperature. 
 
Chemoluminescence 
 
The membrane was treated with 2 mL of Novex® Electrochemiluminescence (ECL) 
reagents A and B (1:1) for up to 2 minutes with gentle shaking. The membrane strips 
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were then transferred to a developing cassette and blotted onto film in the dark room.  
An AGFA Curix 60 processor was used to develop the film and visualise protein 
spots.  
 
7.11 Kirby-Bauer Antibiotic Susceptibility test 
 
 
Luria Bertani broth (LB) was composed of 1 % tryptone, 0.5 % yeast extract and 1 % 
NaCl. E. coli C43 and B. subtilis colonies were isolated from a standard agar plate and 
inoculated in 5 mL of LB broth overnight at 37°C.  0.1 mL of cultured bacteria was 
then added to 2 mL of melted low percent agar. Low percent agar was composed of 
LB + 0.5 % (w/v) agar.  The mixture was vortexed and immediately poured onto an 
agar plate. An L-shaped cell spreader was used to assure the mixture was evenly 
distributed across the plate. Once fully gelled, the plate was divided into eight 
sections and labelled. An antibacterial disc was added to each section. On the 
antibacterial disc 25 μL of a 5 mg/mL inhibitor was added. Ampicillin (125 μg/mL) 
and water were used as the positive and negative controls, respectively. The plates 
were then inverted an incubated overnight at 37°C. 
 
7.12 Microtitre Broth Dilution Technique 
 
 
Luria Bertani broth (LB) was composed of 1% tryptone, 0.5 % yeast extract and 1 % 
NaCl. P. putida, E. coli and B. subtilis colonies were isolated from an agar plate and 
inoculated in 5 mL of LB broth overnight at 37 °C.  A dilution series of the seeded LB 
was performed to get a 10
-1
, 10
-2
, 10
-3
, 10
-4
, 10
-5
, 10
-6
, 10
-7
 and 10
-8
-fold dilutions. The 
dilution series was performed by taking 0.5 mL of the seeded LB and diluting it with 
4.5 mL of LB. This was equivalent to a ten-fold dilution. 0.5 mL of this ten-fold 
dilution was then further diluted in 4.5mL of LB to get a 100-fold dilution. This was 
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repeated until a 10
-8
 -fold dilution was made.  0.5 mL of each dilution was then 
poured onto an agar plate.  An L-shaped cell spreader was used to assure the solution 
was evenly distributed across the plate. The plates were then inverted and incubated 
overnight at 37 °C.  The colonies were counted and the dilution that gave a CFU/mL 
of 10
3
 was chosen for MIC calculations  
On a 96 deep welled plate, 190 μl of the seeded broth (CFU/mL = 103) was added to 
each well. 2.5 mg/mL solutions of protein E analogues were serially diluted to obtain 
7 different concentrations (1250, 625, 312.5, 186, 78.2, 39, and 19.5 μg/mL). 10 μL of 
these diluted inhibitors were added to the 96 deep well plate to give a final volume of 
200 μL and final concentrations of 125, 62.5, 31.25, 15.63, 7.82, 3.90, 1.95 and 0.97 
μg/mL. 10 μL of water was added to one of the wells to serve as a growth control. 
The deep 96 well plate was covered with a sterile adhesive film and incubated 
overnight at 37°C.  The solutions were then transferred to a normal 96 well plate for 
optical density measurements (OD595) using a Tecan GENios plate reader. The 
inhibitor concentration which reduced the growth by 50 % was considered the MIC of 
the compound. 
 
7.13 Fluorometric assay of Gram-negative bacterial permeabilization229 
 
 
A single colony of P. putida was isolated from a standard agar plate and inoculated in 
5 mL of LB overnight at 37°C with shaking. This start-up culture was diluted 100-
fold with LB and grown to OD600 of 0.5 at 37 °C with shaking. The culture was then 
centrifuged for 10 minutes at 1000 g at 25 °C. The pellet was resuspended in half the 
volume of 5mM HEPES buffer, pH 7.2. 
Membrane permealisation of this bacterial suspension by H2N-RW-Oct [3] was 
determined on a Perkin Elmer fluorimeter at an excitation wavelength of 340nm and 
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an emission wavelength of 435nm.  To a Starna
®
 sub-micro fluorimeter cell, 50 μL of 
the bacterial suspension was added to 25 μL of 40 μM NPN and 25 μL of the 
inhibitor. NPN and [3] were dissolved in a HEPES buffer, pH 7.2. The HEPES buffer 
solution was used as the negative control and EDTA (125 μg/mL) was used as the 
positive control. The samples were monitored continuously for 20 minutes. Inhibitors 
were tested in duplicates.   
 
7.14 Effects on the Growth of Bacteria by IPTG and MraY 
 
 
Transformation into E. coli C43 cells 
 
5 μL of empty pET52b vector DNA and 5μL of mraY containing pET52b vector DNA 
were added to 50 μL of E. coli C43 competent cells and incubated over ice for 30 
minutes. The samples were incubated at 42°C in a water bath for 45 seconds and 
immediately transferred to ice for 3 minutes. 300 μL of LB was added to each sample 
and incubated at 37 °C with shaking (180 rpm) for 1 hour.  100 μL of the seeded LB 
was poured to a standard agar plate. An L-shaped cell spreader was used to assure the 
mixture was evenly distributed across the plate. The agar plate was incubated 
overnight at 37 °C.   
 
Monitorisation of growth 
 
A single colony was isolated from the transformed plate and inoculated in 5 mL of 
LB+Amp (100 μg/mL) overnight at 37 °C with shaking. This start-up culture was 
diluted 100-fold with LB and induced with 0.5 mM IPTG. The culture was allowed to 
grow with shaking at 37 °C. The optical density (OD595) of the growing cells was 
measured every 30 minutes using a Thermo Electron UV-VIS spectrophotometer. 
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7.15 MIC of H2N-RW-Oct [3] against E. coli cells overexpressing WT MraY and 
Mray mutants F288L and E287A  
 
Transformation into E. coli C43 cells 
 
MOAC summer project student Amy O’Reilly provided three E. coli mraY constructs 
in a pET52b vector. These constructs contained WT mraY, mutant F288L and mutant 
E287A mraY DNA. 5 μL of pET52b vector DNA were added to 50 μL of E. coli C43 
competent cells and incubated over ice for 30 minutes. To serve as a negative control 
5μL of an empty pET52b vector DNA was added to 50 μL of E. coli C43 competent 
cells and incubated over ice for 30 minutes. The samples were incubated at 42 °C in a 
water bath for 45 seconds and immediately transferred to ice for 3 minutes. 300 μL of 
LB was added to each sample and incubated at 37 °C with shaking (180 rpm) for 1 
hour.  100 μL of the seeded LB was poured to a standard agar plate. An L-shaped cell 
spreader was used to assure the mixture was evenly distributed across the plate. The 
agar plate was incubated overnight at 37 °C.   
 
MIC determination 
 
A single colony was isolated from the transformed plate and inoculated in 5mL of 
LB+Amp (100 μg/mL) overnight at 37 °C with shaking. This start-up culture was 
diluted 100-fold with LB and induced with 0.5 mM IPTG. To a sterile deep well 
microtitre plate, 190 μl of the IPTG-induced seeded broth was added to each well. 10 
μL of H2N-RW-Oct [3] was added to the deep 96 well plate to give a final volume of 
200 μL and final inhibitor concentrations of 500, 450, 400, 350, 300, 250, 125, 62.5, 
31.25, 15.63, 7.82, 3.90, 1.95 and 0.98 μg/mL.  Each inhibitor concentration was 
tested in duplicates. 10 μL of water was added to one of the wells to serve as a growth 
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control. Normal LB was also used as a negative control. The microtire plate was 
covered with a sterile adhesive film and incubated at 37 °C with shaking for 8 hours.  
The solutions were then transferred to a standard 96 well plate for absorbance 
measurements (OD595). The inhibitor concentration which reduced the growth by 50% 
was considered the MIC of the compound. 
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Appendix 1:  Fluorescence Emission Spectrum of 
MraY and MraY mutants in the presence of 
RWXXW analogues  
 
 
A1.1   Activity of H2N-GW-Oct [6] against E. coli MraY 
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A1.2   Activity of H2N-GW-Oct [6] against B. subtilis MraY 
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A1.3   Activity of H2N-GW-Oct [6] against P. aeruginosa MraY 
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A1.4   Activity of H2N-GW-Oct [6] against S. aureus MraY 
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A1.5   Activity of H2N-GW-Oct [6] against M. flavus MraY 
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A1.6   Activity of H2N-GW-OMe [4] against B. subtilis MraY 
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A1.7   Activity of RWGLW [10] against E. coli MraY 
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A1.8   Activity of RWGLW [10] against S. aureus MraY 
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A1.9   Activity of RWGLW [10] against B. subtilis MraY 
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A1.10   Activity of RGGLW [11] against E. coli MraY 
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A1.11   Activity of RGGLW [11] against B. subtilis MraY 
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A1.12   Activity of EHWGGG [15] against E. coli MraY 
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A1.13   Activity of EHWGGG [15] against P. aeruginosa MraY 
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A1.14   Activity of EHWGGG [15] against S. aureus MraY 
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A1.15   Activity of EHWGGG [15] against M. flavus MraY 
 
 
 
 
 
 
 
 
 
 
 
 
 
232 
 
A1.16   Activity of Epep against F288A MraY 
 
 
 
 
A1.16   Activity of Epep against F288L MraY 
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A1.17   Activity of Epep against E287A MraY 
 
 
 
 
 
 
 
 
 
 
 
 
 
234 
 
A1.18   Activity of H2N-GW-Oct [6] against E287A MraY 
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Appendix 2:  IC50 values of compounds with intrinsic 
fluorescence against E. coli MraY 
 
Determined via radiochemical assay by Agnes Mihalyi 
 
 
A2.1   IC50 graph of GWGLW [12] 
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A2.2   IC50 graph of RWGGW [13] 
 
 
 
 
 
A2.3   IC50 graph of RWGLG [13] 
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A2.4   IC50 graph of ERWGGW [16] 
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Appendix 3:  Emission Spectrum of MraY and MraY 
mutants in the presence of UPA’s and UPA analogues 
 
A3.1   Activity of HOOC-RGGGsUr [27] against E. coli MraY 
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A3.2   Activity of HOOC-RGGGsUr [27] against P. aeruginosa MraY 
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A3.3   Activity of HOOC-RGGGsUr [27] against S. aureus MraY 
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A3.4   Activity of HOOC-RGGGsUr [27] against M. flavus MraY 
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A3.5   Activity of HOOC-RGGGsUr [27] against B. subtilis MraY 
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A3.6   Activity of caparazamycin A against E. coli MraY 
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A3.7   Activity of caparazamycin E against E. coli MraY 
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A3.8   Activity of pacidamycin 1&2 against E. coli MraY 
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A3.9   Activity of pacidamycin D against E. coli MraY 
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A3.10   Activity of mureidomycin A against E. coli MraY 
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A3.11   Activity of caparazamycin A against E. coli F288L MraY 
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A3.12   Activity of caparazamycin E against E. coli F288L MraY 
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A3.13   Activity of pacidamycin 1&2 against E. coli F288L MraY 
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A3.14  Activity of pacidamycin D against E. coli F288L MraY 
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A3.15   Activity of mureidomycin A against E. coli F288L MraY 
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A3.16   Activity of caparazamycin A against E. coli E287A MraY 
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A3.17   Activity of caparazamycin E against E. coli E287A MraY 
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A3.18   Activity of pacidamycin 1&2 against E. coli E287A MraY 
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A3.19   Activity of pacidamycin D against E. coli E287A MraY 
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A3.20   Activity of mureidomycin A against E. coli E287A MraY 
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Appendix 4: NMR spectra of RWXXW peptides 
 
Compounds which contained solvent peaks were dried further under high vacuum 
before any biological work was conducted. 
 
1
H-NMR L-Tryptophan methyl ester hydrochloride [17] 
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1
H-NMR L-Tryptophan octyl ester [18] 
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1
H-NMR Glycine octyl ester [19] 
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13
C-NMR Glycine octyl ester [19] 
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1
H-NMR N-octanoyl glycine [20] 
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1
H-NMR L-Arginyl-L-tryptophan methyl ester; H2N-RW-OMe [1] 
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1
H-NMR N-octanoyl-L-arginyl-L-tryptophan methyl ester; Octanoyl-RW-OMe 
[2] 
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1
H-NMR L-Arginyl-L-tryptophan octyl ester; H2N-RW-Oct [3]  
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1
H-NMR Glycyl-L-tryptophan methyl ester; H2N-GW-OMe [4]  
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13
C-NMR Glycyl-L-tryptophan methyl ester; H2N-GW-OMe [4]  
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1
H-NMR N-octanoyl-L-glycyl-L-tryptophan methyl ester; Octanoyl-GW-OMe [5] 
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1
H-NMR Glycyl-L-tryptophan octyl ester; H2N-GW-Oct [6] 
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1
H-NMR N-octanoyl-L-arginyl-glycine; Octanoyl-RG-OH [8] 
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13
C-NMR N-octanoyl-L-arginyl-glycine; Octanoyl-RG-OH [8] 
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1
H-NMR L-Arginyl-glycine octyl ester; H2N-RG-Oct [9] 
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1
H-NMR L-Arginyl-glycine; H2N-RG-OH [7] 
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1
H-NMR L-Arginyl-L-tryptophyl-glycyl-L-leucinyl-L-tryptophan; RWGLW [10] 
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1
H-NMR L-Arginyl-glycyl-glycyl-L-leucinyl-L-tryptophan; RGGLW [11] 
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1
H-NMR L-Arginyl-L-tryptophyl-glycyl-glycyl-L-tryptophan; RWGGW [13] 
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1
H-NMR L-Glutamyl-L-histidyl-L-tryptophyl-glycyl-glycyl-glycine; EHWGGG 
[15] 
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1
H-NMR L-Glutamyl-L-arginyl-L-tryptophyl-glycyl-glycyl-L-tryptophan; 
ERWGGW [16] 
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1
H-NMR 2',3'-O-Isopropylidene uridine [31] 
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13
C-NMR 2',3'-O-Isopropylidene uridine [31] 
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1
H-NMR 5'-succinyl-2', 3'-O-isopropylidene uridine [32] 
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13
C-NMR 5'-succinyl-2', 3'-O-isopropylidene uridine [32] 
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1
H-NMR 5'-Succinyl-2',3'-O-isopropylideneuridyl-glycl-glycyl-glycyl-L-arginine 
[27] 
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1
H-NMR 5'-Succinyl-2',3'-O-isopropylideneuridyl-glycl-glycyl-L-tryptophyl-
glycine [28] 
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1
H-NMR 9H-fluoren-9-ylmethyl (2,5-dioxotetrahydrofuran-3-yl)carbamate; N-
Fmoc-aspartic anhydride [33] 
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13
C-NMR 9H-fluoren-9-ylmethyl (2,5-dioxotetrahydrofuran-3-yl)carbamate; N-
Fmoc-aspartic anhydride [33] 
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1
H-NMR N-(9-Fluorenylmethoxycarbonyl)-L-aspartic acid-β-2',3'-O-
isopropylidine uridyl ester; FAU-A [34a] 
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13
C-NMR N-(9-Fluorenylmethoxycarbonyl)-L-aspartic acid-β-2',3'-O-
isopropylidine uridyl ester; FAU-A [34a] 
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1
H-NMR N-(9-Fluorenylmethoxycarbonyl)-L-aspartic acid- α -2',3'-O-
isopropylidine uridyl ester; FAU-B [34b] 
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13
C-NMR N-(9-Fluorenylmethoxycarbonyl)-L-aspartic acid- α -2',3'-O-
isopropylidine uridyl ester; FAU-B [34b] 
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Appendix 5: UV spectra of purified peptides 
 
L-Arginyl-L-tryptophyl-glycyl-L-leucinyl-L-tryptophan; RWGLW [10]= 93.4% 
pure 
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Glycyl-L-tryptophan octyl ester; H2N-GW-Oct [6] = 98.06% pure 
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5'-Succinyl-2',3'-O-isopropylideneuridyl-glycl-glycyl-glycyl-L-arginine [27] 
 = 89.34% pure 
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L-Arginyl-L-tryptophan octyl ester; H2N-RW-Oct [3] = 91.74% pure 
 
 
